EpCAM Antibodies, Activatable Antibodies, and Immunoconjugates, and Uses Thereof

Novel EpCAM-specific antibodies and immunoconjugates address the limitations of current therapies by providing targeted cancer treatment with reduced side effects, effectively inhibiting tumor growth and improving therapeutic outcomes.

JP7592009B2Active Publication Date: 2024-11-29IMMUNOGEN INC +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2021523230
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-05-10
Filing Date
2019-10-23
Publication Date
2024-11-29
Estimated Expiration
2039-10-23

AI Technical Summary

Technical Problem

Current anti-EpCAM antibody-based therapies face challenges such as systemic intolerance and acute pancreatitis, highlighting the need for novel therapeutic antibodies that overcome these limitations.

Method used

Development of EpCAM-specific antibodies, antibody fragments, and activatable antibodies, along with immunoconjugates, which include specific nucleic acid sequences and vectors, designed to inhibit tumor growth and treat cancers by targeting EpCAM with enhanced specificity and reduced side effects.

Benefits of technology

The new antibodies and immunoconjugates effectively target EpCAM-expressing cancer cells, offering improved therapeutic efficacy with reduced systemic toxicity and enhanced cancer treatment outcomes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007592009000204
    Figure 0007592009000204
  • Figure 0007592009000205
    Figure 0007592009000205
  • Figure 0007592009000206
    Figure 0007592009000206
Patent Text Reader

Abstract

In general, the present disclosure relates to antibodies and antibody fragments that specifically bind to human EpCAM; EpCAM-activatable antibodies; and immunoconjugates thereof; and methods of making and using the antibodies, antibody fragments, activatable antibodies, and immunoconjugates for the diagnosis and treatment of diseases such as cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] In general, the present disclosure relates to antibodies and antibody fragments that specifically bind to human EpCAM; EpCAM-activatable antibodies; and immunoconjugates thereof; and methods of making and using the antibodies, antibody fragments, activatable antibodies, and immunoconjugates for the diagnosis and treatment of diseases such as cancer.

[0002] Epithelial cell adhesion molecule (EpCAM) is a type I transmembrane glycoprotein that contains an extracellular domain, a transmembrane domain, and a single intracellular domain. EpCAM expression in humans is epithelium-specific. Most epithelial cells express EpCAM, except for some specific epithelial cell types, such as squamous epithelial cells and epidermal keratinocytes, hepatocytes, gastric parietal cells, and myoepithelial cells (Balzar et al., J. Mol. Med. 77:699-712 (1999); Momburg et al., Cancer Res 47:2883-2891 (1987)).

[0003] EpCAM is abundantly and uniformly expressed on human carcinomas of various origins (Went et al., Br. J. Cancer 94:128-35(2006); Herlyn et al., Proc Natl. Acad. Sci. USA 76:1438-1442(1979); Went et al., Hum. Pathol. 35:122-128(2004)). EpCAM is overexpressed in most epithelial cancers, including, for example, ovarian, colon, gastric, prostate, and lung cancers. In addition, EpCAM has been shown to inhibit primary and metastatic cancer cells on gastric and gastroesophageal junction adenocarcinomas (Martin, J. Clin. Pathol. 52:701-704 (1999)) and in cell lines derived from colorectal, pancreatic, and breast cancers (Szala, Proc. Natl. Acad. Sci. USA 87:3542-3546 (1990), Packeisen, Hybridoma 18:37-40 (1999)), as well as disseminated NSCLC (non-small cell lung cancer) cells (Passlick, Int. J. Cancer EpCAM has been shown to be expressed in the majority of tumors (87:548-552 (2000)). Another study found that only 4% of 108 immunohistochemical samples of secondary tumors lacked EpCAM expression. EpCAM is also overexpressed in cancer-initiating or cancer stem cells isolated from colon, breast, pancreatic, and prostate cancers (O'Brien et al., Nature 445:106-110 (2007); Marhaba et al., Curr. Mol. Med. 8:784-804 (2008)).

[0004] Normal cells express EpCAM on the basolateral side of the epithelial membrane, whereas cancer cells express EpCAM abundantly on the apical membrane. Antibody-based therapeutics have been designed to take advantage of this expression feature, as the less prominent and exposed EpCAM on normal cells likely means that healthy cells are less likely to be bound by therapeutic anti-EpCAM antibodies.

[0005] Several antibodies against EpCAM have been used in the clinic but have failed for various reasons. Tested EpCAM antibodies take several forms, including naked antibodies, immunotoxins, and bispecific or trispecific antibodies (Baeuerle, Br. J. Cancer, 96:417-423 (2007)). For example, the naked anti-EpCAM antibody adecatumumab (MT201) has been tested in clinical trials for the treatment of colorectal, prostate, and breast cancer. Safety challenges facing current anti-EpCAM antibody-based approaches include systemic intolerance and acute pancreatitis. Thus, although several attempts have been made to develop therapeutic antibodies against EpCAM, there is a great need for the development of novel therapeutic EpCAM antibodies that overcome the shortcomings and limitations of previously developed antibodies. Summary of the Invention

[0006] The present disclosure provides antibodies and antibody fragments that specifically bind to human EpCAM, as well as EpCAM-activatable antibodies, and immunoconjugates comprising the antibodies, antibody fragments, and activatable antibodies. Nucleic acid sequences encoding EpCAM antibodies, EpCAM-binding antibody fragments, and activatable antibodies are also provided as vectors containing the polynucleotides, and as cells containing the polynucleotides and vectors. The present disclosure also provides compositions, such as pharmaceutical compositions, that include EpCAM antibodies, EpCAM-binding antibody fragments, and activatable antibodies. Methods of making and using EpCAM antibodies, EpCAM-binding antibody fragments, activatable antibodies, and compositions are further provided. Such methods include the use of antibodies, antibody fragments, activatable antibodies, immunoconjugates, and other compositions to inhibit tumor growth, as well as methods of making and using antibodies, antibody fragments, activatable antibodies, immunoconjugates, and compositions for the diagnosis and treatment of diseases such as cancer.

[0007] In some embodiments, the present disclosure provides: [1] The antibody or antibody fragment comprises an EpCAM antibody or an EpCAM-binding antibody fragment: (a) a heavy chain CDR1 (VH-CDR1) comprising the sequence X1YX3X4H, where X1 is selected from N and S, X3 is selected from Y, N, F, S, H, D, L, I, and W, and X4 is selected from I and M (SEQ ID NO: 5); (b) Array WX2X3PGX6VYIQYX 12 X 13 KFX 17 G, X2 is selected from I and F, X3 is selected from Y and N, X6 is selected from N and D, and X 12 is selected from N and S, and X 13 is selected from E and Q, and X 17 is selected from K and Q, heavy chain CDR2 (VH-CDR2) (SEQ ID NO: 7); (c) a heavy chain CDR3 (VH-CDR3) comprising the sequence X1GX3X4FAY, where X1 is selected from D and E, X3 is selected from P, A, S, Y, F, G, T, and V, and X4 is selected from Y and W (SEQ ID NO: 8); (d) Array RSSX4SLLHSX 10 GX 12 TYLX 16 X4 is selected from R and K; 10 is selected from N and D, and X 12 is selected from F and I, and X 16 is selected from Y and S; light chain CDR1 (VL-CDR1) (SEQ ID NO: 10); (e) a light chain CDR2 (VL-CDR2) comprising the sequence QTSNLAS (SEQ ID NO: 40); and (f) A light chain CDR3 (VL-CDR3) comprising the sequence X1QX3LELPX8T, where X1 is selected from A, L, and Q, X3 is selected from S, G, Y, and N, and X8 is selected from N and W (SEQ ID NO: 11). [2] The antibody or antibody fragment of [1], wherein the antibody or antibody fragment comprises: (a) a heavy chain CDR1 (VH-CDR1) comprising the sequence NYX3IH, where X3 is selected from Y, N, F, S, H, D, L, I, and W (SEQ ID NO: 6); (b) Array WX2X3PGX6VYIQYX12 X 13 KFX 17 G, X2 is selected from I and F, X3 is selected from Y and N, X6 is selected from N and D, and X 12 is selected from N and S, and X 13 is selected from E and Q, and X 17 is selected from K and Q, heavy chain CDR2 (VH-CDR2) (SEQ ID NO: 7); (c) a heavy chain CDR3 (VH-CDR3) comprising the sequence DGPX4FAY, wherein X4 is selected from Y and W (SEQ ID NO: 9); (d) Array RSSX4SLLHSX 10 GX 12 TYLX 16 X4 is selected from R and K; 10 is selected from N and D, and X 12 is selected from F and I, and X 16 is selected from Y and S; light chain CDR1 (VL-CDR1) (SEQ ID NO: 10); (e) a light chain CDR2 (VL-CDR2) comprising the sequence QTSNLAS (SEQ ID NO: 40); and (f) a light chain CDR3 (VL-CDR3) comprising the sequence AQX3LELPNT, where X3 is selected from S, G, Y, and N (SEQ ID NO: 12); [3] The EpCAM antibody or EpCAM-binding antibody fragment of [1] or [2], wherein the antibody or antibody fragment comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having sequences selected from the group consisting of: (a) SEQ ID NOs: 13-15, 42, 40, and 41, respectively; (b) SEQ ID NOs: 13-15, and 39-41, respectively; (c) SEQ ID NOs: 13, 26, 15, and 39–41, respectively; (d) SEQ ID NOs: 13, 24, 15, 42, 40, and 41, respectively; [4] The EpCAM antibody or EpCAM-binding antibody fragment according to any one of [1] to [3], wherein the antibody or antibody fragment binds to both human EpCAM and cynomolgus EpCAM with a KD of 3.0 nM or less; [5] The EpCAM antibody or EpCAM-binding antibody fragment according to [4], wherein the antibody or antibody fragment specifically binds to an epitope within the extracellular domain of human EpCAM having the amino acid sequence of SEQ ID NO: 2; [6] The antibody or antibody fragment of [5], wherein the antibody or antibody fragment comprises: (a) VH-CDR1 comprising the sequence NYYIH (SEQ ID NO: 13); (b) VH-CDR2 comprising the sequence WIYPGNVYIQYNEKFKG (SEQ ID NO: 14); (c) VH-CDR3 containing the sequence DGPWFAY (SEQ ID NO: 15); (d) VL-CDR1 comprising the sequence RSSRSLLHSDGFTYLY (SEQ ID NO: 42); (e) VL-CDR2 (SEQ ID NO: 40) comprising the sequence QTSNLAS; and (f) VL-CDR3 comprising the sequence AQNLELPNT (SEQ ID NO: 41); [7] The antibody or antibody fragment of [4], wherein the antibody or antibody fragment comprises: (a) VH-CDR1 comprising the sequence NYYIH (SEQ ID NO: 13); (b) VH-CDR2 comprising the sequence WIYPGNVYIQYNEKFKG (SEQ ID NO: 14); (c) VH-CDR3 containing the sequence DGPWFAY (SEQ ID NO: 15); (d) VL-CDR1 containing the sequence RSSKSLLHSDGFTYLY (SEQ ID NO: 39); (e) VL-CDR2 (SEQ ID NO: 40) comprising the sequence QTSNLAS; and (f) VL-CDR3 comprising the sequence AQNLELPNT (SEQ ID NO: 41); [8] The EpCAM antibody or EpCAM-binding antibody fragment of [3], wherein the antibody or antibody fragment comprises a VH and a VL selected from the following: (a) a VH having the sequence of SEQ ID NO: 54, and a VL having the sequence of SEQ ID NO: 89; (b) a VH having the sequence of SEQ ID NO: 54, and a VL having the sequence of SEQ ID NO: 87; (c) a VH having the sequence of SEQ ID NO: 55, and a VL having the sequence of SEQ ID NO: 87; (d) a VH having the sequence of SEQ ID NO: 56, and a VL having the sequence of SEQ ID NO: 88; (e) a VH having the sequence of SEQ ID NO: 55, and a VL having the sequence of SEQ ID NO: 89; (f) a VH having the sequence of SEQ ID NO: 56, and a VL having the sequence of SEQ ID NO: 89; [9] The antibody or antibody fragment of [8], wherein the antibody or antibody fragment comprises a VH of SEQ ID NO: 54 and a VL of SEQ ID NO: 89;

[10] The antibody or antibody fragment of [8], wherein the antibody or antibody fragment comprises a VH of SEQ ID NO: 54 and a VL of SEQ ID NO: 87;

[11] The EpCAM antibody or EpCAM-binding antibody fragment of [8], wherein the antibody or antibody fragment comprises a heavy chain and a light chain selected from the following: (a) an HC having the sequence of SEQ ID NO: 103 and an LC having the sequence of SEQ ID NO: 140; (b) an HC having the sequence of SEQ ID NO: 103 and an LC having the sequence of SEQ ID NO: 138; (c) an HC having the sequence of SEQ ID NO: 105 and an LC having the sequence of SEQ ID NO: 139; (d) an HC having the sequence of SEQ ID NO: 106 and an LC having the sequence of SEQ ID NO: 139; (e) a HC having the sequence of SEQ ID NO: 105 and a LC having the sequence of SEQ ID NO: 140; (f) a HC having the sequence of SEQ ID NO: 106 and a LC having the sequence of SEQ ID NO: 140;

[12] The antibody or antibody fragment according to

[11] , wherein the antibody or antibody fragment comprises an HC of SEQ ID NO: 103 and an LC of SEQ ID NO: 140;

[13] The antibody or antibody fragment according to

[11] , wherein the antibody or antibody fragment comprises an HC of SEQ ID NO: 103 and an LC of SEQ ID NO: 138;

[14] The EpCAM antibody or EpCAM-binding antibody fragment of [1] or [2], wherein the antibody or antibody fragment comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having sequences selected from the group consisting of: (a) SEQ ID NOs: 22, 14, 15, 42, 40, and 41, respectively; (b) SEQ ID NOs: 13, 14, 33, 42, 40, and 41, respectively; (c) SEQ ID NOs: 23, 14, 15, 42, 40, and 41, respectively; and (d) SEQ ID NOs: 25, 14, 15, 42, 40, and 41, respectively;

[15] The antibody or antibody fragment of

[14] , wherein the antibody or antibody fragment comprises: (a) VH-CDR1 comprising the sequence NYHIH (SEQ ID NO: 22); (b) VH-CDR2 comprising the sequence WIYPGNVYIQYNEKFKG (SEQ ID NO: 14); (c) VH-CDR3 containing the sequence DGPWFAY (SEQ ID NO: 15); (d) VL-CDR1 comprising the sequence RSSRSLLHSDGFTYLY (SEQ ID NO: 42); (e) VL-CDR2 (SEQ ID NO: 40) comprising the sequence QTSNLAS; and (f) VL-CDR3 comprising the sequence AQNLELPNT (SEQ ID NO: 41);

[16] The antibody or antibody fragment of

[14] , wherein the antibody or antibody fragment comprises: (a) VH-CDR1 comprising the sequence NYYIH (SEQ ID NO: 13); (b) VH-CDR2 comprising the sequence WIYPGNVYIQYNEKFKG (SEQ ID NO: 14); (c) VH-CDR3 comprising the sequence DGYWFAY (SEQ ID NO: 33); (d) VL-CDR1 comprising the sequence RSSRSLLHSDGFTYLY (SEQ ID NO: 42); (e) VL-CDR2 (SEQ ID NO: 40) comprising the sequence QTSNLAS; and (f) VL-CDR3 comprising the sequence AQNLELPNT (SEQ ID NO: 41);

[17] The EpCAM antibody or EpCAM-binding antibody fragment of

[14] , wherein the antibody or antibody fragment comprises a VH and a VL selected from the following: (a) a VH having the sequence of SEQ ID NO: 75, and a VL having the sequence of SEQ ID NO: 89; (b) a VH having the sequence of SEQ ID NO: 77, and a VL having the sequence of SEQ ID NO: 89; (c) a VH having the sequence of SEQ ID NO: 76, and a VL having the sequence of SEQ ID NO: 89; and (d) a VH having the sequence of SEQ ID NO: 84, and a VL having the sequence of SEQ ID NO: 89;

[18] The antibody or antibody fragment of

[17] , wherein the antibody or antibody fragment comprises a VH of SEQ ID NO: 75 and a VL of SEQ ID NO: 89;

[19] The antibody or antibody fragment of

[17] , wherein the antibody or antibody fragment comprises a VH of SEQ ID NO: 77 and a VL of SEQ ID NO: 89;

[20] The EpCAM antibody or EpCAM-binding antibody fragment of

[17] , wherein the antibody or antibody fragment comprises a heavy chain and a light chain selected from the following: (a) an HC having the sequence of SEQ ID NO: 125 and an LC having the sequence of SEQ ID NO: 140; (b) an HC having the sequence of SEQ ID NO: 127 and an LC having the sequence of SEQ ID NO: 140; (c) an HC having the sequence of SEQ ID NO: 126 and an LC having the sequence of SEQ ID NO: 140; (d) an HC having the sequence of SEQ ID NO: 134 and an LC having the sequence of SEQ ID NO: 140;

[21] The antibody or antibody fragment according to

[20] , wherein the antibody or antibody fragment comprises an HC of SEQ ID NO: 125 and an LC of SEQ ID NO: 140;

[22] The antibody or antibody fragment according to

[20] , wherein the antibody or antibody fragment comprises an HC of SEQ ID NO: 127 and an LC of SEQ ID NO: 140;

[23] The antibody or antibody fragment according to any one of [1] to

[22] , wherein the antibody or antibody fragment is a mouse, non-human mammalian, chimeric, humanized, or human antibody;

[24] The antibody or antibody fragment according to any one of [1] to

[23] , wherein the antibody is a full-length antibody;

[25] The full-length antibody according to item

[24] , wherein the antibody is a human IgG1;

[26] The antibody fragment may be Fab, Fab', F(ab'), Fd, single-chain Fv or scFv, or a disulfide-linked F v , a V-NAR domain, an IgNar, an intrabody, an IgGΔCH2, a minibody, an F(ab')3, a tetrabody, a triabody, a diabody, a single domain antibody, a DVD-Ig, an Fcab, an mAb2, an (scFv)2, or an scFv-Fc;

[27] The activatable antibody (a) a cleavable moiety attached to an antibody or antibody fragment, wherein the cleavable moiety is a polypeptide that functions as a substrate for a protease; and (b) a masking moiety attached to an antibody or antibody fragment, wherein the masking moiety inhibits binding of the antibody or antibody fragment to EpCAM when the activatable antibody is in an uncleaved state; an activatable antibody comprising the antibody or antibody fragment according to any one of [1] to

[26] , wherein the uncleaved activatable antibody has a structural arrangement from the N-terminus to the C-terminus of (masking moiety)-(cleavable moiety)-(antibody or antibody fragment) or (antibody or antibody fragment)-(cleavable moiety)-(masking moiety);

[28] An EpCAM-activatable antibody, (a) an EpCAM antibody or EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of members selected from the group consisting of: (i) SEQ ID NOs: 13-15, 42, 40, and 41, respectively; (ii) SEQ ID NOs: 13-15, and 39-41, respectively; (iii) SEQ ID NOs: 13, 26, 15, and 39-41, respectively; (iv) SEQ ID NOs: 13, 24, 15, 42, 40, and 41, respectively; (b) a masking moiety attached to the EpCAM antibody or EpCAM-binding antibody fragment, wherein the masking moiety inhibits binding of the antibody or antibody fragment to EpCAM when the activatable antibody is in an uncleaved state; and (c) a cleavable moiety attached to an EpCAM antibody or EpCAM-binding antibody fragment, wherein the cleavable moiety is a polypeptide that functions as a substrate for a protease; an EpCAM-activatable antibody comprising:

[29] The EpCAM activatable antibody according to

[28] , wherein the activatable antibody comprises an EpCAM antibody or an EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 13 to 15, 42, 40, and 41, respectively;

[30] The EpCAM activatable antibody of

[29] , wherein the activatable antibody comprises an EpCAM antibody or an EpCAM-binding antibody fragment comprising a VH having the sequence of SEQ ID NO: 54 and a VL having the sequence of SEQ ID NO: 89;

[31] The EpCAM activatable antibody of

[30] , wherein the activatable antibody comprises an EpCAM antibody or an EpCAM-binding antibody fragment comprising a heavy chain having the sequence of SEQ ID NO: 103 and an LC having the sequence of SEQ ID NO: 140;

[32] The EpCAM activatable antibody according to any one of

[29] to

[31] , wherein the activatable antibody comprises a masking portion having an amino acid sequence selected from SEQ ID NOs: 151 to 157;

[33] The EpCAM activatable antibody of

[32] , wherein the activatable antibody comprises a masking moiety having the amino acid sequence of SEQ ID NO: 155;

[34] The EpCAM activatable antibody according to any one of

[29] to

[33] , wherein the activatable antibody comprises a cleavable portion comprising the amino acid sequence of SEQ ID NO: 168 or 169;

[35] An EpCAM-activatable antibody, (a) an EpCAM antibody or EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having sequences selected from the group consisting of: (i) SEQ ID NOs: 22, 14, 15, 42, 40, and 41, respectively; (ii) SEQ ID NOs: 13, 14, 33, 42, 40, and 41, respectively; (iii) SEQ ID NOs: 23, 14, 15, 42, 40, and 41, respectively; and (iv) SEQ ID NOs: 25, 14, 15, 42, 40, and 41, respectively; (b) a masking moiety attached to the EpCAM antibody or EpCAM-binding antibody fragment, wherein the masking moiety inhibits binding of the antibody or antibody fragment to EpCAM when the activatable antibody is in an uncleaved state; and (c) a cleavable moiety attached to an EpCAM antibody or EpCAM-binding antibody fragment, wherein the cleavable moiety is a polypeptide that functions as a substrate for a protease; an EpCAM-activatable antibody comprising:

[36] The EpCAM activatable antibody according to

[35] , wherein the activatable antibody comprises an EpCAM antibody or an EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 22, 14, 15, 42, 40, and 41, respectively;

[37] The EpCAM activatable antibody of

[36] , wherein the activatable antibody comprises an EpCAM antibody or an EpCAM-binding antibody fragment comprising a VH having the sequence of SEQ ID NO: 75 and a VL having the sequence of SEQ ID NO: 89;

[38] The EpCAM activatable antibody of

[37] , wherein the activatable antibody comprises an EpCAM antibody or an EpCAM-binding antibody fragment comprising a heavy chain having the sequence of SEQ ID NO: 125 and a light chain having the sequence of SEQ ID NO: 140;

[39] The EpCAM activatable antibody according to any one of

[36] to

[38] , wherein the activatable antibody comprises a masking portion having an amino acid sequence selected from SEQ ID NOs: 151 to 157 and 162 to 167;

[40] The EpCAM activatable antibody according to

[39] , wherein the activatable antibody comprises a masking moiety having an amino acid sequence selected from SEQ ID NOs: 162 to 167;

[41] The EpCAM activatable antibody according to any one of

[36] to

[40] , wherein the activatable antibody comprises a cleavable portion comprising the amino acid sequence of SEQ ID NO: 168 or 169;

[42] The EpCAM activatable antibody according to

[35] , wherein the activatable antibody comprises an EpCAM antibody or an EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 13, 14, 33, 42, 40, and 41, respectively;

[43] The EpCAM activatable antibody of

[42] , wherein the activatable antibody comprises an EpCAM antibody or an EpCAM-binding antibody fragment comprising a VH having the sequence of SEQ ID NO: 77 and a VL having the sequence of SEQ ID NO: 89;

[44] The EpCAM activatable antibody of

[43] , wherein the activatable antibody comprises an EpCAM antibody or an EpCAM-binding antibody fragment comprising a heavy chain having the sequence of SEQ ID NO: 127 and a light chain having the sequence of SEQ ID NO: 140;

[45] The EpCAM activatable antibody according to any one of

[42] to

[44] , wherein the activatable antibody comprises a masking portion having an amino acid sequence selected from SEQ ID NOs: 151 to 161;

[46] The EpCAM activatable antibody according to

[45] , wherein the activatable antibody comprises a masking moiety having an amino acid sequence selected from SEQ ID NOs: 158 to 161;

[47] The EpCAM activatable antibody according to any one of

[42] to

[46] , wherein the activatable antibody comprises a cleavable portion comprising the amino acid sequence of SEQ ID NO: 168 or 169;

[48] ​​A cell producing the antibody or EpCAM-binding antibody fragment according to any one of [1] to

[26] or the activatable antibody according to any one of

[27] to

[47] ;

[49] A method for producing an EpCAM antibody or an EpCAM-binding antibody fragment, or an EpCAM-activatable antibody, comprising: (a) culturing the cells described in

[48] ; and (b) isolating an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody from the cell or cell culture;

[50] The method according to

[49] , wherein the cells are eukaryotic cells;

[51] The method according to

[50] , wherein the cells are CHO cells;

[52] A diagnostic agent comprising the antibody or antibody fragment according to any one of [1] to

[26] , or the EpCAM activatable antibody according to any one of

[27] to

[47] ;

[53] The diagnostic agent according to

[52] , wherein the antibody, antibody fragment, or activatable antibody is labeled;

[54] The diagnostic agent according to

[53] , wherein the label is selected from a radiolabel, a fluorophore, a chromophore, a contrast agent, and a metal ion;

[55] A polynucleotide or a series of polynucleotides encoding the antibody or antibody fragment according to any one of [1] to

[26] , or the activatable antibody according to any one of

[27] to

[47] ;

[56] A vector or a series of vectors comprising the polynucleotide described in

[55] ;

[57] A host cell comprising the polynucleotide or series of polynucleotides described in

[55] or the vector described in

[56] ;

[58] The following formula: [ka] An immune complex represented by the formula: EpBA is a compound having a lysine residue linked to Cy L1 an EpCAM antibody, EpCAM antibody fragment, or EpCAM activatable antibody covalently linked to W L is an integer between 1 and 20, and Cy L1 is expressed as follows: [ka] or a pharmaceutically acceptable salt thereof, Double line between N and C [ka] is a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H or (C1-C4) alkyl, and when it is a single bond, X is -H or an amine protecting moiety and Y is -OH or -SO3H or a pharmaceutically acceptable salt thereof; W'-NR e’ and R e’ -(CH2-CH2-O) n -R k and n is an integer from 2 to 6, R k is -H or -Me, R x3 is (C1-C6) alkyl, L' is represented by the following formula: -NR5-PC(=O)-(CR a R b ) m -C(=O)-(B1'), or -NR5-PC(=O)-(CR a Rb ) m -SZ s1 -(B2'), R 5 is —H or (C1-C3) alkyl; P is an amino acid residue or a peptide containing 2 to 20 amino acid residues; R a and R b is independently at each occurrence -H, (C1-C3) alkyl, or a charged substituent or ionizable group Q; m is an integer from 1 to 6; Z s1 is the following formula: [ka] wherein q is an integer from 1 to 5;

[59] R a and R b the immunoconjugate according to

[58] , wherein both are H and R5 is H or Me;

[60] The immunoconjugate according to

[58] or

[59] , wherein P is a peptide containing 2 to 5 amino acid residues;

[61] P is Gly-Gly-Gly, Ala-Val, Val-Ala, Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe -Cit, Leu-Cit, Ile-Cit, Trp, Cit, Phe-Ala, Phe-N9-tosyl-Arg, Phe-N9-nitro-Arg, Phe-Phe -Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala-Leu-Ala -Leu (SEQ ID NO: 215), β-Ala-Leu-Ala-Leu (SEQ ID NO: 216), Gly-Phe-Leu-Gly (SEQ ID NO: 217), Val-Arg, Arg-V the immunoconjugate according to any one of

[58] to

[60] , wherein P is selected from Ala, Arg-Arg, Val-D-Cit, Val-D-Lys, Val-D-Arg, D-Val-Cit, D-Val-Lys, D-Val-Arg, D-Val-D-Cit, D-Val-D-Lys, D-Val-D-Arg, D-Arg-D-Arg, Ala-Ala, Ala-D-Ala, D-Ala-Ala, D-Ala-D-Ala, Ala-Met, Met-Ala, Gln-Val, Asn-Ala, Gln-Phe and Gln-Ala; in particular, P is Gly-Gly-Gly, Ala-Val, Ala-Ala, Ala-D-Ala, D-Ala-Ala, or D-Ala-D-Ala;

[62] The immunoconjugate of

[61] , wherein P is Gly-Gly-Gly, Ala-Val, Ala-Ala, Ala-D-Ala, D-Ala-Ala, or D-Ala-D-Ala;

[63] The immunoconjugate according to any one of

[58] to

[62] , wherein Q is —SO 3 H or a pharmaceutically acceptable salt thereof;

[64] The immune complex may have the formula: [ka] TIFF0007592009000006.tif205161TIFF0007592009000007.tif205161TIFF0007592009000008.tif193162TIFF0007592009000009.tif149161 or a pharmaceutically acceptable salt thereof, wherein: W L is an integer from 1 to 10; the double line between N and C [ka] is a single bond or a double bond, provided that when it is a double bond, X is absent and Y is -H; and when it is a single bond, X is -H and Y is -OH or -SO3H, or a pharmaceutically acceptable salt thereof;

[65] Double line between N and C [ka] the immunoconjugate according to any one of

[58] to

[64] , wherein: is a double bond, X is absent, and Y is -H;

[66] Double line between N and C [ka]

[0039] The immunoconjugate according to any one of

[58] to

[64] , wherein: is a single bond; X is -H; and Y is -SO3H or a pharmaceutically acceptable salt thereof;

[67] The immunoconjugate according to

[66] , wherein Y is -SO3H, -SO3Na, or -SO3K;

[68] The immunoconjugate according to

[66] , wherein Y is -SO3Na;

[69] The following formula: [ka] An immune complex represented by the formula: EpBA is a compound having a lysine residue linked to Cy L2an EpCAM antibody, EpCAM antibody fragment, or EpCAM activatable antibody covalently linked to W L is an integer between 1 and 20, Cy L2 is expressed as follows: [ka] where m' is 1 or 2; R1 and R2 are each independently H or (C1-C3) alkyl, and Z s1 is the following formula: [ka] wherein q is an integer from 1 to 5;

[70] The immunoconjugate according to

[69] , wherein m' is 1 and R1 and R2 are both H;

[71] The immunoconjugate according to

[69] , wherein m' is 2 and R1 and R2 are both Me;

[72] The immune complex has the formula: [ka] or a pharmaceutically acceptable salt thereof, W L the immune complex according to

[69] , wherein R is an integer of 1 to 10;

[73] The immune complex may have the formula: [ka] or a pharmaceutically acceptable salt thereof;

[74] The following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein: W L is an integer between 1 and 10, EpBA is an immune complex that is an EpCAM antibody, an EpCAM antibody fragment, or an EpCAM-activatable antibody comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 13-15, 42, 40, and 41, respectively;

[75] The immune complex of

[74] , wherein the isolated antibody or EpCAM-binding antibody fragment comprises a heavy chain variable region (VH) and a light chain variable region (VL) having the sequences of SEQ ID NO: 54 and SEQ ID NO: 89, respectively;

[76] The immunoconjugate of

[74] , wherein the isolated antibody comprises a heavy chain and a light chain having the sequences of SEQ ID NO: 103 and SEQ ID NO: 140, respectively;

[77] The immune complex according to any one of

[74] to

[76] , wherein the immune complex comprises an activatable antibody comprising a masking moiety having an amino acid sequence selected from SEQ ID NOs: 151 to 157;

[78] The immunoconjugate of

[77] , wherein the masking moiety has the amino acid sequence of SEQ ID NO: 155;

[79] The immunoconjugate of

[77] or

[78] , wherein the immunoconjugate comprises an activatable antibody further comprising a cleavable portion of SEQ ID NO: 168 or SEQ ID NO: 169;

[80] The following structural formula: [ka] and EpBA linked via a γ-maleimidobutyric acid N-succinimidyl ester (GMBS) or N-(γ-maleimidobutyryloxy) sulfosuccinimide ester (sulfo-GMBS or sGMBS) linker, wherein the EpBA is an EpCAM antibody, an EpCAM antibody fragment, or an EpCAM-activatable antibody according to any one of [1] to

[47] ;

[81] The immunoconjugate of

[80] , wherein the GMBS or sulfo-GMBS (or sGMBS) linker is represented by the following formula: [ka]

[82] The following formula: [ka] An immune complex represented by the formula: the immunoconjugate according to

[80] or

[81] , wherein EpBA is bound to the maytansinoid compound via the Lys amine group, and q is an integer of 1 to 10;

[83] The immune complex according to any one of

[80] to

[82] , wherein EpBA comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 13 to 15, 42, 40, and 41, respectively;

[84] The immune complex of

[83] , wherein EpBA comprises a heavy chain variable region (VH) and a light chain variable region (VL) having the sequences of SEQ ID NO: 54 and SEQ ID NO: 89, respectively;

[85] The immune complex of

[84] , wherein EpBA comprises a heavy chain and a light chain having the sequences of SEQ ID NO: 103 and SEQ ID NO: 140, respectively;

[86] The immune complex according to any one of

[83] to

[85] , wherein the immune complex comprises an activatable antibody comprising a masking moiety having an amino acid sequence selected from SEQ ID NOs: 151 to 157;

[87] The immunoconjugate of

[86] , wherein the masking moiety has the amino acid sequence of SEQ ID NO: 155;

[88] The immunoconjugate of

[86] or

[87] , wherein the immunoconjugate comprises an activatable antibody further comprising a cleavable portion of SEQ ID NO: 168 or SEQ ID NO: 169;

[89] The immunoconjugate according to any one of

[58] to

[88] , wherein the pharmaceutically acceptable salt is a sodium or potassium salt;

[90] A pharmaceutical composition comprising the antibody, antigen-binding fragment, or activatable antibody according to any one of [1] to

[47] and a pharmaceutically acceptable carrier;

[91] A pharmaceutical composition comprising the immunoconjugate according to any one of

[58] to

[88] and a pharmaceutically acceptable carrier;

[92] A method for killing cancer cells, comprising contacting cancer cells with an effective amount of the antibody, antigen-binding fragment, or activatable antibody described in any one of [1] to

[47] , the immunoconjugate described in any one of

[58] to

[88] , or the pharmaceutical composition described in

[90] or

[91] ;

[93] The method according to

[92] , wherein the cancer cells are epithelial cancer cells, breast cancer cells, lung cancer cells, gastric cancer cells, colorectal cancer cells, prostate cancer cells, ovarian cancer cells, colon cancer cells, rectal cancer cells or cancer stem cells;

[94] The method according to

[92] , wherein the cancer cells are ovarian cancer cells, uterine cancer cells, gastric cancer cells, pancreatic cancer cells, or colorectal cancer cells;

[95] A method for treating EpCAM-expressing cancer, comprising administering a therapeutically effective amount of the antibody or antigen-binding fragment described in any one of [1] to

[47] , the immunoconjugate described in any one of

[58] to

[88] , or the pharmaceutical composition described in

[90] or

[91] to a subject in need thereof;

[96] The method of treatment according to

[95] , wherein the cancer is epithelial cancer;

[97] The method of

[95] , wherein the cancer is breast cancer, lung cancer, stomach cancer, colorectal cancer, prostate cancer, ovarian cancer, colon cancer, esophageal cancer, tracheal cancer, gastric cancer, bladder cancer, uterine cancer, rectal cancer, small intestine cancer, or metastasis thereof;

[98] The method of treatment according to

[95] , wherein the cancer is ovarian cancer, uterine cancer, gastric cancer, pancreatic cancer, colorectal cancer, or metastasis thereof;

[99] The method of treatment according to

[97] , wherein the cancer is lung cancer;

[0100] The method for treating lung cancer according to

[99] , wherein the lung cancer is non-small cell lung cancer;

[0101] The method for treating non-small cell lung cancer according to

[0100] , wherein the non-small cell lung cancer is non-squamous non-small cell lung cancer;

[0102]

[95] The method of treatment according to

[95] , wherein the cancer is ovarian cancer;

[0103]

[95] The method of treatment according to

[95] , wherein the cancer is triple-negative breast cancer;

[0104]

[95] The method of treatment according to

[95] , wherein the cancer is colorectal cancer;

[0105]

[95] The method of treatment according to

[95] , wherein the cancer is esophageal cancer;

[0106] The method of treatment according to

[95] , wherein the cancer is gastric cancer;

[0107]

[95] The method of treatment according to

[95] , wherein the cancer is uterine cancer;

[0108]

[95] The method of treatment according to

[95] , wherein the cancer is pancreatic cancer;

[0109] an EpCAM antibody, EpCAM-binding antibody fragment, or immunoconjugate thereof, comprising (i) a heavy chain comprising an amino acid sequence identical to the amino acid sequence of the heavy chain encoded by the plasmid deposited with the ATCC® under the designation PTA-125343, and (ii) a light chain comprising an amino acid sequence identical to the amino acid sequence of the light chain variable region encoded by the plasmid deposited with the ATCC® under the designation PTA-125342;

[0110] an EpCAM-activatable antibody, EpCAM-binding activatable antibody fragment, or immunoconjugate thereof, comprising: (i) a heavy chain comprising an amino acid sequence identical to the amino acid sequence of the heavy chain encoded by the plasmid deposited with the ATCC® under the designation PTA-125343; and (ii) a light chain comprising an amino acid sequence identical to the amino acid sequence of the light chain variable region encoded by the plasmid deposited with the ATCC® under the designation PTA-125344; and / or

[0111] An EpCAM-activatable antibody, EpCAM-binding activatable antibody fragment, or immunoconjugate thereof comprising: (i) a heavy chain comprising an amino acid sequence identical to the amino acid sequence of the heavy chain encoded by the plasmid deposited with the ATCC (registered trademark) as PTA-125343; and (ii) a light chain comprising an amino acid sequence identical to the amino acid sequence of the light chain variable region encoded by the plasmid deposited with the ATCC (registered trademark) as PTA-125345. [Brief explanation of the drawings]

[0008] [Figure 1A-B] Binding curves of the mouse EpCAM antibody mEpCAM23 to HSC2 cells (FIG. 1A) and cynomolgus monkey epithelial cells (FIG. 1B) are shown. [Figure 2A-B] Figure 2 shows the sequence alignment between the variable regions of the original muEpCAM-23 light and heavy chain sequences and their closest human germline counterparts. Based on the alignment results, the human germline sequences selected as the acceptor frameworks for the VL and VH domains of the EpCAM-23 antibody were IGKV2D-29*02 (Figure 2A) and IGHV1-3*01 (Figure 2B), respectively. [Figure 3A-F] Binding curves of various humanized antibodies of mEpCAM23 are shown. In particular, Figure 3A shows the binding of mEpCAM23 to HSC2 cells, Figure 3B shows the binding of mEpCAM23 to primary cynomolgus monkey kidney epithelial cells, Figure 3C shows the binding of various humanized EpCAM23 antibodies to HSC2 cells, and Figure 3D shows the binding of various humanized EpCAM23 antibodies to primary cynomolgus monkey kidney epithelial cells. Figure 3E shows the binding of the site-specific modified antibody huEpCAM23Gv4.2-C442 to HSC2 cells, and Figure 3F shows the binding of the same antibody to primary cynomolgus monkey kidney epithelial cells. [Figure 4A-B] 4A and 4B show sequence alignments of the variable regions of the original murine EpCAM-23 antibody, grafted version Gv2.2, and grafted version Gv4.2. In particular, FIG. 4A shows the alignment of the variable regions of the antibody light chains, and FIG. 4B shows the alignment of the variable regions of the antibody heavy chains. [Figure 5A-N]Figure 5 shows the binding curves of various affinity variants of huEpCAM23Gv4.2 on HSC2 cells and primary cynomolgus monkey kidney epithelial cells. In particular, Figure 5A shows the binding of Gv4a.2, Gv4b.2, and Gv4c.2 to huEpCAM-mFc; Figure 5B shows the binding of Gv4a.2, Gv4b.2, and Gv4c.2 to cynoEpCAM-mFc; Figure 5C shows the binding of Gv4.2a, Gv4.2b, Gv4.2c, and Gv4.2d to huEpCAM-mFc; Figure 5D shows the binding of Gv4.2a, Gv4.2b, Gv4.2c, and Gv4.2d to cynoEpCAM-mFc; and Figure 5E shows the binding of Gv4a.2a, Gv4b.2a, and Gv4b.2a to cynoEpCAM-mFc. Figure 5F shows the binding of Gv4a.2a, Gv4b.2a, and Gv4c.2a to primary cynomolgus monkey kidney epithelial cells; Figure 5G shows the binding of Gv4a.2b, Gv4a.2d, Gv4b.2b, Gv4b.2d, Gv4c.2b, and Gv4c.2d to HSC2 cells; and Figure 5H shows the binding of Gv4a.2b, Gv4a.2d, Gv4b.2b, Gv4b.2d, Gv4c.2b, and Gv4c.2d to primary cynomolgus monkey kidney epithelial cells. Figure 5I shows the binding of Gv4.2H, Gv4.2K, Gv4.2L, Gv4.2O, Gv4.2P, Gv4.2Q, Gv4.2R, and Gv4.2S to HSC2 cells; Figure 5J shows the binding of 1361-D, 1361-H, 1361-I, and 1361-L to HSC2 cells; and Figure 5K shows the binding of 1565-A, 1565-F, 1565-G, 1565-S, 1565-T, 1565-V, and 1565-Y to HSC2 cells. Figure 5L shows the binding of Gv4.2H, Gv4.2K, Gv4.2L, Gv4.2O, Gv4.2P, Gv4.2Q, Gv4.2R, and Gv4.2S to primary cynomolgus monkey kidney epithelial cells; Figure 5M shows the binding of 1361-D, 1361-H, 1361-I, and 1361-L to primary cynomolgus monkey kidney epithelial cells; and Figure 5N shows the binding of 1565-A, 1565-F, 1565-G, 1565-S, 1565-T, 1565-V, and 1565-Y to primary cynomolgus monkey kidney epithelial cells. [Figure 6A-B]6A and 6B show the binding curves of untreated and uPA-activated huEpCAM23Gv4.2 activatable antibodies with various masks to HSC2 cells and primary cynomolgus monkey kidney epithelial cells. In particular, Figure 6A shows the binding of untreated and uPA-activated huEpCAM23 with substrate 3014 and masks Ep01-2, Ep02, Ep03, Ep04, Ep05, Ep07, and Ep11 to HSC2 cells, and Figure 6B shows the binding of untreated and uPA-activated huEpCAM23 with substrate 3014 and masks Ep02, Ep03, Ep04, Ep05, and Ep07 to primary cynomolgus monkey kidney epithelial cells. [Figure 7A-B] 7A and 7B show the binding curves of various uPA-treated activatable antibody-drug conjugates of huEpCAM23 to HSC2 cells. In particular, Figure 7A shows the binding of uPA-treated huEpCAM23Gv4.2-sSPDB-DM4 with substrate 3014 and masks Ep01-2, Ep02, Ep03, Ep04, Ep05, Ep07, and Ep11 to HSC2 cells, and Figure 7B shows the binding of uPA-activated huEpCAM23Gv4.2-lys-DGN549 with substrate 3014 and masks Ep01-2, Ep02, Ep03, Ep04, Ep05, Ep07, and Ep11 to HSC2 cells. [Figure 8A-D] Binding curves of various activatable antibody-drug conjugates with substrate 2014 or 3014 to HSC2 cells are shown. In particular, Figure 8A shows the binding of untreated and uPA-activated huEpCAM23Gv4.2-Ep05-2014-sSPDB-DM4 to HSC2 cells, Figure 8B shows the binding of untreated and uPA-activated huEpCAM23Gv4.2-Ep05-3014-sSPDB-DM4 to HSC2 cells, Figure 8C shows the binding of untreated and uPA-activated huEpCAM23Gv4.2-Ep05-3014-lys-DGN549 to HSC2 cells, and Figure 8D shows the binding of untreated and uPA-activated huEpCAM23Gv4.2-Ep05-3014-GMBS-DM21L and untreated and uPA-activated huEpCAM23Gv4.2-Ep05-2014-GMBS-DM21L to HSC2 cells. [Figure 9]1 shows an alignment of the extracellular domains of human EpCAM (SEQ ID NO: 1) and mouse EpCAM (SEQ ID NO: 210) after cleavage of the signal peptide. [Figure 10A-B] Figure 10A shows the alignment of the extracellular domains of human EpCAM (SEQ ID NO: 1), mouse EpCAM (SEQ ID NO: 210), and various chimeric EpCAM variants (SEQ ID NOs: 211-214). Figure 10A shows the alignment of amino acid residues 1-160, and Figure 10B shows the alignment of amino acid residues 161-243. [Figure 11] Binding curves of huEpCAM23Gv4.2 to the extracellular domains of human EpCAM and mouse EpCAM are shown. [Figures 12A-K] Dose-response curves of antibody-drug conjugates (ADCs) of huEpCAM23Gv4.2 in various cell lines are shown. In particular, Figures 12A-12E show the dose-response curves of huEpCAM23Gv4.2-sSPDB-DM4 in H1568 cells (Figure 12A), H292 cells (Figure 12B), H2110 cells (Figure 12C), LoVo cells (Figure 12D), and Detroit562 cells (Figure 12E). Figure 12F shows the dose-response curves of huEpCAM23Gv4.2-lys-DGN549 and huEpCAM23Gv4.2-C442-DGN549 in H2110 cells. Figures 12G-12K show the dose-response curves of huEpCAM23Gv4.2-GMBS-DM21L in Calu3 cells (Figure 12G), Detroit562 cells (Figure 12H), EBC-1 cells (Figure 12I), H2110 cells (Figure 12J), and H441 cells (Figure 12K). [Figures 13A-D] Dose-response curves of untreated and uPA-activated activatable antibody-drug conjugate (AADC) huEpCAM23Gv4.2-sSPDB-DM4 in various cell lines are shown. In particular, dose-response curves of untreated and uPA-activated huEpCAM23Gv4.2-Ep05-2014-sSPDB-DM4 and untreated and uPA-activated huEpCAM23Gv4.2-Ep05-3014-sSPDB-DM4 are shown for Calu3 cells (Figure 13A), OV90 cells (Figure 13B), EBC-1 cells (Figure 13C), and H2110 cells (Figure 13D). [Figure 14A-D] 14A and 14B show dose-response curves of untreated and uPA-activated AADC of huEpCAM23Gv4.2-GMBS-DM21L in various cell lines. In particular, dose-response curves of untreated and uPA-activated huEpCAM23Gv4.2-Ep05-2014-GMBS-DM21L and untreated and uPA-activated huEpCAM23Gv4.2-Ep05-3014-GMBS-DM21L are shown for Calu3 cells (FIG. 14A), Detroit562 cells (FIG. 14B), EBC-1 cells (FIG. 14C), and H2110 cells (FIG. 14D). [Figure 15A-D] Dose-response curves of untreated and uPA-activated AADC of huEpCAM23-lys-DGN549 in various cell lines are shown. In particular, dose-response curves of untreated and uPA-activated huEpCAM23Gv4.2-Ep05-3014-lys-DGN549 are shown for H2110 cells (FIG. 15A), EBC-1 cells (FIG. 15B), Calu3 cells (FIG. 15C), and OV90 cells (FIG. 15D). [Figure 16] 1 shows the antitumor activity of huEpCAM23Gv4.2-lys-DGN549 in an H2110 non-small cell lung cancer xenograft model. [Figures 17A-F]Figure 17 shows the antitumor activity of various AADCs of huEpCAM23Gv4.2 in an H2110 non-small cell lung cancer xenograft model. In particular, Figure 17A shows the antitumor activity of huEpCAM23-Lys-DGN549 with masks Ep02, Ep01, Ep11, and Ep04, Figure 17B shows the antitumor activity of huEpCAM23-Lys-DGN549 with masks Ep03, Ep05, Ep07, and Ep04, and Figure 17C shows the antitumor activity of huEpCAM23-Ep05-3014-lys-DGN549 and huEpCAM23-Ep07-3014-lys-DGN549 compared to the non-cleavable complexes. Figure 17D shows the antitumor activity of huEpCAM23Gv4.2-Ep01-02-2014-sSPDB-DM4 compared to the non-cleavable conjugate and ADC huEpCAM23Gv4.2-sSPDB-DM4, Figure 17E shows the antitumor activity of huEpCAM23Gv4.2-Ep05-2014-sSPDB-DM4 and huEpCAM23Gv4.2-Ep05-3014-sSPDB-DM4 compared to the non-cleavable conjugate, and Figure 17F shows the antitumor activity of huEpCAM23Gv4.2-Ep05-2014-lys-DGN549 and huEpCAM23Gv4.2-Ep05-3014-lys-DGN549 compared to the non-cleavable conjugate. [Figure 18] 1 shows the antitumor activity of various AADCs of huEpCAM23Gv4.2-sSPDB-DM4 in a Calu3 non-small cell lung cancer xenograft model. [Figure 19] 1 shows the antitumor activity of various AADCs of huEpCAM23Gv4.2-sSPDB-DM4 in an H292 non-small cell lung cancer xenograft model. [Figure 20] 1 shows the antitumor activity of Ep05-3014-DM4, Ep05-2014-DM4, Ep05-3014-DM21, and Ep05-2014-DM21 in CB-17 SCID mice bearing Detroit 562 HNSCC xenografts. [Figure 21] 1 shows the antitumor activity of Ep05-3014-DM21 and Ep05-2014-DM21 in CB-17 SCID mice bearing NCI-H441 NSCLC xenografts. [Figure 22] 1 shows the antitumor activity of Ep05-2014-DM21 in OV-90EOC xenograft-bearing CB-17 SCID mice. [Figure 23] 1 shows the antitumor activity of Ep05-2014-DM21 in CB-17 SCID mice bearing Calu-3 NSCLC xenografts. [Figure 24] 1 shows the tolerability of EpCAM-targeted ADC (huEpCAM23Gv4.2-sSPDB-DM4 (anti-EpCAM-DM4)) and EpCAM-targeted AADC (huEpCAM23Gv4.2-Ep05-2014-sSPDB-DM4 (M05-2014-DM4)) and huEpCAM23Gv4.2-Ep05-3014-sSPDB-DM4 (M05-3014-DM4)) in cynomolgus monkeys. [Figure 25A-E]

[0029] Figure 25 shows blood biochemistry tests of cynomolgus monkeys administered EpCAM-targeted ADC (huEpCAM23Gv4.2-sSPDB-DM4) or EpCAM-targeted AADC (huEpCAM23Gv4.2-Ep05-2014-sSPDB-DM4). In particular, Figure 25A shows the A / G ratio, Figure 25B shows the urea nitrogen concentration, Figure 25C shows the creatinine concentration, Figure 25D shows the lipase concentration, and Figure 25E shows the amylase concentration. [Figure 26] Pharmacokinetic profiles of cynomolgus monkeys receiving 8 mg / kg of EpCAM-targeted ADC (huEpCAM23Gv4.2-sSPDB-DM4 (anti-EpCAM-DM4 ADC)) or 8 mg / kg of EpCAM-targeted AADC (huEpCAM23Gv4.2-Ep05-2014-sSPDB-DM4 (M05-2014-DM4 AADC)), or huEpCAM23Gv4.2-Ep05-3014-sSPDB-DM4 (M05-3014-DM4 AADC)). [Figure 27] 1 shows the tolerability of huEpCAM23Gv4.2-Ep05-2014-DM21L (Ep05-2014-DM21L) and huEpCAM23Gv4.2-Ep05-3014-DM21L (Ep05-3014-DM21L) in cynomolgus monkeys. [Figure 28A-E]28A shows blood biochemistry tests of cynomolgus monkeys administered 12 mg / kg of huEpCAM23Gv4.2-Ep05-2014-DM21L (Ep05-2014-DM21L) and huEpCAM23Gv4.2-Ep05-3014-DM21L (Ep05-3014-DM21L). In particular, FIG. 28A shows the A / G ratio, FIG. 28B shows the urea nitrogen concentration, FIG. 28C shows the creatinine concentration, FIG. 28D shows the lipase concentration, and FIG. 28E shows the amylase concentration. [Figure 29] Pharmacokinetic profile of cynomolgus monkeys receiving 12 mg / kg of huEpCAM23Gv4.2-Ep05-2014-DM21L (Ep05-2014-DM21). [Figure 30] 1 shows an expanded analysis of EpCAM expression in indication-specific tissue microarrays. DETAILED DESCRIPTION OF THE INVENTION

[0009] The present disclosure provides antibodies and antigen-binding antibody fragments that specifically bind to human EpCAM, including activatable antibodies (activatable EpCAM antibodies or EpCAM-binding antibody fragments), as well as immunoconjugates comprising the antibodies, antibody fragments, and activatable antibodies. EpCAM is known to be involved in epithelial cell-cell adhesion and to play a role in intracellular signaling, differentiation, proliferation, and migration. Overexpression of EpCAM has been linked to the pathogenesis of diseases and disorders such as cancer. For example, EpCAM is highly expressed in various cancer types, such as breast cancer, lung cancer, liver cancer, gastric cancer, head and neck cancer, prostate cancer, pancreatic cancer, ovarian cancer, colon cancer, and kidney cancer, as well as most cancers (and metastases) of epithelial origin. EpCAM is also highly expressed in tumor-initiating cells / cancer stem cells. The provided EpCAM antibodies, EpCAM-binding antibody fragments, EpCAM-activatable antibodies, and immunoconjugates have uses, including the treatment of such diseases and cancers.

[0010] definition For ease of understanding, a number of terms and phrases are defined below. As used herein, the term "epithelial cell adhesion molecule" or "EpCAM" refers to any native human EpCAM unless otherwise indicated. The term also encompasses naturally occurring variants of EpCAM, such as splice variants, allelic variants, and isoforms. EpCAM polypeptides can be isolated from various sources, such as human or cynomolgus monkey tissue or other biological samples. EpCAM is also known as CD326, 17-1A antigen, HEA125, MK-1, EGP-2, EGP314, EGP40, GA733-2, KSA, TACSTD1, TROP1, KS1 / 4, M4S1, DIAR5, MIC18, HNPCC8, and ESA. Examples of EpCAM sequences include, but are not limited to, NCBI Reference No. NP_002345.2 (amino acid residues 24-314 corresponding to mature EpCAM, amino acids 24-265 corresponding to the extracellular region of mature EpCAM (SEQ ID NO: 1)). The extracellular region of mature EpCAM can be further divided into three domains: D1 (amino acids 1 to 36 of SEQ ID NO:1 (SEQ ID NO:2)), D2 (amino acids 43 to 112 of SEQ ID NO:1 (SEQ ID NO:3)), and D3 (amino acids 113 to 243 of SEQ ID NO:1 (SEQ ID NO:4)).

[0011] As used herein, "antibody," "antigen-binding antibody fragment," and the like include any protein- or peptide-containing molecule comprising at least a portion of an immunoglobulin molecule, such as, but not limited to, at least one complementarity-determining region (CDR) of a heavy or light chain, or an antigen-binding portion thereof. Such antibodies optionally further affect at least one EpCAM activity, for example, but not limited to, such antibodies modulate, reduce, increase, antagonize, stimulate, partially stimulate, partially antagonize, reduce, moderate, block, inhibit, suppress, and / or interfere with at least one EpCAM activity or binding in vitro, in situ, in vivo, and / or ex vivo. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment affects at least one EpCAM-mediated activity or function selected from ligand binding, receptor signaling, membrane binding, cell migration, cell proliferation, receptor-binding activity, RNA, DNA, or protein production and / or synthesis.

[0012] Antibodies are heterotetrameric glycoproteins composed of two identical light chains (LC) and two identical heavy chains (HC). Generally, each light chain is linked to a heavy chain by one covalent disulfide bond, although the number of disulfide bonds varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has spaced intrachain disulfide bridges. Each heavy chain has a variable domain (VH) at one end followed by several constant domains. Each light chain has a variable region (VL) at one end and a constant region at the other end. The constant region of the light chain aligns with the first constant region of the heavy chain, and the variable region of the light chain aligns with the variable region of the heavy chain. Antibody light chains of any vertebrate species can be assigned to one of two distinct types, kappa and lambda, based on the amino acid sequence of their constant regions. Immunoglobulins can be divided into five major classes, IgA, IgD, IgE, IgG, and IgM, depending on the amino acid sequence of the constant region of the heavy chains. IgA and IgG are further subdivided into isotypes: IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4.

[0013] The term "antibody" also includes fragments, specified portions, and variants thereof, including antibody mimetics, or portions of antibodies or specified fragments or portions thereof that mimic the structure and / or function of antibodies, including single-chain antibodies and antigen (e.g., EpCAM)-binding antibody fragments. Functional fragments include antigen-binding fragments that bind to mammalian antigens such as EpCAM, either alone or in combination with other antigens. For example, antibody fragments capable of binding to antigens or portions thereof, including, but not limited to, Fab (e.g., by papain digestion), Fab' (e.g., by pepsin digestion and partial reduction), and F(ab')2 (e.g., by pepsin digestion), facb (e.g., by plasmin digestion), pFc' (e.g., by pepsin or plasmin digestion), Fd (e.g., by pepsin digestion, partial reduction, and reassembly), Fv, or scFv (e.g., by molecular biology techniques) fragments, are included in the present invention (see, e.g., Colligan, Immunology).

[0014] Such fragments can be produced by enzymatic cleavage, synthetic, or recombinant techniques known in the art and / or disclosed herein. Antibodies can also be produced in various truncated forms using antibody genes in which one or more stop codons have been introduced upstream of the natural stop site. For example, a combination gene encoding a F(ab')2 heavy chain portion can be engineered to include DNA sequences encoding the CH1 domain and / or hinge region of the heavy chain. Various portions of the antibody can be linked chemically by conventional techniques, or prepared as a contiguous protein using genetic engineering techniques.

[0015] The term "antibody fragment" refers to a portion of an intact antibody, usually the antigen-binding or variable region of the intact antibody. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab'), single-chain (scFv) and Fv fragments, diabodies, linear antibodies, single-chain antibody molecules, single Fab arm "one-arm" antibodies, and multispecific antibodies formed from antibody fragments, among others.

[0016] Antibody fragments include any protein- or peptide-containing molecule that includes at least a portion of an immunoglobulin molecule, such as, but not limited to, at least one heavy or light chain complementarity determining region (CDR) or ligand-binding portion thereof, a heavy or light chain variable region, a heavy or light chain constant region, a framework region or any portion thereof, or at least a portion of an antigen or antigen receptor or binding protein, that can be incorporated into the EpCAM antibodies provided herein.

[0017] The term "variable" refers to the fact that the sequences of certain portions of antibody variable regions vary extensively among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, variability is not uniformly distributed throughout the variable regions of antibodies. Variability is concentrated in three segments called complementarity-determining regions (CDRs) or hypervariable regions in both the light and heavy chain variable regions. The more highly conserved portions of the variable regions are called framework regions (FRs). Natural heavy and light chain variable regions each contain four FR regions, primarily in a β-sheet configuration, connecting three CDRs, which form loops that connect, and in some instances, form part of, the β-sheet structure. The CDRs of each chain, along with those from other chains, are held in close proximity by the FR regions and contribute to the formation of the antibody's target binding site. The constant regions are not directly involved in binding an antibody to an antigen but exhibit various effector functions, such as the participation of antibodies in antibody-dependent cellular cytotoxicity. There are at least two techniques for determining CDRs: (1) an approach based on interspecies sequence variability (i.e., Kabat et al., Sequences of Proteins of Immunological Interest, (5th ed., 1991, National Institutes of Health, Bethesda, Md.)), and (2) an approach based on crystallographic investigation of antigen-antibody complexes (Al-lazikani et al., J. Molec. Biol. 273:927-948 (1997)). In addition, a combination of these two approaches may be used to determine CDRs in the art.

[0018] When referring to residues in the variable region (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain), the Kabat numbering system is typically used (e.g., Kabat et al., Sequences of Immunological Interest. 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)).

[0019] Amino acid position numbering as in Kabat refers to the numbering system used for the heavy or light chain variable regions of the compilation of antibodies in Kabat et al., Sequences of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991). Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, the FRs or CDRs of the variable region. For example, a heavy chain variable region may contain a single amino acid insertion after residue 52 of H2 (residue 52a according to Kabat) and inserted residues after heavy chain FR residue 82 (e.g., residues 82a, 82b, and 82c according to Kabat, etc.). The Kabat numbering of residues can be determined by alignment of a given antibody with the "standard" Kabat numbered sequence at regions of homology in the antibody sequence. Chothia instead relies on the position of the structural loops (Chothia et al., J. Mol. Biol. 196:901-917 (1987)). The end of the Chothia CDR-H1 loop, when numbered using the Kabat numbering convention, varies between H32 and H34, depending on the length of the loop (this is because the Kabat numbering scheme places insertions at H35A and H35B; if both 35A and 35B are absent, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34). The AbM hypervariable regions are a compromise between the Kabat CDRs and the Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software.

[0020] The terms "EpCAM antibody," "EpCAM antibody," "antibody that specifically binds EpCAM," "EpCAM-binding antibody fragment," and "antibody fragment that specifically binds EpCAM" refer to an antibody that can bind to EpCAM with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent that targets EpCAM. The magnitude of binding of the EpCAM antibody to an unrelated, non-EpCAM protein is less than about 10% of the binding of the antibody to EpCAM, as measured, for example, by radioimmunoassay (RIA). [Table 1]

[0021] The term "epitope" refers to a protein determinant capable of specific binding to an antibody. Epitopes usually consist of chemically active surface groupings of molecules, such as amino acids or sugar side chains, and usually have specific three-dimensional structural characteristics and specific charge characteristics. When the antigen is a polypeptide, epitopes can be formed from both contiguous and noncontiguous amino acids juxtaposed by tertiary folding of the protein. Epitopes formed from contiguous amino acids are usually retained upon protein denaturation, whereas epitopes formed by tertiary folding are usually lost upon protein denaturation. Epitopes usually include at least three amino acids, more usually at least five or eight to ten amino acids, in a unique spatial conformation.

[0022] A "blocking" antibody is an antibody that inhibits or reduces the biological activity of an antigen, such as EpCAM, to which it binds. Preferred blocking antibodies substantially or completely inhibit the biological activity of the antigen. Desirably, the biological activity is reduced by 10%, 20%, 30%, 50%, 70%, 80%, 90%, 95%, or even 100%. In one embodiment, a blocking antibody reduces EpCAM-associated tyrosine kinase activity by 10%, 20%, 30%, 50%, 70%, 80%, 90%, 95%, or even 100%.

[0023] An "isolated" antibody is one that has been separated and / or recovered from its natural environment. Contaminant components of that natural environment are substances that would interfere with diagnostic or therapeutic uses of the antibody and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody is purified (1) to greater than 95% by weight of the antibody, and most preferably to greater than 99% by weight, as determined, for example, by the Lowry method; (2) to at least the N-terminal 15 residues or sufficient to obtain internal amino acid sequence using a spinning cup sequencing instrument; or (3) to homogeneity by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) under reducing or nonreducing conditions with Coomassie blue or, preferably, silver staining. Isolated antibody includes EpCAM antibodies in situ within recombinant cells, since at least one component of the antibody's natural environment will likely be absent. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

[0024] "Human antibody" refers to an antibody produced by a human or an antibody having an amino acid sequence corresponding to an antibody produced by a human, generated by any technique known in the art. This definition of a human antibody includes intact or full-length antibodies, activatable antibodies, antigen (e.g., human or cynomolgus EpCAM)-binding antibody fragments, and / or at least one human heavy and / or light chain polypeptide antibody, such as an antibody comprising a mouse light chain and a human heavy chain polypeptide.

[0025] As used herein, the term "chimeric antibody" refers to an antibody in which the sequences of the immunoglobulin molecules are derived from two or more species. Typically, the variable regions of both the light and heavy chains correspond to the variable regions from one species of mammal (e.g., mouse, rat, rabbit, etc.) having the desired specificity, affinity, and capacity, while the constant regions are homologous to antibody sequences from another species (usually human) to avoid eliciting an immune response in that species.

[0026] As used herein, the term "humanized antibody" refers to a form of a non-human (e.g., murine) antibody that is a specific immunoglobulin chain, chimeric immunoglobulin, or antigen-binding antibody fragment containing minimal non-human (e.g., murine) sequence. Typically, humanized antibodies are human immunoglobulins in which residues from the complementarity-determining regions (CDRs) are replaced with residues from CDRs of non-human species (e.g., mouse, rat, rabbit, hamster) having the desired specificity, affinity, and capacity (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science 239:1534-1536 (1988)). In some cases, Fv framework region (FR) residues of a human immunoglobulin are replaced with corresponding residues in an antibody from a non-human species having the desired specificity, affinity, and capacity. Humanized antibodies can be further modified by substituting additional residues in the Fv framework regions and / or within the substituted non-human residues to improve and optimize antibody specificity, affinity, and / or capacity. Generally, the antibody contains substantially all, at least one, usually two or three, variable regions, including all or substantially all, of the CDR regions corresponding to a non-human immunoglobulin, while all or substantially all of the FR regions are of human immunoglobulin consensus sequences. The antibody can also contain at least a portion of an immunoglobulin constant region or domain (Fc), typically the Fc of a human immunoglobulin. Examples of methods used to generate humanized antibodies are described in U.S. Patent No. 5,225,539.

[0027] Antibody "effector functions" refer to the biological activities attributable to the Fc region of an antibody (a native-sequence Fc region or an amino acid sequence variant Fc region) and vary depending on the antibody isotype. Examples of antibody effector functions include C1q binding and complement-dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).

[0028] "Human effector cells" are leukocytes that express one or more FcRs and perform effector functions. In certain embodiments, the cells express at least FcγRIII and perform ADCC or ADCP effector functions. Examples of human leukocytes that mediate ADCC or ADCP include peripheral blood mononuclear cells (PBMCs), natural killer (NK) cells, monocytes, cytotoxic T cells, and neutrophils. Effector cells can be isolated from natural sources, such as blood.

[0029] As used herein, the term "Fc region" includes the polypeptides containing the constant region of an antibody, excluding the first constant region immunoglobulin domain. Thus, Fc refers to the last two constant region immunoglobulin domains of IgA, IgD, and IgG, and the last three constant region immunoglobulin domains of IgE and IgM, as well as the flexible hinge N-terminal to these domains. For IgA and IgM, Fc may include the J chain. For IgG, Fc includes immunoglobulin domains Cγ2 and Cγ3 (Cγ2 and Cγ3) and the hinge between Cγ1 (Cγ1) and Cγ2 (Cγ2). Although the boundaries of the Fc region may vary, the human IgG heavy chain Fc region is usually defined to include residues C226 or P230 at its carboxyl terminus, with numbering according to the EU index set forth in Kabat et al. (1991, NIH Publication 91-3242, National Technical Information Service, Springfield, Va.). The "EU index as set forth in Kabat" refers to the residue numbering of the human IgG1 EU antibody set forth in Kabat et al., supra. Fc can refer to this region alone, or to this region in the context of an antibody, antibody fragment, or Fc fusion protein. An Fc variant protein can be an antibody, an Fc fusion, or any protein or protein domain comprising an Fc region. Particularly preferred are proteins comprising variant Fc regions, which are non-naturally occurring variants of Fc. Polymorphisms have been observed at a number of different Fc positions, including but not limited to Kabat 270, 272, 312, 315, 356, and 358; therefore, slight differences may exist between the presented sequence and prior art sequences, which will be understood by those of skill in the art based on the present teachings.

[0030] As used herein, the terms "conjugate," "immunoconjugate," "ADC," or "AADC" refer to a compound or derivative thereof linked to a cell-binding agent (i.e., an EpCAM antibody, an EpCAM-binding antibody fragment, or an EpCAM-activatable antibody), and are defined by the general formula: CLA, where C = compound, L = linker, and A = EpCAM-binding agent (EpBA) (e.g., an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody disclosed herein). In some embodiments, the general formula: DLA, where D = drug, L = linker, and A = cell-binding agent (e.g., an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody) can also be used.

[0031] A "linker" is any chemical moiety capable of stably and covalently linking a compound, typically a drug such as a maytansinoid or indolinobenzodiazepine compound, to a cell-binding agent, e.g., an anti-EpCAM antibody or an EpCAM-binding antibody fragment. The linker may be susceptible to or substantially resistant to acid-induced cleavage, photo-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage, and disulfide bond cleavage under conditions under which the compound or antibody remains active. Suitable linkers are well known in the art and include, for example, disulfide groups, thioether groups, acid-labile groups, photolabile groups, peptidase-labile groups, and esterase-labile groups. Linkers also include peptide linkers and charged linkers disclosed herein and known in the art, and hydrophilic versions thereof.

[0032] As used herein, unless otherwise indicated, "abnormal cell growth" refers to cell growth independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes, for example, the abnormal growth of: (1) tumor cells (tumors) that grow due to expression of mutant tyrosine kinases or overexpression of receptor tyrosine kinases; (2) benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation occurs; (3) any tumor that grows due to receptor tyrosine kinases; (4) any tumor that grows due to aberrant serine / threonine kinase activation; (5) benign and malignant cells of other proliferative diseases in which aberrant serine / threonine kinase activation occurs; and (6) benign and malignant cells of other proliferative diseases.

[0033] The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. A "tumor" contains one or more cancerous cells. Examples of cancer include, but are not limited to, carcinoma, blastoma, sarcoma, myeloma, leukemia, or lymphoid malignancies. As defined herein, the term "cancer" or "cancerous" includes "precancerous" conditions that may become cancerous if untreated. In certain embodiments, the cancer is an epithelial cancer. Examples of epithelial cancers include breast cancer, lung cancer, liver cancer, gastric cancer, head and neck cancer, prostate cancer, pancreatic cancer, ovarian cancer, colon cancer, and kidney cancer. Additional cancers that can be diagnosed or treated with the provided EpCAM antibodies, EpCAM-binding antibody fragments, EpCAM-activatable antibodies, or immunoconjugates include esophageal cancer, tracheal cancer, brain cancer, carcinoma, cholangiocarcinoma, endometrial cancer, cervical cancer, gastric cancer, bladder cancer, uterine cancer, testicular cancer, rectal cancer, skin cancer (melanoma), small intestine cancer, bladder cancer, bile duct cancer, and salivary gland cancer. In some embodiments, the cancer is ovarian cancer, uterine cancer, gastric cancer, pancreatic cancer, or colorectal cancer.

[0034] The terms "cancer cells," "tumor cells," and grammatical equivalents refer to the entire population of cells derived from a tumor or precancerous lesion, and include both non-tumorigenic cells, which comprise the majority of tumor cells, and tumorigenic stem cells (cancer stem cells).

[0035] As used herein, the term "cytotoxic agent" means a substance that inhibits or prevents one or more cellular functions and / or causes cell death.

[0036] As used herein, "treatment" refers to clinical intervention to alter the natural course of an individual or treated cell, and can be performed for prophylaxis or during the course of clinical pathology. The intended effect of treatment includes preventing the onset or recurrence of disease, alleviating symptoms, reducing any direct or indirect pathological consequences of disease, preventing metastasis, slowing the rate of disease progression, ameliorating or remission of disease state, and improving remission or prognosis. In some embodiments, the methods and compositions provided herein are useful for delaying the onset of a disease or disorder.

[0037] The terms "treating," or "treatment," or "treat," or "palliative," or "alleviating," and the like, refer to 1) therapeutic measures that cure, delay, lessen the symptoms, and / or halt the progression of a diagnosed condition or disorder, and 2) prophylactic or preventative measures that prevent and / or slow the onset of the targeted condition or disorder. Thus, a subject in need of treatment includes a subject already with the disorder, a subject prone to having the disorder, or a subject in whom the disorder is to be prevented. In certain embodiments, a subject is successfully "treated" for cancer by the methods provided herein if the patient exhibits one or more of the following: a reduction in the number or complete absence of cancer cells; a reduction in tumor size; a suppression or absence of cancer cell invasion into surrounding organs, such as the spread of cancer into soft tissue and bone; a suppression or absence of tumor metastasis; a suppression or absence of tumor growth; a reduction in one or more symptoms associated with a particular cancer; a reduction in morbidity and mortality; an improvement in quality of life; a reduction in the tumorigenicity, tumorigenic frequency, or tumorigenic capacity of the tumor; a reduction in the number or frequency of cancer stem cells in the tumor, differentiation of tumorigenic cells to a non-tumorigenic state; or some combination of effects.

[0038] An "effective amount" of an antibody disclosed herein is an amount sufficient to carry out a specifically stated purpose. A "therapeutically effective amount" means an amount effective, at the necessary dosage and for the necessary period of time, to achieve a desired therapeutic result. A "therapeutically effective amount" of a therapeutic agent (e.g., a conjugate or immunoconjugate) may vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody to elicit a desired individual response. A therapeutically effective amount is also an amount in which any toxic or detrimental effects of the therapeutic agent are outweighed by the therapeutically beneficial effects.

[0039] "Therapeutic agent" encompasses both biologics such as antibodies, peptides, proteins, enzymes, chemotherapeutic agents, or conjugates or immunoconjugates.

[0040] The terms "subject," "individual," "animal," "patient," and "mammal" refer to any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or treatment is desired. Mammalian subjects include, but are not limited to, humans, non-human primates, domestic animals, livestock, rodents, and the like, which can be recipients of a particular treatment.

[0041] The terms "polynucleotide" and "nucleic acid," used interchangeably herein, refer to a polymer of nucleotides of any length, including DNA and RNA. Nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or their analogs, any substrate that can be incorporated into a polymer by DNA or RNA polymerase. Polynucleotides can contain modified nucleotides, such as methylated nucleotides and their analogs. If present, modifications to the nucleotide structure can be imparted before or after assembly of the polymer. The sequence of nucleotides can be interrupted by non-nucleotide components. Polynucleotides can be further modified after polymerization, such as by the attachment of a labeling component. Other types of modifications include, for example, "caps," substitution of one or more natural nucleotides with analogs, intranucleotide modifications such as those with uncharged linkages (e.g., methylphosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those containing pendants such as proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, metal oxides, etc.), those containing alkylators, those with modified linkages (e.g., α-anomeric nucleic acids, etc.), and unmodified forms of polynucleotides. Additionally, any hydroxyl groups normally present in the sugar can be replaced with, for example, phosphonate groups, phosphate groups, protected with standard protecting groups, or activated to create additional linkages to additional nucleotides or to attach to solid supports. The 5' and 3' terminal OH groups can be phosphorylated or substituted with amines or organic capping group moieties of from about 1 to about 20 carbon atoms. Other hydroxyl groups can also be derivatized to standard protecting groups.Polynucleotides can also contain analogous forms of ribose or deoxyribose sugars commonly known in the art, including, for example, 2'-O-methyl-, 2'-O-allyl, 2'-fluoro-, or 2'-azido ribose, carbocyclic sugar analogs, alpha anomeric sugars, epimeric sugars, e.g., arabinose, xylose, lyxose, pyranose sugars, furanose sugars, sedopeptulose, acyclic analogs, and abasic nucleoside analogs such as methyl riboside. One or more phosphodiester linkages can be replaced by alternative linking groups. These alternative linking groups include, but are not limited to, embodiments in which phosphate is replaced by P(O)S ("thioate"), P(S)S ("dithioate"), (O)NR2 ("amidate"), P(O)R, P(O)OR', CO, or CH2 ("formacetal"), where each R or R' is independently H or unsubstituted alkyl (1-20C) optionally containing a substituted or ether (-O-) linkage, aryl, alkenyl, cycloalkyl, cycloalkenyl, or araldyl. Not all linkages in a polynucleotide need be the same. The foregoing statement applies to all polynucleotides referred to herein, including RNA and DNA.

[0042] The term "vector" refers to a construct that can deliver and optionally express one or more target genes or sequences into a host cell. Examples of vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmids, cosmids or phage vectors, DNA or RNA expression vectors bound to cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells such as producer cells.

[0043] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. A polymer can be linear or branched, it can contain modified amino acids, and it can be interrupted by non-amino acids. The term also encompasses amino acid polymers that are modified naturally or by intervention, for example, by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or conjugation with a labeling moiety. Also included in the definition are polypeptides containing, for example, one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art.

[0044] As known in the art, the term "identical" refers to a measure of the relationship between two polynucleotides or two polypeptides, as determined by comparing their sequences. Sequence identity or similarity is defined as the percentage of amino acid residues in a candidate sequence that are identical (i.e., the same residues) or similar (i.e., amino acid residues from the same group based on common side chain properties, see below) to EpCAM antibody residues, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent identity for the overall sequence. Neither N-terminal, C-terminal, nor internal extensions, deletions, nor insertions into the antibody sequence outside the variable region should be construed as affecting sequence identity or similarity. Generally, the two sequences being compared are aligned to maximize the correlation between the sequences. The alignment of the two sequences is examined, and the number of positions that give exact amino acid nucleotide correspondences between the two sequences is determined; this is divided by the total length of the alignment; and multiplied by 100 to obtain a percent identity figure. This percent identity figure can be determined over the entire length of the sequences being compared, which is particularly appropriate for highly homologous sequences of the same or very similar length, or over a shorter, fixed length, which is more appropriate for sequences of unequal lengths or with lower levels of homology. Similarly, percent similarity can be determined in a similar manner based on the presence of identical and similar residues.

[0045] Percent identity can be measured using sequence comparison software or algorithms or visual inspection. Various algorithms and software are known in the art and can be used to align amino acid or nucleotide sequences. One such non-limiting example of a sequence alignment algorithm is the algorithm described in Karlin et al., Proc. Natl. Acad. Sci. 87:2264-2268 (1990) and modified in Karlin et al., Proc. Natl. Acad. Sci. 90:5873-5877 (1993), which was incorporated into the NBLAST and XBLAST programs (Altschul et al., Nucleic Acids Res., 25:3389-3402 (1991)). In certain embodiments, gapped BLAST can be used as described in Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997). BLAST-2, WU-BLAST-2 (Altschul et al., Meth. Enzym. 266:460-480 (1996)), ALIGN, ALIGN-2 (Genentech, South San Francisco, California), or Megalign (DNASTAR®) are additional publicly available software programs that can be used to align sequences. In certain embodiments, the percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software (e.g., using the NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 90 and a length weight of 1, 2, 3, 4, 5, or 6). In certain alternative embodiments, the GAP program in the GCG software package, which incorporates the algorithm of Needleman and Wunsch (J. Mol. Biol. (48): 444-453 (1970)), can be used to determine the percent identity between two amino acid sequences (e.g., using a Blossum 62 matrix or a PAM250 matrix and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, or 5).Alternatively, in certain embodiments, percent identity between nucleotide or amino acid sequences can be determined using the algorithm of Myers and Miller (CABIOS 4:11-17 (1989)). For example, percent identity can be determined using the ALIGN program (version 2.0) further using PAM120 as a residue table, a gap length penalty of 12, and a gap penalty of 4. Appropriate parameters for maximal alignment with particular alignment software can be determined by one of skill in the art. In certain embodiments, the default parameters of the alignment software are used. In certain embodiments, the percentage identity "X" of a first amino acid sequence to a second amino acid sequence is calculated as 100x(Y / Z), where Y is the number of amino acid residues scored as perfect matches in an alignment of the first and second sequences (aligned by visual inspection or by a particular sequence alignment program), and Z is the total number of residues in the second sequence. If the length of the first sequence is longer than the length of the second sequence, then the percent identity of the first sequence to the second sequence will be longer than the percent identity of the second sequence to the first sequence.

[0046] As a non-limiting example, whether any particular polynucleotide has a particular percentage of sequence identity (e.g., at least 80% identical, at least 85% identical, at least 90% identical, and in some embodiments at least 95%, 96%, 97%, 98%, or 99% identical) to a reference sequence can, in certain embodiments, be determined using the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, Wis. 53711). Bestfit uses the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981), to find the best segment of homology between two sequences. When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for example, 95% identical to a reference sequence provided herein, the parameters are set so that the % identity is calculated over the entire length of the reference nucleotide sequence and so that gaps in homology of up to 5% of the total number of nucleotides in the reference sequence are allowed.

[0047] " Conservative amino acid substitution " refers to the substitution of one amino acid residue with another amino acid residue that has a similar side chain.Families of amino acid residues with similar side chains have been defined in the art, and include, for example, amino acids with basic side chains (for example, lysine, arginine, histidine), amino acids with acidic side chains (for example, aspartic acid, glutamic acid), amino acids with uncharged polar side chains (for example, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), amino acids with non-polar side chains (for example, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), amino acids with β-branched side chains (for example, threonine, valine, isoleucine), and amino acids with aromatic side chains (for example, tyrosine, phenylalanine, tryptophan, histidine).For example, the substitution of tyrosine with phenylalanine is a conservative substitution. In some embodiments, conservative substitutions in the sequences of the polypeptides and antibodies provided herein do not abrogate binding of a polypeptide or antibody comprising the amino acid sequence to the antigen to which the polypeptide or antibody binds. Methods for identifying conservative nucleotide and amino acid substitutions that do not eliminate antigen binding are well known in the art (see, e.g., Brummell, Biochem. 32:1180-1187 (1993); Kobayashi, Protein Eng. 12(10):879-884 (1999); and Burks, Proc. Natl. Acad. Sci. 94:412-417 (1997)).

[0048] As used herein, "alkyl" refers to a saturated, straight- or branched-chain, monovalent hydrocarbon radical of 1 to 20 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-methyl-1-propyl, -CHCH(CH), 2-butyl, 2-methyl-2-propyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, 1-heptyl, 1-octyl, and the like. Preferably, alkyl has 1 to 10 carbon atoms. More preferably, the alkyl has 1 to 4 carbon atoms.

[0049] The number of carbon atoms in a group may be designated herein by the prefix "Cx-xx," where x and xx are integers. For example, a "C1-4 alkyl" is an alkyl group having from 1 to 4 carbon atoms.

[0050] The terms "compound" or "cytotoxic compound" or "cytotoxic drug" are used interchangeably. They are intended to include compounds whose structures or formulas or any derivatives are disclosed herein, or whose structures or formulas or any derivatives are incorporated by reference. The term also includes stereoisomers, geometric isomers, tautomers, solvates, metabolites, and salts (e.g., pharmaceutically acceptable salts) of compounds of all formulas disclosed herein. The term also includes any solvates, hydrates, and polymorphs of any of the foregoing. In certain embodiments, the specific recitation of "stereoisomers," "geometric isomers," "tautomers," "solvates," "metabolites," "salts," "complexes," "complex salts," "solvates," "hydrates," or "polymorphs" provided herein when the term "compound" is used without recitation of these other forms should not be construed as an intended omission of these forms in other disclosed embodiments.

[0051] The term "imine-reactive reagent" refers to a reagent that can react with an imine group. Examples of imine-reactive reagents include, but are not limited to, sulfite (HSO, HSO, or HSO formed with a cation). -, SO32- or HSO2-), metabisulfites (H2S2O5 or salts of S2O52- formed with cations), mono-, di-, tri-, and tetrathiophosphates (PO3SH3, PO2S2H3, POS3H3, PS4H3 or salts of PO3S3-, PO2S23-, POS33-, or PS43- formed with cations), thiophosphate esters ((RiO)2PS(ORi), RiSH, RiSOH, RiSO2H, RiSO3H), various amines (hydroxylamine ( For example, NH2OH), hydrazine (e.g., NH2NH2), NH2O-Ri, Ri'NH-Ri, NH2-Ri), NH2-CO-NH2, NH2-C(=S)-NH2, thiosulfate (H2S2O3 or a salt of S2O3 2- formed with a cation), dithionite (H2S2O4 or a salt of S2O4 2- formed with a cation), phosphorodithioate (P(=S)(ORk)(SH)(OH) or a salt thereof formed with a cation), hydroxamic acid (RkC(=O)NHOH or a cation), and hydroxybenzoates such as hydroxybenzoates, ... Rj is a straight-chain or branched-chain alkyl having 1 to 6 carbon atoms, and Rk is a straight-chain, branched-chain, or cyclic alkyl, alkenyl or alkynyl, aryl, heterocyclyl, or heteroaryl having 1 to 10 carbon atoms (preferably, Rk is a straight-chain or branched-chain alkyl having 1 to 4 carbon atoms, and more preferably, Rk is methyl, ethyl, or propyl). Preferably, the cation is a monovalent cation such as Na+ or K+.Preferably, the imine-reactive reagent is selected from sulfite, hydroxylamine, urea and hydrazine. More preferably, the imine-reactive reagent is NaHSO3 or KHSO3.

[0052] The term "cation" refers to a positively charged ion. Cations can be monovalent (e.g., Na+, K+, NH4+, etc.), divalent (e.g., Ca2+, Mg2+, etc.), or polyvalent (e.g., Al3+, etc.). Preferably, the cation is monovalent.

[0053] As used herein, the expression "pharmaceutically acceptable salt" means a pharmaceutically acceptable organic or inorganic salt of a compound provided herein. Representative salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate "mesylate", ethanesulfonate, benzenesulfonate, p-toluenesulfonate, pamoate (i.e., 1,1'-methylenebis(2-hydroxy-3-naphthoate)), alkali metal (e.g., sodium and potassium) salts, alkaline earth metal (e.g., magnesium) salts, and ammonium salts. A pharmaceutically acceptable salt may involve the inclusion of another molecule, such as an acetate ion, a succinate ion, or another counterion. The counterion may be any organic or inorganic moiety that stabilizes the charge of the parent compound. Furthermore, a pharmaceutically acceptable salt may have more than one charged atom in its structure. In cases where multiple charged atoms are part of a pharmaceutically acceptable salt, it may have multiple counterions. Thus, a pharmaceutically acceptable salt may have one or more charged atoms and / or one or more counterions.

[0054] If the compound provided herein is a base, the desired pharmaceutically acceptable salt can be prepared by any suitable method available in the art, for example, by treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, methanesulfonic acid, phosphoric acid, and the like; or an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid (e.g., glucuronic acid or galacturonic acid), an alpha hydroxy acid (e.g., citric acid, or tartaric acid), an amino acid (e.g., aspartic acid or glutamic acid), an aromatic acid (e.g., benzoic acid or cinnamic acid), a sulfonic acid (e.g., p-toluenesulfonic acid or ethanesulfonic acid), and the like.

[0055] If the compound provided herein is an acid, the desired pharmaceutically acceptable salt can be prepared by any suitable method, for example, by treating the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary), an alkali metal hydroxide, or an alkaline earth metal hydroxide. Examples of suitable salts include, but are not limited to, amino acids such as glycine and arginine; organic salts derived from ammonia, primary, secondary, or tertiary amines, and cyclic amines such as piperidine, morpholine, and piperazine; and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.

[0056] As used herein, the term "solvate" means a compound that further includes a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces, such as water, isopropanol, acetone, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine dichloromethane, 2-propanol, etc. Solvates or hydrates of a compound are readily prepared by adding at least one molar equivalent of a hydroxylic solvent, such as methanol, ethanol, 1-propanol, 2-propanol, or water, to the compound to solvate or hydrate the imine moiety.

[0057] A "metabolite" or "catabolic product" is a product of a particular compound, its derivative, or conjugate, or its salt, produced by metabolism or catabolism in the body. Metabolites of a compound, its derivative, or conjugate can be identified using routine techniques known in the art, and their activity can be determined using tests such as those disclosed herein. Such products can result, for example, from oxidation, hydroxylation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, etc., of the administered compound. Thus, the present disclosure includes metabolites of compounds of the disclosed EpCAM compositions disclosed herein, their derivatives, or conjugates, including compounds, derivatives, or conjugates produced by a process comprising contacting a disclosed EpCAM compound, its derivative, or conjugate with a mammal for a period of time sufficient to yield a metabolic product thereof.

[0058] The term "pharmaceutically acceptable" indicates that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients comprising the formulation and / or the mammal being treated therewith.

[0059] The term "protecting group" or "protecting moiety" refers to a substituent commonly used to block or protect a particular function while reacting with other functional groups in a compound, its derivative, or its composite. For example, an "amine protecting group" or "amino protecting moiety" is a substituent that is attached to an amino group and blocks or protects the amino functionality of the compound. Such groups are well known in the art (see, for example, P. Wuts and T. Greene, 2007, Protective Groups in Organic Synthesis, Chapter 7, J. Wiley & Sons, NJ) and are exemplified by carbamates such as methyl and ethyl carbamates, FMOC, substituted ethyl carbamates, carbamates that cleave by 1,6-β elimination (also known as "self-immolating"), ureas, amides, peptides, alkyl derivatives, and aryl derivatives. Suitable amino-protecting groups include acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and 9-fluorenylmethyleneoxycarbonyl (Fmoc). For a general review of protecting groups and their uses, see T.W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 2007.

[0060] The term "amino acid" refers to a natural or unnatural amino acid. In one embodiment, an amino acid is represented by NH-C(Ra'Ra')-C(=O)OH, where Ra and Ra' are each independently H, an optionally substituted linear, branched, or cyclic alkyl, alkenyl, or alkynyl having 1 to 10 carbon atoms; aryl, heteroaryl, or heterocyclyl; or Ra and the N-terminal nitrogen atom may together form a heterocyclic ring (e.g., proline). The term "amino acid residue" refers to the corresponding residue when one hydrogen atom is removed from the amine and / or carboxy terminus of the amino acid, e.g., -NH-C(Ra'Ra')-C(=O)O-.

[0061] The term "peptide" refers to a short chain of amino acid monomers linked by peptide (amide) bonds. In some embodiments, a peptide contains 2-20 amino acid residues. In other embodiments, a peptide contains 2-10 amino acid residues. In still other embodiments, a peptide contains 2-5 amino acid residues. As used herein, when a peptide is a portion of a cytotoxic agent or linker described herein represented by a specific sequence of amino acids, the peptide can be attached to the remainder of the cytotoxic agent or linker in either direction. For example, a dipeptide X1-X2 includes X1-X2 and X2-X1. Similarly, a tripeptide X1-X2-X3 includes X1-X2-X3 and X3-X2-X1, and a tetrapeptide X1-X2-X3-X4 includes X1-X2-X3-X4 and X4-X2-X3-X1. X1, X2, X3, and X4 represent amino acid residues.

[0062] The term "reactive ester group" refers to an ester group that can easily react with an amine group to form an amide bond. Representative reactive ester groups include, but are not limited to, N-hydroxysuccinimide ester, N-hydroxyphthalimide ester, N-hydroxysulfosuccinimide ester, paranitrophenyl ester, dinitrophenyl ester, pentafluorophenyl ester, and derivatives thereof, which facilitate the formation of an amide bond. In certain embodiments, the reactive ester group is an N-hydroxysuccinimide ester or an N-hydroxysulfosuccinimide ester.

[0063] The term "amine reactive group" refers to a group that can react with an amine group to form a covalent bond. Representative amine reactive groups include, but are not limited to, reactive ester groups, acyl halides, sulfonyl halides, imide esters, or reactive thioester groups. In certain embodiments, the amine reactive group is a reactive ester group. In one embodiment, the amine reactive group is an N-hydroxysuccinimide ester or an N-hydroxysulfosuccinimide ester.

[0064] The term "thiol-reactive group" refers to a group that can react with a thiol (-SH) group to form a covalent bond. Exemplary thiol-reactive groups include, but are not limited to, maleimide, haloacetyl, alloacetamide, vinyl sulfone, vinyl sulfonamide, or vinyl pyridine. In one embodiment, the thiol-reactive group is maleimide.

[0065] As used in this specification and claims, the singular forms "a," "an," and "the" include the plural forms unless the context clearly dictates otherwise.

[0066] As used herein, "and / or" should be interpreted as a specific disclosure of each of two or more specified features or components, with or without the others. Thus, the term "and / or" used in phrases such as "A and / or B" is intended herein to include "A and B," "A or B," "A (alone) and B (alone)." Similarly, the term "and / or" used in phrases such as "A, B and / or C" encompasses each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0067] Whenever an embodiment is disclosed herein with the term "comprising," other similar embodiments described with the terms "consisting of" and / or "consisting essentially of" are also provided.

[0068] EpCAM antibodies and EpCAM-binding antibody fragments Proteins that specifically bind to human EpCAM are provided. In some embodiments, the proteins are referred to herein as "EpCAM-binding agents" or EpBAs.

[0069] In further embodiments, the EpCAM-binding substance is an EpCAM antibody, an EpCAM-binding antibody fragment, or an EpCAM-activatable antibody. In some embodiments, the EpBA is a full-length EpCAM antibody (i.e., a full-length antibody that specifically binds to EpCAM). In some embodiments, the EpCAM antibody is a monoclonal antibody. In some embodiments, the EpCAM antibody is a recombinant antibody, a human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody (e.g., a bispecific antibody), or an EpCAM-binding antibody fragment thereof. In some embodiments, the EpCAM antibody specifically binds to human EpCAM. In further embodiments, the EpCAM antibody specifically binds to human EpCAM and cynomolgus EpCAM. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment is a murine, other rodent, chimeric, humanized, or fully human monoclonal antibody.

[0070] In some embodiments, the EpCAM antibody is an EpCAM-binding antibody fragment. In further embodiments, the EpCAM-binding antibody fragment is a Fab, Fab', F(ab')2, Fv fragment, diabody, or single-chain antibody molecule. In a further aspect, the EpCAM antibody is an EpCAM-binding antibody fragment, which may be a single-chain Fv (scFv), a disulfide-linked Fv, a V-NAR domain, an IgNar, an intrabody, an IgGΔCH2, a minibody, F(ab')3, an scAb, a dAb, a tetrabody, a triabody, a diabody, a single-domain heavy chain antibody, a single-domain light chain antibody, a DVD-Ig, an Fcab, or an mAb. 2 , (scFv)2, scFv-Fc or bis-scFv.

[0071] The EpCAM antibodies and EpCAM-binding antibody fragments provided herein optionally have a wide range of affinity (K D In a preferred embodiment, the antibody binds to human EpCAM with high affinity. For example, a human or human engineered or humanized or resurfaced mAb binds to human EpCAM with a high affinity of about 10 as measured by a flow cytometry-based assay, enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), or KinExA®. -7 M or less, for example, but not limited to, 0.1 to 9.9 (or any range or value therebetween) x 10 -7 , 10 -8 , 10 -9 , 10 -10 , 10 -11 , or 10 -12 M, or any range or value of K between them D In some embodiments, the EpCAM antibody can bind to a human antigen at a concentration of about 10 -9 M or less, and especially about 10 -9 ~10 -10 It binds with a Kd of M.

[0072] The affinity or avidity of an antibody or antibody fragment to EpCAM can be experimentally measured by any suitable method known in the art, such as flow cytometry, enzyme-linked immunosorbent assay (ELISA), or radioimmunoassay (RIA), or kinetics (e.g., BIACORE™) according to standard operating procedures. Direct binding assays and competitive binding assay formats can be routinely employed (see, for example, Berzofsky, et al., "Antibody-Antigen Interactions," In Fundamental Immunology, Paul, WE, Ed., Raven Press: New York, NY (1984); Kuby, Janis, Immunology, WH Freeman and Company: New York, NY (1992); and the methods disclosed herein). The measured affinity of a particular antibody-EpCAM interaction may vary when measured under different conditions (e.g., salt concentration, pH, temperature). Therefore, measurements of affinity and other EpCAM binding parameters (e.g., KD or Kd, Kon, Koff) are preferably performed using standardized solutions of antibody and EpCAM and standardized buffers such as those known in the art and described herein.

[0073] In one embodiment, binding assays are performed using flow cytometry on cells expressing the EpCAM antigen on their surface. For example, such EpCAM-positive cells are collected at 1x10 per sample in 100 μL of FACS buffer (RPMI-1640 medium supplemented with 2% normal goat serum). 5Cells are incubated with various concentrations of EpCAM antibody. Cells are then pelleted, washed, and incubated with 100 μL of FITC-labeled goat anti-mouse IgG antibody (e.g., available from Jackson ImmunoResearch) in FACS buffer for 1 hour. Cells are pelleted again, washed with FACS buffer, and resuspended in 200 μL of 1% formaldehyde in PBS. Samples are acquired using, for example, a FACSCalibur™ flow cytometer equipped with an HTS multiwell sampler and analyzed using CellQuest® Pro (all available from BD Biosciences, San Diego, US). For each sample, the mean fluorescence intensity (FL1) (MFI) is output and plotted against antibody concentration on a semi-logarithmic plot to generate a binding curve. A sigmoidal dose-response curve is fitted to the binding curve, and EC values ​​are calculated using a program such as GraphPad Prism v4 (GraphPad software, San Diego, CA) with default parameters. 50 Calculate the EC value for each antibody. 50 The value can be used as a measure of the apparent dissociation constant "Kd" or "KD".

[0074] In certain embodiments, EpCAM antibodies are modified to alter their binding affinity to EpCAM and / or EpCAM antigen fragments. Binding characteristics can be measured using standard procedures known in the art by various in vitro assays, including, for example, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), or kinetics (e.g., BIACORE™ analysis).

[0075] In one embodiment, the EpCAM antibody or EpCAM-binding antibody fragment is -5 Less than M or 10 -6 Less than M or 10 -7 Less than M or 10 -8 Less than M or 10 -9 Less than M or 10 -10 Less than M or 10 -11Less than M or 10 -12 Less than M or 10 -13 Specifically binds to human or cynomolgus EpCAM and / or EpCAM antigen fragments with a dissociation constant or KD or Kd (koff / k) of less than 1.0x10 M. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment specifically binds to human or cynomolgus EpCAM and / or EpCAM antigen fragments with a dissociation constant or KD or Kd (koff / k) of less than 1.0x10 M. -9 M or less, 2.0x10 -9 M or less, 3.0x10 -9 M or less, 4.0x10 -9 M or less, 5.0x10 -9 M or less, 6.0x10 -9 M or less, 7.0x10 -9 M or less, 8.0x10 -9 M or smaller, or 9.0x10 -9 In certain embodiments, the EpCAM antibody or EpCAM-binding antibody fragment specifically binds to both human and cynomolgus EpCAM and / or EpCAM antigen fragments with a KD of 3.0x10 M or less. -9 K below M D In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment binds to human EpCAM at a binding affinity of about 0.4x10 -9 In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment binds to human EpCAM with a KD of about 0.8x10 -9 K of M D In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment binds to cynomolgus EpCAM at about 0.8x10 -9 In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment binds to cynomolgus EpCAM with a KD of about 2.2 x 10 -9 In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment binds to cynomolgus EpCAM with a KD of about 2.8 x 10 -9 It binds to M's KD.

[0076] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment specifically binds to an epitope within the extracellular domain of human EpCAM (SEQ ID NO: 1). The extracellular region of human EpCAM can be further divided into three distinct domains: D1 (SEQ ID NO: 2), D2 (SEQ ID NO: 3), and D3 (SEQ ID NO: 4). In certain embodiments, the EpCAM antibody or EpCAM-binding antibody fragment specifically binds to an epitope within the first extracellular domain (D1) of human EpCAM.

[0077] In one embodiment, the EpCAM antibody or EpCAM-binding antibody fragment comprises X1YX3X4H, where X1 is selected from N and S, X3 is selected from Y, N, F, S, H, D, L, I, and W, and X4 is selected from I and M. VH-CDR1 (SEQ ID NO: 5); sequence WX2X3PGX6VYIQYX 12 X 13 KFX 17 G, X2 is selected from I and F, X3 is selected from Y and N, X6 is selected from N and D, and X 12 is selected from N and S, and X 13 is selected from E and Q, and X 17 is selected from K and Q; and X1GX3X4FAY, wherein X1 is selected from D and E, X3 is selected from P, A, S, Y, F, G, T, and V, and X4 is selected from Y and W.

[0078] In a further embodiment, the present disclosure provides RSSX4SLLHSX 10 GX 12 TYLX 16 X4 is selected from R and K; 10 is selected from N and D, and X 12 is selected from F and I, and X 16is selected from Y and S; light chain VL-CDR2 (SEQ ID NO: 40) comprising QTSNLAS; and VL-CDR3 (SEQ ID NO: 11) comprising X1QX3LELPX8T, wherein X1 is selected from A, L, and Q, X3 is selected from S, G, Y, and N, and X8 is selected from N and W. In some embodiments, the disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising a heavy chain CDR1 (VH-CDR1) comprising the sequence of SEQ ID NO: 13; a heavy chain CDR2 (VH-CDR2) comprising the sequence of SEQ ID NO: 14; a heavy chain CDR3 (VH-CDR3) comprising the sequence of SEQ ID NO: 15; a light chain CDR1 (VL-CDR1) comprising the sequence of SEQ ID NO: 42; a light chain CDR2 (VL-CDR2) comprising the sequence of SEQ ID NO: 40; and a light chain CDR3 (VL-CDR3) comprising the sequence of SEQ ID NO: 41.

[0079] In some embodiments, the VH-CDR1 comprises the sequence NYX3IH, where X3 is selected from Y, N, F, S, H, D, L, I, and W (SEQ ID NO: 6). In some embodiments, the VH-CDR3 comprises the sequence DGPX4FAY, where X4 is selected from Y and W (SEQ ID NO: 9). In some embodiments, the VL-CDR3 comprises the sequence AQX3LELPNT, where X3 is selected from S, G, Y, and N (SEQ ID NO: 12). In some embodiments, the disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising a heavy chain CDR1 (VH-CDR1) comprising the sequence of SEQ ID NO: 13; a heavy chain CDR2 (VH-CDR2) comprising the sequence of SEQ ID NO: 14; a heavy chain CDR3 (VH-CDR3) comprising the sequence of SEQ ID NO: 15; a light chain CDR1 (VL-CDR1) comprising the sequence of SEQ ID NO: 42; a light chain CDR2 (VL-CDR2) comprising the sequence of SEQ ID NO: 40; and a light chain CDR3 (VL-CDR3) comprising the sequence of SEQ ID NO: 41.

[0080] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a set of complementarity-determining regions (CDRs): heavy chain variable region (VH)-CDR1, VH-CDR2, VH-CDR3, light chain variable region (VL)-CDR1, VL-CDR2 and VL-CDR3, and the heavy chain CDRs are disclosed in Table 2. [Table 2] TIFF0007592009000024.tif144161

[0081] In some embodiments, the present disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising a heavy chain CDR of a single row in Table 2. In some embodiments, the present disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising a VH-CDR1 selected from SEQ ID NOs: 13 and 16-25; a VH-CDR2 selected from SEQ ID NOs: 14 and 26-29; and a VH-CDR3 selected from SEQ ID NOs: 15 and 30-38. In some embodiments, the present disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising a VH-CDR1 of SEQ ID NO: 13; a VH-CDR2 of SEQ ID NO: 14; and a VH-CDR3 of SEQ ID NO: 15. In some embodiments, the present disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising a VH-CDR1 of SEQ ID NO: 13; a VH-CDR2 of SEQ ID NO: 26; and a VH-CDR3 of SEQ ID NO: 15.

[0082] In one embodiment, the disclosure provides an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody comprising a VH-CDR1 comprising NYYIH (SEQ ID NO: 13) or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions; a VH-CDR2 comprising WIYPGNVYIQYNEKFKG (SEQ ID NO: 14) or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions; and a heavy chain CDR3 comprising DGPWFAY (SEQ ID NO: 15) or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions.

[0083] In some embodiments, the present disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising a VH-CDR1 of SEQ ID NO: 22, a VH-CDR2 of SEQ ID NO: 14, and a VH-CDR3 of SEQ ID NO: 15. In some embodiments, the present disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising a VH-CDR1 of SEQ ID NO: 13, a VH-CDR2 of SEQ ID NO: 14, and a VH-CDR3 of SEQ ID NO: 33. In some embodiments, the present disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising a VH-CDR1 of SEQ ID NO: 23, a VH-CDR2 of SEQ ID NO: 14, and a VH-CDR3 of SEQ ID NO: 15. In some embodiments, the present disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising a VH-CDR1 of SEQ ID NO: 25, a VH-CDR2 of SEQ ID NO: 14, and a VH-CDR3 of SEQ ID NO: 15.

[0084] In one embodiment, the disclosure provides an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody comprising a VH-CDR1 comprising NYHIH (SEQ ID NO: 22) or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions; a VH-CDR2 comprising WIYPGNVYIQYNEKFKG (SEQ ID NO: 14) or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions; and a heavy chain CDR3 comprising DGPWFAY (SEQ ID NO: 15) or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions. In one embodiment, the disclosure provides an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody comprising a VH-CDR1 comprising NYYIH (SEQ ID NO: 13) or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions; a VH-CDR2 comprising WIYPGNVYIQYNEKFKG (SEQ ID NO: 14) or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions; and a heavy chain CDR3 comprising DGYWFAY (SEQ ID NO: 33) or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions.

[0085] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a set of complementarity-determining regions (CDRs): heavy chain variable region (VH)-CDR1, VH-CDR2, VH-CDR3, light chain variable region (VL)-CDR1, VL-CDR2 and VL-CDR3, and the light chain CDRs are disclosed in Table 3. [Table 3]

[0086] In some embodiments, the present disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising a light chain CDR of a single row in Table 3. In some embodiments, the present disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising a VL-CDR1 selected from SEQ ID NOs: 39 and 42-45; a VL-CDR2 of SEQ ID NO: 40; and a VL-CDR3 selected from SEQ ID NOs: 41 and 46-51. In some embodiments, the present disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising a VL-CDR1 of SEQ ID NO: 42; a VL-CDR2 of SEQ ID NO: 40; and a VL-CDR3 of SEQ ID NO: 41. In some embodiments, the present disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising a VL-CDR1 of SEQ ID NO: 39; a VL-CDR2 of SEQ ID NO: 40; and a VL-CDR3 of SEQ ID NO: 41.

[0087] In one embodiment, the disclosure provides an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody comprising a VL-CDR1 comprising RSSRSLLHSDGFTYLY (SEQ ID NO: 42) or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions; a VL-CDR2 comprising QTSNLAS (SEQ ID NO: 40) or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions; and a VL-CDR3 comprising AQNLELPNT (SEQ ID NO: 41) or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions. In one embodiment, the disclosure provides an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody comprising a VL-CDR1 comprising RSSKSLLHSDGFTYLY (SEQ ID NO: 39) or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions; a VL-CDR2 comprising QTSNLAS (SEQ ID NO: 40) or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions; and a VL-CDR3 comprising AQNLELPNT (SEQ ID NO: 41) or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions.

[0088] In some embodiments, the disclosure provides an EpCAM antibody or an EpCAM-binding antibody fragment comprising a VH-CDR1 selected from SEQ ID NOs: 13 and 16-25, a VH-CDR2 selected from SEQ ID NOs: 14 and 26-29, and a VH-CDR3 selected from SEQ ID NOs: 15 and 30-38, a VL-CDR1 selected from SEQ ID NOs: 39 and 42-45, a VL-CDR2 of SEQ ID NO: 40, and a VL-CDR3 selected from SEQ ID NOs: 41 and 46-51. In some embodiments, the disclosure provides an EpCAM antibody or an EpCAM-binding antibody fragment comprising a VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 13-15, 42, 40, and 41. In some embodiments, the disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 13-15, 39-41, respectively. In some embodiments, the disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 13, 26, 15, and 39-41, respectively. In some embodiments, the present disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 13, 26, 15, 42, 40, and 41, respectively.

[0089] In some embodiments, the disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 22, 14, 15, 42, 40, and 41, respectively. In some embodiments, the disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 13, 14, 33, 42, 40, and 41, respectively. In some embodiments, the disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 23, 14, 15, 42, 40, and 41, respectively. In some embodiments, the disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 25, 14, 15, 42, 40, and 41, respectively.

[0090] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a heavy chain variable region (VH) sequence disclosed in Table 4. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a VH sequence disclosed in Table 4. [Table 4] TIFF0007592009000027.tif240161TIFF0007592009000028.tif65162

[0091] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, less than 15, or no amino acid substitutions, deletions, and / or insertions from a reference VH sequence selected from SEQ ID NOs: 53-84. In some embodiments, the insertions, substitutions, deletions, and / or insertions are in the framework regions of the reference sequence. In some embodiments, the substitutions are conservative. In other embodiments, the substitutions are non-conservative.

[0092] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH having a sequence selected from SEQ ID NOs: 53-84. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH having a sequence selected from SEQ ID NOs: 53-56. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH having the sequence of SEQ ID NO: 54. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a sequence selected from SEQ ID NOs: 53-56. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 54.

[0093] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH having a sequence selected from SEQ ID NOs: 75-77 and 84. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH having the sequence of SEQ ID NO: 75. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH having the sequence of SEQ ID NO: 77. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a sequence selected from SEQ ID NOs: 75-77 and 84. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 75. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO:77.

[0094] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a light chain variable region (VL) sequence disclosed in Table 5. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VL sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a VL sequence disclosed in Table 5. [Table 5] TIFF0007592009000030.tif56161

[0095] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VL sequence having a total of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, less than 15, or no amino acid substitutions, deletions, and / or insertions from a reference VH sequence selected from SEQ ID NOs: 86-99. In some embodiments, the insertions, substitutions, deletions, and / or insertions are in the framework regions of the reference sequence. In some embodiments, the substitutions are conservative. In other embodiments, the substitutions are non-conservative.

[0096] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VL having a sequence selected from SEQ ID NOs: 86-99. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VL having a sequence selected from SEQ ID NOs: 86-89. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VL having the sequence of SEQ ID NO: 89. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VL having the sequence of SEQ ID NO: 87. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a sequence selected from SEQ ID NOs: 86-89. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VL sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 89. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VL sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO:87.

[0097] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH comprising a sequence selected from SEQ ID NOs: 53-84 and a VL comprising a sequence selected from SEQ ID NOs: 86-89. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH comprising the sequence of SEQ ID NO: 54 and a VL comprising the sequence of SEQ ID NO: ...7. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH comprising the sequence of SEQ ID NO: 55 and a VL comprising the sequence of SEQ ID NO: 87. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH comprising the sequence of SEQ ID NO: 56 and a VL comprising the sequence of SEQ ID NO: 88. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH comprising the sequence of SEQ ID NO: 55 and a VL comprising the sequence of SEQ ID NO: 89. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH comprising the sequence of SEQ ID NO: 56 and a VL comprising the sequence of SEQ ID NO: 89.

[0098] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH comprising the sequence of SEQ ID NO: 75 and a VL comprising the sequence of SEQ ID NO: 89. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH comprising the sequence of SEQ ID NO: 77 and a VL comprising the sequence of SEQ ID NO: 89. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH comprising the sequence of SEQ ID NO: 76 and a VL comprising the sequence of SEQ ID NO: 89. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH comprising the sequence of SEQ ID NO: 84 and a VL comprising the sequence of SEQ ID NO: 89.

[0099] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment competes for binding to human EpCAM with an antibody comprising the VH and VL sequences disclosed in Tables 4 and 5, respectively.

[0100] In one embodiment, the present disclosure provides an EpCAM antibody or EpCAM-binding antibody fragment that competes for binding to human EpCAM with an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL) selected from: (a) a heavy chain variable region (VH) of SEQ ID NO: 54 and a light chain variable region (VL) of SEQ ID NO: 89; (b) a VH of SEQ ID NO: 54 and a VL of SEQ ID NO: 87; (c) a VH of SEQ ID NO: 75 and a VL of SEQ ID NO: 89; and (d) a VH of SEQ ID NO: 77 and a VL of SEQ ID NO: 89.

[0101] An EpCAM antibody or EpCAM-binding antibody fragment is said to compete with a reference molecule for binding to EpCAM if it binds to human EpCAM to a degree that blocks the binding of the reference molecule to human EpCAM to some extent. The ability of proteins to compete for binding to EpCAM, and thus to prevent, block, or "cross-block" each other's binding to EpCAM, can be determined by any standard competitive binding assay known in the art, including, for example, competitive ELISA assays, surface plasmon resonance (SPR; BIACORE®, Biosensor, Piscataway, NJ), or by the method described by Scatchard et al. (Ann. NY Acad. Sci. 51:660-672 (1949)). An antibody can be said to competitively inhibit the binding of a reference EpCAM antibody to human EpCAM by, for example, at least 90%, at least 80%, at least 70%, at least 60%, or at least 50%.

[0102] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment further comprises a heavy chain constant region or a fragment thereof. In some aspects, the antibody or antibody fragment comprises a heavy chain immunoglobulin constant region selected from the group consisting of: (a) a human IgA constant region or a fragment thereof; (b) a human IgD constant region or a fragment thereof; (c) a human IgE constant domain or a fragment thereof; (d) a human IgG1 constant region or a fragment thereof; (e) a human IgG2 constant region or a fragment thereof; (f) a human IgG3 constant region or a fragment thereof; (g) a human IgG4 constant region or a fragment thereof; and (h) a human IgM constant region or a fragment thereof. In certain embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a heavy chain constant region or a fragment thereof, for example, a human IgG constant region or a fragment thereof. In further embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a heavy chain immunoglobulin constant domain that has, or has been mutated to have, an altered effector function and / or half-life.

[0103] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a heavy chain sequence disclosed in Table 6. [Table 6] TIFF0007592009000032.tif239161TIFF0007592009000033.tif239161TIFF00075920090 00034.tif239161TIFF0007592009000035.tif239161TIFF0007592009000036.tif236162

[0104] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a heavy chain (HC) sequence selected from SEQ ID NOs: 102-134. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a heavy chain (HC) sequence selected from SEQ ID NOs: 102-106. In specific embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises the HC sequence of SEQ ID NO: 103. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises an HC sequence selected from SEQ ID NOs: 125-127 and 134. In specific embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises the HC sequence of SEQ ID NO: 125. In specific embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises the HC sequence of SEQ ID NO: 127.

[0105] In a further embodiment, the EpCAM antibody or EpCAM-binding antibody fragment comprises a light chain immunoglobulin constant region. In a further embodiment, the antibody comprises a human Ig kappa constant region or a human Ig lambda constant region.

[0106] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a light chain sequence disclosed in Table 7. [Table 7] TIFF0007592009000038.tif200161

[0107] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a light chain (LC) sequence selected from SEQ ID NOs: 137-150. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a light chain (LC) sequence selected from SEQ ID NOs: 137-140. In a specific embodiment, the EpCAM antibody or EpCAM-binding antibody fragment comprises the LC sequence of SEQ ID NO: 140. In another embodiment, the EpCAM antibody or EpCAM-binding antibody fragment comprises the LC sequence of SEQ ID NO: 138.

[0108] In a further embodiment, the EpCAM antibody or EpCAM-binding antibody fragment comprises an HC having the sequence selected from SEQ ID NOs: 102-134 and an LC having the sequence selected from SEQ ID NOs: 137-150. In a further embodiment, the EpCAM antibody or EpCAM-binding antibody fragment comprises an HC having the sequence of SEQ ID NO: 103 and an LC having the sequence of SEQ ID NO: 140. In a further embodiment, the EpCAM antibody or EpCAM-binding antibody fragment comprises an HC having the sequence of SEQ ID NO: 103 and an LC having the sequence of SEQ ID NO: 138. In a further embodiment, the EpCAM antibody or EpCAM-binding antibody fragment comprises an HC having the sequence of SEQ ID NO: 105 and an LC having the sequence of SEQ ID NO: 138. In a further embodiment, the EpCAM antibody or EpCAM-binding antibody fragment comprises an HC having the sequence of SEQ ID NO: 106 and an LC having the sequence of SEQ ID NO: 139. In a further embodiment, the EpCAM antibody or EpCAM-binding antibody fragment comprises an HC having the sequence of SEQ ID NO: 105 and an LC having the sequence of SEQ ID NO: 140. In further embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises an HC having the sequence of SEQ ID NO: 106 and an LC having the sequence of SEQ ID NO: 140. In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises an HC having the sequence of SEQ ID NO: 125 and an LC having the sequence of SEQ ID NO: 140. In further embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises an HC having the sequence of SEQ ID NO: 127 and an LC having the sequence of SEQ ID NO: 140. In further embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises an HC having the sequence of SEQ ID NO: 126 and an LC having the sequence of SEQ ID NO: 140. In further embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises an HC having the sequence of SEQ ID NO: 134 and an LC having the sequence of SEQ ID NO: 140.

[0109] In some embodiments, the EpCAM antibody comprises an altered (e.g., mutated or genetically modified) Fc region. For example, in some aspects, the Fc region is altered to reduce or enhance the antibody's effector function, alter the antibody's serum half-life, or other functional properties. In certain cases, such as antibodies whose mechanism of action requires blocking or antagonism but not killing of target antigen-bearing cells, reducing or eliminating effector function is desirable. Enhanced effector function is typically desirable when targeting unwanted cells, such as tumors and foreign cells expressing low levels of FcγR, e.g., tumor-specific B cells with low levels of FcγRIIB (e.g., non-Hodgkin's lymphoma, CLL, and Burkitt's lymphoma). Immunoconjugates of the present invention having such conferred or altered effector function activity are useful for treating and / or preventing diseases, disorders, or infections in which enhanced effector function activity is desirable. In some embodiments, the Fc region is an isotype selected from IgM, IgA, IgG, IgE, or other isotypes.

[0110] The Fc region of the EpCAM antibody and EpCAM-binding antibody fragment may be capable of binding to one or more Fc receptors (e.g., FcγR), although in certain embodiments, the antibody or antibody fragment comprises a variant Fc region that has altered binding to FcγRIA (CD64), FcγRIIA (CD32A), FcγRIIB (CD32B), FcγRIIIA (CD16a), or FcγRIIIB (CD16b) (compared to the binding exhibited by the wild-type Fc region), e.g., has enhanced binding to an activating receptor and / or has substantially reduced or no binding ability to an inhibitory receptor. Thus, the Fc region of the EpCAM antibody or EpCAM-binding antibody fragment may comprise part or all of the CH2 domain and / or part or all of the CH3 domain of a complete Fc region, or may comprise variant CH2 and / or variant CH3 sequences (e.g., may comprise one or more insertions and / or one or more deletions relative to the CH2 or CH3 domains of the complete Fc region). Such an Fc region may include non-Fc polypeptide portions, or may include portions of a non-natural complete Fc region, or may include a non-natural orientation of the CH2 and / or CH3 domains (e.g., two CH2 domains or two CH3 domains, or a CH3 domain linked to a CH2 domain in the N-terminal to C-terminal direction, etc.).

[0111] Fc region modifications identified as altering effector function are known in the art, including modifications that enhance binding to activating receptors (e.g., FcγRIIa (CD16A)) and reduce binding to inhibitory receptors (e.g., FcγRIIB (CD32B) (see, e.g., Stavenhagen, et al., Cancer Res. 57(18):8882-8890 (2007)). Table 8 lists examples of exemplary single, double, triple, quadruple, and quintuple substitutions (numbering is according to the EU index in Kabat, and substitutions are relative to the amino acid sequence of SEQ ID NO: 304) of exemplary modifications that enhance binding to activating receptors and / or reduce binding to inhibitory receptors. [Table 8]

[0112] Exemplary variants of human IgG1 Fc regions that confer reduced binding to CD32B and / or increased binding to CD16A include F243L, R292P, Y300L, V305I, or P396L substitutions, where the numbering is that of the EU index of Kabat. These amino acid substitutions may be present in any combination in the human IgG1 Fc region. In one embodiment, the variant human IgG1 Fc region includes F243L, R292P, and Y300L substitutions. In another embodiment, the variant human IgG1 Fc region includes F243L, R292P, Y300L, V305I, and P396L substitutions.

[0113] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises an immunoglobulin heavy chain constant region that comprises a modification that reduces effector function (e.g., Idusogie et al., J. Immunol. 166:2571-2575 (2001); Sazinsky et al., PNAS USA 105:20167-20172 (2008); Davis et al., J. Rheumatol. 34:2204-2210 (2007); Bolt et al., Eur. J. Immunol. 23:403-411 (1993); Alegre et al., Transplantation 57:1537-1543 (1994); Xu et al., Cell Immunol. 200:16-26 (2000); Cole et al., Transplantation 68:563-571 (1999); Hutchins et al., PNAS USA 92:11980-11984 (1995); Reddy et al., J. Immunol. 164:1925-1933 (2000); WO97 / 11971, and WO07 / 106585; US Appl. Publ. 2007 / 0148167A1; McEarchern et al., Blood 109:1185-1192 (2007); Strohl, Curr. Op. Biotechnol. 20:685-691 (2009); and Kumagai et al., J. Clin. Pharmacol. 47:1489-1497 (2007), the contents of each of which are incorporated herein by reference in their entireties.

[0114] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment preferably exhibits reduced binding (or substantially no binding) to an effector receptor selected from the group consisting of FcγRIA (CD64), FcγRIIA (CD32A) (allotypes R131 and H131), FcγRIIB (CD32B), FcγRIIIA (CD16a) (allotypes V158 and F158), and FcγRIIIB (CD16b) (allotypes FcγIIIb-NA1 and FcγIIIb-NA2) compared to the binding exhibited by the wild-type IgG Fc region (SEQ ID NO: 304). In some embodiments, the effector receptor binding affinity of the EpCAM antibody or EpCAM-binding antibody fragment Fc region variant is reduced by at least 10-fold, at least 50-fold, or at least 100-fold compared to the binding affinity of the corresponding antibody or antibody-binding fragment comprising the wild-type Fc region of the corresponding immunoglobulin.

[0115] In certain embodiments, the EpCAM antibody or EpCAM-binding antibody fragment exhibits reduced effector function (reduced ADCC) and comprises an IgG Fc region comprising an alteration at one or more amino acid positions selected from the group consisting of 233, 234, 235, 236, 237, 238, 239, 265, 266, 267, 269, 270, 271, 295, 296, 297, 298, 300, 324, 325, 327, 328, 329, 331, and 332 (amino acid positions numbered according to the EU index as set forth in Kabat). In one embodiment, the CH2-CH3 domain of the EpCAM antibody comprises any one, two, three, or four of the following substitutions: L234A, L235A, D265A, N297Q, N297A, and N297G, as numbered according to the EU index as set forth in Kabat. In another embodiment, the CH2-CH3 domain contains an N297Q substitution, an N297A substitution, or an L234A and L235A substitution. These mutations abolish FcR binding. Alternatively, the EpCAM antibody or EpCAM-binding antibody fragment comprises the CH2-CH3 domain of a native Fc region that essentially exhibits reduced (or substantially abolished) FcγRIIIA (CD16a) binding and / or reduced effector function (compared to the binding and effector function exhibited by the wild-type IgG1 Fc region (SEQ ID NO: 304)). In a specific embodiment, the Fc constant region of the EpCAM antibody comprises an IgG2 Fc region (SEQ ID NO: 305) or an IgG4 Fc region (SEQ ID NO: 306). Because the N297A, N297G, N297Q, L234A, L235A, and D265A substitutions abolish effector function, it may be preferable to avoid these substitutions in circumstances where effector function is desirable.

[0116] A preferred IgG1 sequence for the CH2 and CH3 domains of an Fc region-containing EpCAM antibody or EpCAM-binding antibody fragment with reduced or abolished effector function contains the substitutions L234A / L235A (shown underlined) (SEQ ID NO: 307): APE AAGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG

[0117] A preferred IgG1 sequence for the CH2 and CH3 domains of an Fc region-containing EpCAM antibody or EpCAM-binding antibody fragment with reduced or abolished effector function contains the substitution N297A (shown underlined) (SEQ ID NO: 308): APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQY A STY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG

[0118] A preferred IgG1 sequence for the CH2 and CH3 domains of an Fc region-containing EpCAM antibody or EpCAM-binding antibody fragment with reduced or abolished effector function contains the substitution N297Q (underlined) (SEQ ID NO: 309): APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQY QSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG

[0119] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises one or more modifications corresponding to the following: IgG1-C220S, C226S, C229S, P238S; IgG1-C226S, C229S; IgG1-C226S, C229S, E233P, L234V, L235A; IgG1-L234A, L235A; IgG1-L234F, L235E, P331S; IgG1-L234F, L235E, P331S; IgG1-H268Q, A330S, P331S; IgG1-G236R, L328R; IgG1-L235G, G236R, IgG1-N29 7A; IgG1-N325A, L328R; IgG1-N325L, L328R; IgG1-K326W, E333S; IgG2-V234A, G237A; IgG2-E333S; IgG2-H268Q, V309L, A330S, A331S; IgG4-S228P, L236E; IgG4-F234A, L235A; IgG4-F234A, G237A, E318A; IgG4-L235A, G237A, E318A; IgG4-L236E; IgG2-EU sequence 118-260; and IgG4-EU sequence 261-447; position numbering is according to the EU index in Kabat.

[0120] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a heavy chain immunoglobulin constant domain with reduced CDC activity. In certain embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises an IgG1 heavy chain constant region comprising a mutation that reduces CDC activity (e.g., WO1997 / 11971 and WO2007 / 106585; U.S. Application Publication No. 2007 / 0148167A1; Lazar et al., PNAS USA 103:4005-4010 (2006); Bruckheimer et al., Neoplasia 11:509-517 (2009); Strohl, Curr. Op. Biotechnol. 20:685-691 (2009); and Sazinsky et al., PNAS USA 105:20167-20172 (2008), each of which is incorporated herein by reference in its entirety). Examples of heavy chain constant domain sequence modifications that reduce CDC include one or more modifications corresponding to the following: IgG1-C226S, C229S, E233P, L234V, L235A; IgG1-C226S, P230S; IgG1-L234F, L235E, P331S; IgG1-S239D, A330L, I332E; IgG2-EU sequence 118-260; IgG4-EU sequence 261-447; and IgG2-H268Q, V309L, A330S, A331S (according to the EU index).

[0121] In some embodiments, the provided EpCAM antibody or EpCAM-binding antibody fragment comprises a heavy chain immunoglobulin constant domain containing one or more half-life-extending amino acid modifications (e.g., substitutions). Numerous mutations that can extend the half-life of Fc region-containing molecules are known in the art and are included as components of the EpCAM antibody and EpCAM-binding antibody fragment provided herein. See, for example, U.S. Patent Nos. 6,277,375; 7,083,784; 7,217,797 and 8,088,376, U.S. Publication Nos. 2002 / 0147311; and 2007 / 0148164; and PCT Publication Nos. WO1998 / 23289; WO2009 / 058492; and WO2010 / 033279. The contents of each of these are incorporated herein by reference in their entirety.

[0122] The serum half-life of a protein comprising an Fc region can be extended by increasing the binding affinity of the Fc region to FcRn. As used herein, the term "half-life" refers to a pharmacokinetic property of a molecule that is a measure of the average survival time of the molecule after administration. Half-life can be expressed, for example, as the time required for 50 percent (50%) of a known amount of the molecule in serum (i.e., circulating half-life) or in other tissues to be removed from the body of a subject (e.g., a human patient or other mammal) or a specific compartment thereof. Generally, extending half-life results in an increase in the mean residence time (MRT) of the administered molecule in the circulation.

[0123] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises a half-life extending amino acid substitution at one or more positions selected from the group consisting of: 238, 250, 252, 254, 256, 257, 256, 265, 272, 286, 288, 303, 305, 307, 308, 309, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, ​​413, 424, 428, 433, 434, 435, and 436 (amino acid position numbering according to the EU index). In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises one or more amino acid substitutions of amino acid residues at positions 251-257, 285-290, 308-314, 385-389, and 428-436 (amino acid position numbering according to the EU index). In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises one or more of: an amino acid substitution at Kabat position 252 with Tyr, Phe, Trp, or Thr; an amino acid substitution at Kabat position 254 with Thr; an amino acid substitution at Kabat position 256 with Ser, Arg, Gln, Glu, Asp, or Thr; an amino acid substitution at Kabat position 257 with Leu; an amino acid substitution at Kabat position 309 with Pro; an amino acid substitution at Kabat position 311 with Ser; an amino acid substitution at Kabat position 428 with Thr, Leu, Phe, or Ser; an amino acid substitution at Kabat position 433 with Arg, Ser, Iso, Pro, or Gln; or an amino acid substitution at Kabat position 434 with Trp, Met, Ser, His, Phe, or Tyr. More specifically, the EpCAM antibody or EpCAM-binding antibody fragment domain may comprise amino acid substitutions relative to the wild-type human IgG constant domain, such as substitution of the amino acid at Kabat position 252 with Tyr, substitution of the amino acid at Kabat position 254 with Thr, and substitution of the amino acid at Kabat position 256 with Glu.

[0124] In some embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises at least one substitution selected from T250Q, M252Y, S254T, T256E, K288D, T307Q, V308P, A378V, M428L, N434A, N434S, N434H, N434Y, H435K, and Y436I (numbering is according to the EU index in Kabat). In further embodiments, the EpCAM antibody or EpCAM-binding antibody fragment comprises substitutions selected from: (a) M252Y, S254T and T256E; (b) M252Y and S254T; (c) M252Y and T256E; (d) T250Q and M428L; (e) T307Q and N434A; (f) A378V and N434A; (g) N434A and Y436I; (h) V308P and N434A; and (i) K288D and H435K.

[0125] In a preferred embodiment, the EpCAM antibody or EpCAM-binding antibody fragment comprises a variant IgG Fc region comprising any one, two, or three of the following substitutions: M252Y, S254T, and T256E. The present disclosure further provides EpCAM antibodies or EpCAM-binding antibody fragments having variant Fc regions comprising: (a) one or more mutations that alter effector function and / or FcγR; (b) one or more mutations that extend serum half-life.

[0126] EpCAM activatable antibody In further embodiments, the present disclosure provides EpCAM-activatable antibodies (e.g., activatable EpCAM antibodies and activatable EpCAM-binding antibody fragments). In some embodiments, the EpCAM-activatable antibodies comprise an EpCAM antibody or EpCAM-binding antibody fragment that specifically binds to EpCAM (e.g., human EpCAM) linked to a masking moiety (MM), such that binding of the MM reduces the ability of the EpCAM antibody or EpCAM-binding antibody fragment to bind to EpCAM. In some embodiments, the MM is linked via a sequence comprising a substrate for a protease, e.g., a protease active in diseased tissue and / or co-localized with EpCAM at the target therapeutic site. The EpCAM-activatable antibodies are preferably stable in circulation, activated at the intended therapeutic and / or diagnostic site, but not in normal, e.g., healthy tissue, or other tissue not targeted for therapeutic and / or diagnostic treatment, and, upon activation, exhibit binding to EpCAM at a level at least equivalent to that of the corresponding unmodified antibody. Also provided are immunoconjugates comprising the EpCAM-activatable antibodies, nucleic acids or sequences of nucleic acids encoding the EpCAM-activatable antibodies, and vectors and host cells comprising the nucleic acids. Pharmaceutical compositions comprising the activatable antibodies, immunoconjugates, nucleic acids, vectors, and host cells are also provided.

[0127] In some embodiments, the EpCAM activatable antibody or antibody fragment is (a) a cleavable moiety attached to an antibody or antibody fragment, wherein the cleavable moiety is a polypeptide that functions as a substrate for a protease; and (b) a masking moiety attached to an antibody or antibody fragment, wherein the masking moiety inhibits binding of the antibody or antibody fragment to EpCAM when the activatable antibody is in an uncleaved state; wherein the uncleaved activatable antibody has an N- to C-terminal structural arrangement of (masking moiety)-(cleavable moiety)-(antibody or antibody fragment) or (antibody or antibody fragment)-(cleavable moiety)-(masking moiety). An EpCAM-activatable antibody, (a) an EpCAM antibody or EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of members selected from the group consisting of: (i) SEQ ID NOs: 13-15, 42, 40, and 41, respectively; (ii) SEQ ID NOs: 13-15, and 39-41, respectively; (iii) SEQ ID NOs: 13, 26, 15, and 39-41, respectively; (iv) SEQ ID NOs: 13, 24, 15, 42, 40, and 41, respectively; (b) a masking moiety attached to the EpCAM antibody or EpCAM-binding antibody fragment, wherein the masking moiety inhibits binding of the antibody or antibody fragment to EpCAM when the activatable antibody is in an uncleaved state; and (c) a cleavable moiety attached to an EpCAM antibody or EpCAM-binding antibody fragment, wherein the cleavable moiety is a polypeptide that functions as a substrate for a protease; wherein the uncleaved activatable antibody has an N-terminal to C-terminal structural arrangement of (masking moiety)-(cleavable moiety)-(antibody or antibody fragment) or (antibody or antibody fragment)-(cleavable moiety)-(masking moiety).

[0128] An activated EpCAM-activatable antibody binds to human EpCAM and comprises (i) an EpCAM antibody or EpCAM-binding antibody fragment (Ab) that specifically binds to human EpCAM (e.g., as disclosed herein); (ii) a masking moiety (MM) that inhibits binding of the EpCAM-activatable antibody to EpCAM when the EpCAM-activatable antibody is in an uncleaved state; and (c) a cleavable moiety (CM), a polypeptide that functions as a substrate for a protease, attached to the EpCAM antibody or EpCAM-binding antibody fragment. In some embodiments, the uncleaved EpCAM-activatable antibody has an N- to C-terminal structural configuration of MM-CM-Ab or Ab-CM-MM. In some embodiments, the EpCAM-activatable antibody comprises a linking peptide between the MM and the CM. In some embodiments, the EpCAM-activatable antibody comprises a linking peptide between the CM and the Ab.

[0129] In some embodiments, the uncleaved EpCAM activatable antibody specifically binds to mammalian EpCAM with a dissociation constant of 1 nM or less, 5 nM or less, 10 nM or less, 15 nM or less, 20 nM or less, 25 nM or less, 50 nM or less, 100 nM or less, 150 nM or less, 250 nM or less, 500 nM or less, 750 nM or less, 1000 nM or less, and 2000 nM or less.

[0130] In some embodiments, the uncleaved EpCAM activatable antibody specifically binds to mammalian EpCAM (e.g., human EpCAM or cynomolgus EpCAM) with a dissociation constant of 1 nM or more, 5 nM or more, 10 nM or more, 15 nM or more, 20 nM or more, 25 nM or more, 50 nM or more, 100 nM or more, 150 nM or more, 250 nM or more, 500 nM or more, 750 nM or more, 1000 nM or more, and 2000 nM or more.

[0131] In some embodiments, the uncleaved EpCAM-activatable antibody has a cleavage activity of 1 nM to 2000 nM, 1 nM to 1000 nM, 1 nM to 750 nM, 1 nM to 500 nM, 1 nM to 250 nM, 1 nM to 150 nM, 1 nM to 100 nM, 1 nM to 50 nM, 1 nM to 25 nM, 1 nM to 15 nM, 1 nM to 10 nM, 1 nM to 5 nM, 5 nM to 2000 nM, 5 nM to 1000 nM, 5 nM to 750 nM, 5 nM to 500 nM, 5 nM to 250 nM, 5 nM to 150 nM, 5 nM to 100 nM, 5 nM to 50 nM, 5 nM to 25 nM, 5 nM to 15 nM M, 5nM~10nM, 10nM~2000nM, 10nM~1000nM, 10nM~750nM, 10nM~500nM, 10nM ~250nM, 10nM~150nM, 10nM~100nM, 10nM~50nM, 10nM~25nM, 10nM~15nM, 15 nM~2000nM, 15nM~1000nM, 15nM~750nM, 15nM~500nM, 15nM~250nM, 15nM~1 50nM, 15nM~100nM, 15nM~50nM, 15nM~25nM, 25nM~2000nM, 25nM~1000nM, 25 nM~750nM, 25nM~500nM, 25nM~250nM, 25nM~150nM, 25nM~100nM, 25nM~50n M, 50nM~2000nM, 50nM~1000nM, 50nM~750nM, 50nM~500nM, 50nM~250nM, 50 nM~150nM, 50nM~100nM, 100nM~2000nM, 100nM~1000nM, 100nM~750nM, 100 nM~500nM, 100nM~250nM, 100nM~150nM, 150nM~2000nM, 150nM~1000nM, 150 Mammalian EpCAM (e.g., EpCAM-1) with a dissociation constant in the range of nM to 750 nM, 150 nM to 500 nM, 150 nM to 250 nM, 250 nM to 2000 nM, 250 nM to 1000 nM, 250 nM to 750 nM, 250 nM to 500 nM, 500 nM to 2000 nM, 500 nM to 1000 nM, 500 nM to 750 nM, 500 nM to 500 nM, 500 nM to 250 nM, 500 nM to 150 nM, 500 nM to 100 nM, 500 nM to 50 nM, 750 nM to 2000 nM, 750 nM to 1000 nM, or 1000 nM to 2000 nM.It specifically binds to human EpCAM or cynomolgus monkey EpCAM.

[0132] In some embodiments, an activating-state EpCAM activatable antibody specifically binds to mammalian EpCAM (e.g., human EpCAM or cynomolgus EpCAM) with a dissociation constant of 0.01 nM, 0.05 nM, 0.1 nM, 0.5 nM, 1 nM, 5 nM, or 10 nM or less. In some embodiments, an activating-state EpCAM activatable antibody specifically binds to mammalian EpCAM with a dissociation constant of 0.01 nM, 0.05 nM, 0.1 nM, 0.5 nM, 1 nM, 5 nM, or 10 nM or more.

[0133] In some embodiments, the activated state of an EpCAM activatable antibody is between 0.01 nM and 100 nM, 0.01 nM and 10 nM, 0.01 nM and 5 nM, 0.01 nM and 1 nM, 0.01 and 0.5 nM, 0.01 nM and 0.1 nM, 0.01 nM and 0.05 nM, 0.05 nM and 100 nM, 0.05 nM and 10 nM, 0.05 nM and 5 nM, 0.05 nM and 1 nM, 0.05 and 0.5 nM, 0.05 nM and 0.1 nM, 0.1 nM and 100 nM Specifically binds to mammalian EpCAM (e.g., human EpCAM or cynomolgus EpCAM) with a dissociation constant in the range of 0.1 nM to 10 nM, 0.1 nM to 5 nM, 0.1 nM to 1 nM, 0.1 to 0.5 nM, 0.5 nM to 100 nM, 0.5 nM to 10 nM, 0.5 nM to 5 nM, 0.5 nM to 1 nM, 1 nM to 100 nM, 1 nM to 10 nM, 1 nM to 5 nM, 5 nM to 100 nM, 5 nM to 10 nM, or 10 nM to 100 nM.

[0134] In some embodiments, the EpCAM-activatable antibody specifically binds to human EpCAM with a dissociation constant of less than 1 nM. In some embodiments, the EpCAM-activatable antibody specifically binds to cynomolgus EpCAM with a dissociation constant of less than 1 nM. In some embodiments, the EpCAM-activatable antibody specifically binds to human EpCAM and cynomolgus EpCAM with a dissociation constant of less than 1 nM.

[0135] In some embodiments, the serum half-life of the EpCAM-activatable antibody is longer than the serum half-life of the corresponding antibody; e.g., the pK of the EpCAM-activatable antibody is longer than the pK of the corresponding antibody. In some embodiments, the serum half-life of the EpCAM-activatable antibody is similar to the serum half-life of the corresponding antibody.

[0136] In some embodiments, the EpCAM-activatable antibody comprises an EpCAM antibody or EpCAM-binding antibody fragment comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 set forth in a row of Table 2. In some embodiments, the EpCAM-activatable antibody comprises an EpCAM antibody or EpCAM-binding antibody fragment comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 having sequences set forth in a row of Table 3.

[0137] In some embodiments, the EpCAM-activatable antibody comprises an EpCAM antibody or EpCAM-binding antibody fragment comprising a VH-CDR1 selected from SEQ ID NOs: 13 and 16-25; a VH-CDR2 selected from SEQ ID NOs: 14 and 26-29; and a VH-CDR3 selected from SEQ ID NOs: 15 and 30-38; a VL-CDR1 selected from SEQ ID NOs: 39 and 42-45; a VL-CDR2 of SEQ ID NO: 40; and a VL-CDR3 selected from SEQ ID NOs: 41 and 46-51.

[0138] In some embodiments, the EpCAM-activatable antibody comprises an EpCAM antibody or an EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having sequences selected from the group consisting of: (i) SEQ ID NOs: 13-15, 42, 40, and 41, respectively; (ii) SEQ ID NOs: 13-15 and 39-41, respectively; (iii) SEQ ID NOs: 13, 26, 15, and 39-41, respectively; and (iv) SEQ ID NOs: 13, 26, 15, 42, 40, and 41, respectively. In some embodiments, the EpCAM-activatable antibody comprises an EpCAM antibody or an EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 13-15, 42, 40, and 41, respectively.

[0139] In some embodiments, the EpCAM activatable antibody comprises an EpCAM antibody or EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having sequences selected from the group consisting of: (i) SEQ ID NOs: 22, 14, 15, 42, 40, and 41, respectively; (ii) SEQ ID NOs: 13, 14, 33, 42, 40, and 41, respectively; (iii) SEQ ID NOs: 23, 14, 15, 42, 40, and 41, respectively; and (iv) SEQ ID NOs: 25, 14, 15, 42, 40, and 41, respectively. In some embodiments, the EpCAM-activatable antibody comprises an EpCAM antibody or an EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 22, 14, 15, 42, 40, and 41, respectively. In some embodiments, the EpCAM-activatable antibody comprises an EpCAM antibody or an EpCAM-binding antibody fragment comprising VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 having the sequences of SEQ ID NOs: 13, 14, 33, 42, 40, and 41, respectively.

[0140] In some embodiments, the EpCAM activatable antibody comprises a VH disclosed in Table 4. In some embodiments, the EpCAM activatable antibody comprises a VL disclosed in Table 5. In some embodiments, the EpCAM activatable antibody comprises a VH having the sequence of SEQ ID NO:54 and a VL having the sequence of SEQ ID NO:89. In some embodiments, the EpCAM activatable antibody comprises an EpCAM antibody or EpCAM-binding antibody fragment comprising a VH having the sequence of SEQ ID NO:75 and a VL having the sequence of SEQ ID NO:89. In some embodiments, the EpCAM activatable antibody comprises an EpCAM antibody or EpCAM-binding antibody fragment comprising a VH having the sequence of SEQ ID NO:77 and a VL having the sequence of SEQ ID NO:89.

[0141] In some embodiments, the EpCAM activatable antibody comprises a VH sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a sequence selected from SEQ ID NOs: 54, 75, and 77. In some embodiments, the EpCAM activatable antibody comprises a VL sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence of SEQ ID NO: 89.

[0142] In some embodiments, the EpCAM activatable antibody comprises a HC disclosed in Table 6. In some embodiments, the EpCAM activatable antibody comprises a LC disclosed in Table 7. In some embodiments, the EpCAM activatable antibody comprises a HC having the sequence of SEQ ID NO: 103 and a LC having the sequence of SEQ ID NO: 140. In some embodiments, the EpCAM activatable antibody comprises a HC having the sequence of SEQ ID NO: 125 and a LC having the sequence of SEQ ID NO: 140. In some embodiments, the EpCAM activatable antibody comprises a HC having the sequence of SEQ ID NO: 127 and a light chain having the sequence of SEQ ID NO: 140.

[0143] In some embodiments, the EpCAM-activatable antibody comprises an EpCAM antibody or an EpCAM-binding antibody fragment that specifically binds to an epitope within the extracellular region of human EpCAM (SEQ ID NO: 1). In certain embodiments, the EpCAM-activatable antibody comprises an EpCAM antibody or an EpCAM-binding antibody fragment that specifically binds to an epitope within the first extracellular domain (D1) of human EpCAM (SEQ ID NO: 2).

[0144] In some embodiments, the EpCAM activatable antibody comprises X1YX3X4H, where X1 is selected from N and S, X3 is selected from Y, N, F, S, H, D, L, I, and W, and X4 is selected from I and M, VH-CDR1 (SEQ ID NO: 5); sequence WX2X3PGX6VYIQYX 12 X 13 KFX 17 G, X2 is selected from I and F, X3 is selected from Y and N, X6 is selected from N and D, and X 12 is selected from N and S, and X 13 is selected from E and Q, and X 17 is selected from K and Q; and VH-CDR3 (SEQ ID NO: 8) wherein X1 is selected from D and E, X3 is selected from P, A, S, Y, F, G, T, and V, and X4 is selected from Y and W. In some embodiments, the EpCAM activatable antibody comprises a VH-CDR2 (SEQ ID NO: 7) comprising X1GX3X4FAY, where X1 is selected from D and E, X3 is selected from P, A, S, Y, F, G, T, and V, and X4 is selected from Y and W. 10 GX 12 TYLX 16 X4 is selected from R and K; 10 is selected from N and D, and X 12 is selected from F and I, and X 16is selected from Y and S; light chain VL-CDR2 (SEQ ID NO: 40) comprising QTSNLAS; and VL-CDR3 (SEQ ID NO: 11) comprising X1QX3LELPX8T, where X1 is selected from A, L, and Q, X3 is selected from S, G, Y, and N, and X8 is selected from N and W. In some embodiments, the EpCAM activatable antibody comprises a VH-CDR1 comprising the sequence of SEQ ID NO: 13; a VH-CDR2 comprising the sequence of SEQ ID NO: 14; a heavy chain VH-CDR3 comprising the sequence of SEQ ID NO: 15; a VL-CDR1 comprising the sequence of SEQ ID NO: 42; a VL-CDR2 comprising the sequence of SEQ ID NO: 40; and a VL-CDR3 comprising the sequence of SEQ ID NO: 41.

[0145] In some embodiments, the VH-CDR1 of the EpCAM-activatable antibody comprises the sequence NYX3IH, where X3 is selected from Y, N, F, S, H, D, L, I, and W (SEQ ID NO: 6). In some embodiments, the VH-CDR3 of the EpCAM-activatable antibody comprises the sequence DGPX4FAY, where X4 is selected from Y and W (SEQ ID NO: 9). In some embodiments, the VL-CDR3 of the EpCAM-activatable antibody comprises the sequence AQX3LELPNT, where X3 is selected from S, G, Y, and N (SEQ ID NO: 12). In some embodiments, the EpCAM-activatable antibody comprises a VH-CDR1 comprising the sequence of SEQ ID NO: 13; a VH-CDR2 comprising the sequence of SEQ ID NO: 14; a heavy chain VH-CDR3 comprising the sequence of SEQ ID NO: 15; a VL-CDR1 comprising the sequence of SEQ ID NO: 42; a VL-CDR2 comprising the sequence of SEQ ID NO: 40; and a VL-CDR3 comprising the sequence of SEQ ID NO: 41.

[0146] Suitable components of the disclosed EpCAM-activatable antibodies also include EpCAM antibodies or EpCAM-binding antibody fragments that cross-compete for binding to human EpCAM and / or cynomolgus EpCAM with an EpCAM antibody comprising a VH having the sequence of SEQ ID NO: 54 and a VL having the sequence of SEQ ID NO: 89. Additional suitable EpCAM-activatable antibodies cross-compete for binding to human EpCAM and / or cynomolgus EpCAM with an EpCAM antibody comprising a VH having the sequence of SEQ ID NO: 75 and a VL having the sequence of SEQ ID NO: 89. Additional suitable EpCAM-activatable antibodies cross-compete for binding to human EpCAM and / or cynomolgus EpCAM with an EpCAM antibody comprising a VH having the sequence of SEQ ID NO: 77 and a VL having the sequence of SEQ ID NO: 89.

[0147] The EpCAM activatable antibodies provided herein comprise a masking moiety (MM). In some embodiments, the masking moiety (or "mask") is an amino acid sequence that is linked or otherwise attached to the EpCAM antibody and is positioned within the EpCAM activatable antibody construct so that the masking moiety reduces the ability of the EpCAM antibody to specifically bind to EpCAM. Suitable masking moieties are identified using any of a variety of known techniques. For example, peptide masking moieties are identified using the methods described in WO2009 / 025846 (the contents of which are incorporated herein by reference in their entirety).

[0148] In some embodiments, the MM of the activatable antibody has a dissociation constant for binding to the Ab that is greater than the dissociation constant of the Ab to EpCAM, hi some embodiments, the MM has a dissociation constant for binding to the Ab that is equal to or less than the dissociation constant of the Ab to EpCAM.

[0149] In some embodiments, the MM has a dissociation constant for binding to the Ab that is less than the dissociation constant of the Ab to EpCAM.

[0150] In some embodiments, the dissociation constant (Kd) of the MM for the Ab is 2, 3, 4, 5, 10, 25, 50, 100, 250, 500, 1,000, 2,500, 5,000, 10,000, 50,000, 100,000, 500,000, 1,000,000, 5,000,000, 10,000,000, 50,000,000 or more times greater than the dissociation constant of the Ab for its target, or 1-5, 5-10, 10-100, 10-1,000, 10-10,000, 10-100,000, 10-1,000,000 or more times greater than the dissociation constant of the Ab for its target. 0, 10-10,000,000, 100-1,000, 100-10,000, 100-100,000, 100-1,000,000, 100-10,000,000, 1,000-10,000, 1,000-100,000, 1,000-1,000,000, 1000-10,000,000, 10,000-100,000, 10,000-10,000,000, 100,000-1,000,000, or 100,000-10,000,000 times or more.

[0151] In some embodiments, when the EpCAM-activatable antibody is in a cleaved state, the MM does not interfere with or compete with the Ab for binding to EpCAM. In some embodiments, the MM is a polypeptide between 2 and 40 amino acids in length. In some embodiments, the MM is a polypeptide up to 40 amino acids in length.

[0152] In some embodiments, the MM polypeptide sequence differs from that of EpCAM. In some embodiments, the MM polypeptide sequence is 50% or less identical to any natural binding partner of the Ab. In some embodiments, the MM polypeptide sequence differs from that of EpCAM and is 40%, 30%, 25%, 20%, 15%, or 10% or less identical to any natural binding partner of the Ab.

[0153] In some embodiments, binding of the MM to the Ab reduces the ability of the Ab to bind to EpCAM, such that the dissociation constant (IQ) of the Ab for EpCAM when bound to MM is at least 2, 5, 10, 20, 40, 100, 1000, 10,000 times greater than the IQ of the Ab for EpCAM when not bound to MM.

[0154] In some embodiments, in an in vitro assay using, for example, a target displacement assay such as that described in WO2010 / 081173 (the contents of which are incorporated herein by reference), in the presence of EpCAM, MM reduces the ability of an Ab to bind to EpCAM by at least 90% when the CM is uncleaved compared to when the CM is cleaved.

[0155] When an Ab is modified with MM and in the presence of human EpCAM, the specific binding of the Ab to human EpCAM is reduced or inhibited compared to the specific binding of an Ab not modified with MM or the parent Ab to human EpCAM.

[0156] The IQ of the MM-modified Ab against human EpCAM is at least 5, 10, 25, 50, 100, 250, 500, 1,000, 2,500, 5,000, 10,000, 50,000, 100,000, 500,000, 1,000,000, 5,000,000, 10,000,000, 50,000,000 or more times greater than the IQ of the non-MM-modified Ab or parent Ab against human EpCAM, or is at least 5-10, 10-100, 10-1,000, 10-10,000, 10-100,000, 10- 1,000,000, 10-10,000,000, 100-1,000, 100-10,000, 100-100,000, 100-1,000,000, 100-10,000,000, 1,000-10,000, 1,000-100,000, 1,000-1,000,000, 10,000-100,000, 10,000-1,000,000, 10,000-10,000,000, 100,000-1,000,000, or 100,000-10,000,000 times larger. Conversely, the binding affinity of the MM-modified Ab to human EpCAM is at least 2, 3, 4, 5, 10, 25, 50, 100, 250, 500, 1,000, 2,500, 5,000, 10,000, 50,000, 100,000, 500,000, 1,000,000, 5,000,000, 10,000,000, 50,000,000 or more times greater, or 5-10, 10-100, 10-1,000, 10-10,000, 10-100, or 10-100 times greater, than the binding affinity of the non-MM-modified or parent Ab to human EpCAM. ,000, 10 to 1,000,000, 10 to 10,000,000, 100 to 1,000, 100 to 10,000, 100 to 100,000, 100 to 1,000,000, 100 to 10,000,000, 1,000 to 10,000,000, 1,000 to 100,000, 10,000 to 100,000, 10,000 to 1,000,000, 10,000 to 10,000,000, 100,000 to 1,000,000, or 100,000 to 10,000,000 times smaller.

[0157] In some embodiments, the dissociation constant (Kd) of the MM for the Ab is approximately equal to the Kd of the Ab for human EpCAM. In some embodiments, the dissociation constant (Kd) of the MM for the Ab is equal to or less than the dissociation constant of the Ab for human EpCAM. In some embodiments, the dissociation constant (Kd) of the MM for the Ab is less than the dissociation constant of the Ab for human EpCAM. In some embodiments, the dissociation constant (Kd) of the MM for the Ab is greater than the dissociation constant of the Ab for human EpCAM.

[0158] In some embodiments, the MM has a dissociation constant for binding to the Ab that is equal to or less than the dissociation constant for binding of the Ab to human EpCAM.

[0159] In some embodiments, the MM has a dissociation constant for binding to the Ab that is equal to or greater than the dissociation constant for binding of the Ab to human EpCAM. In some embodiments, the MM has a K for binding to the Ab that is about equal to the K for binding of the Ab to human EpCAM. d In some embodiments, the MM has a dissociation constant for binding to the Ab that is less than the dissociation constant for binding of the Ab to human EpCAM. In some embodiments, the MM has a K d In some embodiments, the MM has a Kd for binding to the Ab that is 2, 3, 4, 5, 10, 25, 50, 100, 250, 500, or 1,000 times greater than the Kd for binding of the Ab to human EpCAM. d In some embodiments, the MM has a K d has a Kd for binding to Ab that is 1 to 5, 2 to 5, 2 to 10, 5 to 10, 5 to 20, 5 to 50, 5 to 100, 10 to 100, 10 to 1,000, 20 to 100, 20 to 1,000, or 100 to 1,000 times greater than the Kd for binding to Ab.

[0160] In some embodiments, the MM has a binding affinity for the Ab that is less than the binding affinity of the Ab to human EpCAM. In some embodiments, the MM has a binding affinity for the Ab that is less than or equal to the binding affinity of the Ab to human EpCAM. In some embodiments, the MM has a binding affinity for the Ab that is approximately equal to the binding affinity of the Ab to human EpCAM. In some embodiments, the MM has a binding affinity for the Ab that is greater than or equal to the binding affinity of the Ab to human EpCAM. In some embodiments, the MM has a binding affinity for the Ab that is greater than the binding affinity of the Ab to human EpCAM.

[0161] In some embodiments, the MM has a binding affinity for the Ab that is 2, 3, 4, 5, 10, 25, 50, 100, 250, 500, or 1,000-fold less than the binding affinity of the Ab to human EpCAM. In some embodiments, the MM has a binding affinity for the Ab that is 1-5, 2-5, 2-10, 5-10, 5-20, 5-50, 5-100, 10-100, 10-1,000, 20-100, 20-1,000, or 100-1,000-fold less than the binding affinity of the Ab to human EpCAM. In some embodiments, the MM has a binding affinity for the Ab that is 2-20-fold less than the binding affinity of the Ab to human EpCAM. In some embodiments, the MM is not covalently bound to the Ab, and at an equimolar concentration relative to the EpCAM-activatable antibody, the MM does not inhibit the binding of the Ab to human EpCAM.

[0162] When an Ab is modified with MM and in the presence of human EpCAM, the specific binding of the Ab to human EpCAM is reduced or inhibited compared to the specific binding of an Ab not modified with MM or the parent Ab to human EpCAM. The ability of an Ab to bind to human EpCAM when modified with MM may be reduced by at least 50%, 60%, 70%, 80%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, and even 100% over a period of at least 2, 4, 6, 8, 12, 28, 24, 30, 36, 48, 60, 72, 84, or 96 hours, or 5, 10, 15, 30, 45, 60, 90, 120, 150, or 180 days, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months or more, as measured in an in vivo or in vitro assay, compared to the binding of an Ab or parent Ab to human EpCAM that is not modified with MM.

[0163] The MM inhibits the binding of the Ab to human EpCAM. The MM binds to the antigen-binding domain of the Ab and inhibits the binding of the Ab to human EpCAM. The MM can sterically inhibit the binding of the Ab to human EpCAM. The MM can allosterically inhibit the binding of the Ab to its target. In these embodiments, when the Ab is modified with or conjugated to a MM and in the presence of the target, the Ab exhibits enhanced binding to human EpCAM for at least 2, 4, 6, 8, 12, 28, 24, 30, 36, 48, 60, 72, 84, or 96 hours, or for 5, 10, 15, 30, 45, 60, 90, 120, 140, 160, 180, 200, 220, 240, 260, 280, 240, 300, 360, 480, 600, 720, 840, or 96 hours, as measured in an in vivo or in vitro assay, compared to the binding of the Ab not modified with the MM or the parent Ab, or the Ab not conjugated to the MM, to human EpCAM. Over a period of 150, or 180 days, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months or more, there is no or substantially no binding of Ab to human EpCAM, or there is no more than 0.001%, 0.01%, 0.1%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, or 50% binding of Ab to human EpCAM.

[0164] When an Ab is bound to or modified by an MM, the MM "masks," or reduces, or otherwise inhibits, the specific binding of the Ab to human EpCAM. When an Ab is bound to or modified by an MM, such binding or modification may result in a conformational change that reduces or inhibits the ability of the Ab to specifically bind to its target.

[0165] Abs bound to or modified with MM can be represented by the following formula (from the amino (N)-terminal region to the carboxyl (C)-terminal region): (MM)-(Ab) (Ab)-(MM) (MM)-L-(Ab) (Ab)-L-(MM) wherein MM is a masking moiety, Ab is an EpCAM antibody, an EpCAM-binding antigen fragment, and L is a linker. In many embodiments, it may be desirable to insert one or more linkers, e.g., flexible linkers, into the composition to provide flexibility.

[0166] In certain embodiments, the MM is not a natural binding partner of the Ab. In some embodiments, the MM has no or substantially no homology to any natural binding partner of the Ab. In some embodiments, the MM is 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% or less similar to any natural binding partner of the Ab. In some embodiments, the MM is 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% or less identical to any natural binding partner of the Ab. In some embodiments, the MM is 25% or less identical to any natural binding partner of the Ab. In some embodiments, the MM is no more than 50% identical to any of the Ab's natural binding partners. In some embodiments, the MM is no more than 20% identical to any of the Ab's natural binding partners. In some embodiments, the MM is no more than 10% identical to any of the Ab's natural binding partners.

[0167] In some embodiments, the MM comprises a sequence disclosed in Table 9. In some embodiments, the MM comprises a sequence selected from SEQ ID NOs: 151-157. In some embodiments, the MM comprises a sequence selected from SEQ ID NOs: 158-161. In some embodiments, the MM comprises a sequence selected from SEQ ID NOs: 162-167. In some embodiments, the MM comprises the sequence of SEQ ID NO: 155. [Table 9]

[0168] The EpCAM-activatable antibodies provided herein comprise a cleavable moiety. In some embodiments, the cleavable moiety (or "substrate") comprises an amino acid sequence that is a substrate for a protease, typically an extracellular protease. Suitable substrates are identified using any of a variety of known techniques. For example, peptide substrates are identified using the methods described in U.S. Pat. Nos. 7,666,817 and 8,563,269; and WO 2014 / 026136 (the contents of each of which are incorporated herein by reference in their entirety). (See also Boulware et al., Biotechnol Bioeng. 106(3):339-346 (2010)).

[0169] In some embodiments, EpCAM-activatable antibodies include Abs that are modified with a MM and also include one or more cleavable moieties (CM). Such EpCAM-activatable antibodies exhibit activatable / switchable binding to human EpCAM. EpCAM-activatable antibodies typically include an antibody or antigen-binding antibody fragment (Ab) modified with or attached to a masking moiety (MM) and a modifiable or cleavable moiety (CM). In some embodiments, the CM includes an amino acid sequence that functions as a substrate for at least one protease.

[0170] The components of the EpCAM-activatable antibody are arranged so that in the presence of human EpCAM, when the MM and CM are cleaved (or relatively active), the EpCAM-activatable antibody binds to human EpCAM, but when the EpCAM-activatable antibody is in an uncleaved (or relatively inactive) state in the presence of human EpCAM, the specific binding of the EpCAM-activatable antibody to human EpCAM is reduced or inhibited. Specific binding of the EpCAM-activatable antibody to human EpCAM can be reduced by inhibition or masking of the ability of the EpCAM-activatable antibody to specifically bind to human EpCAM by the MM.

[0171] The IQ of an EpCAM-activatable antibody modified with MM and CM against human EpCAM is at least 5, 10, 25, 50, 100, 250, 500, 1,000, 2,500, 5,000, 10,000, 50,000, 100,000, 500,000, 1,000,000, 5,000,000, 10,000,000, 50,000,000 or more times greater, or 5-10, 10-100, 10-1,000, 10-10,000, 10 ~100,000, 10~1,000,000, 10~10,000,000, 100~1,000, 100~10,000, 100~100,000, 100~1,000,000, 1,000~10,000, 1,000~100,000, 1,0 00 to 1,000,000, 1000 to 10,000,000, 10,000 to 100,000, 10,000 to 1,000,000, 10,000 to 10,000,000, 100,000 to 1,000,000, or 100,000 to 10,000,000 times or more larger.Conversely, the binding affinity of an Ab modified with MM and CM to human EpCAM is at least 5, 10, 25, 50, 100, 250, 500, 1,000, 2,500, 5,000, 10,000, 50,000, 100,000, 500,000, 1,000,000, 5,000,000, 10,000,000, 50,000,000 or more times greater, or 5-10, 10-100, 10-1,000, 10-10,000 times greater, than the binding affinity of an EpCAM-activatable antibody or parent Ab that is not modified with MM and CM to human EpCAM. , 10~100,000, 10~1,000,000, 10~10,000,000, 100~1,000, 100~10,000, 100~1,000,000, 100~10,000,000, 1,000~10,000,000, 1,000~10,000, 1,000~100,000 , 1,000-1,000,000, 1000-10,000,000, 10,000-100,000, 10,000-1,000,000, 10,000-10,000,000, 100,000-1,000,000, or 100,000-10,000,000 times smaller.

[0172] When an EpCAM-activatable antibody is modified with MM and CM and in the presence of human EpCAM but not in the presence of a modifying agent (e.g., at least one protease), the specific binding of the EpCAM-activatable antibody to human EpCAM is reduced or inhibited compared to the specific binding of an EpCAM-activatable antibody or parent Ab that is not modified with MM and CM to human EpCAM. The ability of the EpCAM activatable antibody when modified with MM and CM to bind to human EpCAM may be reduced by at least 50%, 60%, 70%, 80%, 90%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, and even 100% for at least 2, 4, 6, 8, 12, 28, 24, 30, 36, 48, 60, 72, 84, or 96 hours, or 5, 10, 15, 30, 45, 60, 90, 120, 150, or 180 days, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months or longer, as measured in an in vivo or in vitro assay, compared to the binding to human EpCAM of the parent Ab or an EpCAM activatable antibody that is not modified with MM and CM.

[0173] As used herein, the term "cleaved state" refers to the state of an EpCAM-activatable antibody after modification of the CM by at least one protease. As used herein, the term "uncleaved or intact state" refers to the state of an EpCAM-activatable antibody in the absence of cleavage of the CM by a protease. As discussed above, the terms "activatable antibody" or "activatable antibody" herein refer to an EpCAM-activatable antibody in both its uncleaved (native or intact) state as well as its cleaved state. Those skilled in the art will recognize that in some embodiments, a cleaved EpCAM-activatable antibody lacks MM due to cleavage of the CM by a protease, and may release at least MM (e.g., when the MM is not covalently bound to the EpCAM-activatable antibody (e.g., when a disulfide bond between cysteine ​​residues)).

[0174] Activatable or switchable means that when the EpCAM-activatable antibody is in an inhibited, masked, unprocessed, or uncleaved state (i.e., a first conformation), the EpCAM-activatable antibody exhibits a first level of binding to a target, and when in an uninhibited, unmasked, and / or cleaved state (i.e., a second conformation), it exhibits a second level of binding to human EpCAM, the second level of target binding being greater than the first level of binding. Generally, human EpCAM is more accessible to an Ab of an EpCAM-activatable antibody in the presence of a cleaving agent, i.e., a protease, that can cleave EpCAM than in the absence of such a cleaving agent. Thus, when the EpCAM-activatable antibody is in the uncleaved state, the Ab is inhibited from binding to human EpCAM and can be masked from human EpCAM binding (i.e., the first conformation prevents the Ab from binding to human EpCAM), and in the cleaved state, the Ab is inhibited or unmasked from binding to the target.

[0175] The CM and Ab of an EpCAM-activatable antibody are selected so that the Ab serves as a binding moiety for a given target and the CM serves as a substrate for a protease. In some embodiments, the protease co-localizes with human EpCAM at a therapeutic or diagnostic site of a subject. As used herein, co-localization means being at the same site or a relatively nearby site. In some embodiments, the protease cleaves the CM and produces an activating antibody that binds to a target located near the cleavage site. The EpCAM-activatable antibody disclosed herein is particularly useful, for example, when a protease capable of cleaving a site in the CM is present at a relatively higher level in target-containing tissue at a therapeutic or diagnostic site than in tissue at a non-therapeutic site (e.g., healthy tissue). In some embodiments, the CM of the present disclosure is also cleaved by one or more other proteases. In some embodiments, it is one or more other proteases that co-localize with human EpCAM and are involved in cleaving the CM in vivo.

[0176] In some embodiments, the EpCAM activatable antibody results in reduced toxicity and / or adverse side effects that may otherwise result from binding of the EpCAM activatable antibody at non-therapeutic sites if the EpCAM activatable antibody is not masked or inhibited from binding to human EpCAM.

[0177] In general, an EpCAM-activatable antibody can be designed by selecting an Ab of interest and constructing the remainder of the EpCAM-activatable antibody so that, when structurally constrained, the MM masks the EpCAM-activatable antibody or reduces its binding to human EpCAM. Structural design criteria can be considered for this functional feature.

[0178] EpCAM-activatable antibodies are provided that exhibit a desired dynamic range of switchable phenotypes for target binding between inhibited and uninhibited conformations. Dynamic range typically refers to the ratio of (a) the maximum detectable level of a parameter under a first set of conditions to (b) the minimum detectable value of that parameter under a second set of conditions. For example, in the case of an EpCAM-activatable antibody, dynamic range refers to the ratio of (a) the maximum detectable level of target protein binding to the EpCAM-activatable antibody in the presence of at least one protease capable of cleaving the CM of the EpCAM-activatable antibody to (b) the minimum detectable level of target protein binding to the EpCAM-activatable antibody in the absence of the protease. The dynamic range of an EpCAM-activatable antibody can be calculated as the ratio of the dissociation constant of treatment with an EpCAM-activatable antibody cleaving agent (e.g., an enzyme) to the dissociation constant of treatment with the EpCAM-activatable antibody cleaving agent. The greater the dynamic range of the EpCAM-activatable antibody, the better the switchable phenotype of the EpCAM-activatable antibody.

[0179] An EpCAM activatable antibody having a relatively high dynamic range value (e.g., a value greater than 1) exhibits a more desirable switching phenotype, whereby target protein binding by the EpCAM activatable antibody occurs to a greater extent (e.g., occurs primarily) in the presence of a cleaving agent (e.g., an enzyme) capable of cleaving the CM of the EpCAM activatable antibody than in the absence of the cleaving agent.

[0180] EpCAM-activatable antibodies can be provided in a variety of structural configurations. Representative formulas for EpCAM-activatable antibodies are provided below. It is specifically contemplated that the N- to C-terminal order of Ab, MM, and CM can be reversed within an EpCAM-activatable antibody. It is also specifically contemplated that the amino acid sequences of CM and MM can overlap, e.g., such that a CM is contained within a MM.

[0181] For example, an EpCAM-activatable antibody can be represented by the following formula (from the amino (N)-terminal region to the carboxyl (C)-terminal region): (MM)-(CM)-(Ab) (Ab)-(CM)-(MM) wherein MM is a masking moiety, CM is a cleavable moiety, and Ab is an EpCAM antibody or an EpCAM-binding antibody fragment. While the above formula shows MM and CM as separate components, it should be noted that in all exemplary embodiments (including formulas) disclosed herein, the amino acid sequences of MM and CM can overlap, e.g., such that CM is fully or partially contained within MM. Additionally, the above formula provides additional amino acid sequences that can be placed at the N- or C-terminus of the EpCAM-activatable antibody component.

[0182] In some embodiments, the EpCAM-activatable antibody comprises a CM that is cleaved by a protease. In some embodiments, the protease that cleaves the CM is active, e.g., upregulated or unregulated, in the diseased tissue, and the protease cleaves the CM in the EpCAM-activatable antibody when the EpCAM-activatable antibody is exposed to the protease.

[0183] In some embodiments, the protease co-localizes with EpCAM in tissues, and the protease cleaves the CM in the EpCAM activatable antibody when the EpCAM activatable antibody is exposed to the protease.

[0184] In some embodiments, a CM is placed in the EpCAM-activatable antibody, such that when the EpCAM-activatable antibody is in an uncleaved state, binding of the EpCAM-activatable antibody to EpCAM is reduced to occur with a dissociation constant that is at least 2, 5, 10, 20, 40, 50, 100, or 200 times greater than the dissociation constant of unmodified Ab binding to EpCAM, whereas in a cleaved state (i.e., when the EpCAM-activatable antibody is in a cleaved state), the Ab binds to EpCAM.

[0185] In some embodiments, the CM is a polypeptide up to 15 amino acids in length. In some embodiments, a CM is a polypeptide comprising a first cleavable portion (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and a second cleavable portion (CM2) that is a substrate for at least one serine protease (SP). In some embodiments, each of the CM1 and CM2 substrate sequences of the CM1-CM2 substrate is independently a polypeptide up to 15 amino acids in length.

[0186] In some embodiments, the CM is a substrate for at least one protease that is, or is thought to be, upregulated or deregulated in cancer, in some embodiments, the CM is a substrate for at least one protease that is, or is thought to be, upregulated in inflammation, in some embodiments, the CM is a substrate for at least one protease that is, or is thought to be, upregulated or deregulated in autoimmune disease.

[0187] In some embodiments, the CM is a substrate for at least one protease selected from matrix metalloproteinases (MMPs), thrombin, neutrophil elastase, cysteine ​​proteases, legumain, and serine proteases such as matriptase (MT-SP1); and urokinase (uPA). Without being bound by theory, these proteases are believed to be upregulated or unregulated in at least one of cancer, inflammation, and / or autoimmune disease.

[0188] Representative substrates include, but are not limited to, substrates cleavable by one or more of the following enzymes or proteases: ADAMS / ADAMTS (e.g., ADAM8, ADAM9, ADAM10, ADAM12, ADAM15, ADAM17 / TACE, ADAMDECl, ADAMTS1, ADAMTS4, ADAMTS5); aspartic proteases (e.g., BACE, renin); aspartic cathepsins (e.g., cathepsins, cathepsin D and cathepsin E); caspases (e.g., caspase 1-10, and caspase 14); cysteine ​​cathepsins (e.g., cathepsin B, cathepsin C, cathepsin K, cathepsin L, cathepsin S, cathepsin V / L2, and cathepsin X / Z / P); cysteine ​​proteinases (e.g., cruzipain, legumain, and otubain-2); KLKs (e.g., KLK4-8, KLK10, KLK11, KLK13, and and KLK14); metalloproteinases (e.g., meprin, neprilysin, PSMA, and BMP1); MMPs (e.g., MMP1-3, MMP7-17, MMP19, MMP20, MMP23, MMP24, MMP26, and MMP27); serine proteases (e.g., activator protein C, cathepsin A, cathepsin C, chymase, and coagulation factor proteases such as FVIIa, FIXa, FXa, FXIa, and FXIIa) enzymes, elastases (e.g., human neutrophil elastase); granzyme B; guanidinobenzoatase; HtrAl; lactoferrin; Marapsin; NS3 / 4A; PACE4; plasmin; PSA, tPA; thrombin; tryptase; uPA; type II transmembrane serine proteases (TTSPs) (e.g., DESC1, DPP-4, FAP, hepsin, matriptase-2, MT-SP1 / matriptase, and TMPRSS2-4).

[0189] In some embodiments, the CM is selected for use with a specific protease, for example, a protease known to co-exist with the target of an EpCAM activatable antibody.

[0190] In some embodiments, the CM is a substrate for at least one MMP. Examples of MMPs include MMP1-3, MMP7-17, MMP19, MMP20, MMP23, MMP24, MMP26, and MMP27. In some embodiments, the CM is a substrate for a protease selected from MMP9, MMP14, MMP1, MMP3, MMP13, MMP17, MMP11, and MMP19. In some embodiments, the CM is a substrate for MMP9. In some embodiments, the CM is a substrate for MMP14.

[0191] Suitable CMs that can be incorporated into activatable antibodies provided in the usual manner are known in the art. See, e.g., WO2016 / 179285, e.g., pages 40-47, the contents of which are incorporated herein by reference in their entirety.

[0192] In some embodiments, the CM is a substrate for neutrophil elastase. In some embodiments, the CM is a substrate for a serine protease. In some embodiments, the CM is a substrate for legumain. In some embodiments, the CM is a substrate for matriptase. In some embodiments, the CM is a substrate for a serine protease. In some embodiments, the CM is a substrate for a cysteine ​​protease, such as a cathepsin. In other embodiments, the CM is a substrate for uPA.

[0193] In certain embodiments, the CM is a substrate for uPA. In some embodiments, the CM comprises a sequence disclosed in Table 10. [Table 10]

[0194] In some embodiments, the CM comprises the sequence AVGLLAPPGGLSGRSDNI (SEQ ID NO: 168). In some embodiments, the CM comprises the sequence ISSGLLSGRSDNI (SEQ ID NO: 169).In some embodiments, the CM is a substrate for at least two proteases. In some embodiments, each protease is selected from the following: ADAMS / ADAMTS (e.g., ADAM8, ADAM9, ADAM10, ADAM12, ADAM15, ADAM17 / TACE, ADAMDECl, ADAMTS1, ADAMTS4, ADAMTS5); aspartic proteases (e.g., BACE, renin); aspartic cathepsins (e.g., cathepsin D and cathepsin E); caspases (e.g., caspases 1-10, and caspase 14); cysteine ​​cathepsins (e.g., cysteine ​​cathepsins); Cathepsins (e.g., cathepsin B, cathepsin C, cathepsin K, cathepsin L, cathepsin S, cathepsin V / L2, and cathepsin X / Z / P); cysteine ​​proteinases (e.g., cruzipain, legumain, and otubain-2); KLKs (e.g., KLK4-8, KLK10, KLK11, KLK13, and KLK14); metalloproteinases (e.g., meprin, neprilysin, PSMA, and BMP1); MMPs (e.g., MMP1-3, MMP7-17, MMP19, MMP20, MMP21, MMP22, MMP23, MMP24, MMP25, MMP26, MMP27, MMP28, MMP29, MMP30, MMP31, MMP32, MMP33, MMP34, MMP35, MMP36, MMP37, MMP38, MMP39, MMP39, MMP40, MMP41, MMP42, MMP43, MMP44, MMP45, MMP46, MMP47, MMP48, MMP49 ... 20, MMP23, MMP24, MMP26, and MMP27); serine proteases (e.g., activated protein C, cathepsin A, cathepsin C, chymase, and coagulation factor proteases such as FVIIa, FIXa, FXa, FXIa, and FXIIa), elastases (e.g., human neutrophil elastase); granzyme B; guanidinobenzoatase; HtrAl; lactoferrin; Marapsin; NS3 / 4A; PACE4; plasmin; PSA, tPA; thrombin; tryptase; u PA; type II transmembrane serine proteases (TTSPs) (e.g., DESC1, DPP-4, FAP, hepsin, matriptase-2, MT-SP1 / matriptase, and TMPRSS2-4). In some embodiments, the CM is a substrate for at least two proteases, one of which is selected from MMPs, thrombin, neutrophil elastase, cysteine ​​proteases, uPA, legumain, and matriptase, and the other proteases are selected from those described above.In some embodiments, the CM is a substrate for at least two proteases selected from the group of MMP, thrombin, neutrophil elastase, cysteine ​​protease, uPA, legumain, and matriptase.

[0195] In some embodiments, the EpCAM-activatable antibody comprises at least a first CM and a second CM. In some embodiments, the first CM and the second CM are each polypeptides 15 amino acids or less in length. In some embodiments, the first CM and the second CM in the uncleaved EpCAM-activatable antibody have the N- to C-terminal structural arrangement MM-CM1-CM2-Ab or Ab-CM2-CM1-MM. In some embodiments, at least one of the first CM and the second CM is a polypeptide that functions as a substrate for a protease selected from MMP, thrombin, neutrophil elastase, cysteine ​​protease, uPA, legumain, and matriptase in the target tissue. In some embodiments, the first CM is cleaved by a first cleavage agent selected from MMP, thrombin, neutrophil elastase, cysteine ​​protease, uPA, legumain, and matriptase in the target tissue, and the second CM is cleaved by a second cleavage agent in the target tissue. In some embodiments, the other protease is selected from the list shown in the previous paragraph. In some embodiments, the first cleaving agent and the second cleaving agent are the same protease selected from MMP, thrombin, neutrophil elastase, cysteine ​​protease, uPA, legumain, and matriptase, and the first CM and the second CM are different substrates for the enzyme. In some embodiments, the first cleaving agent and the second cleaving agent are the same protease selected from the list in the previous paragraph. In some embodiments, the first cleaving agent and the second cleaving agent are different proteases selected from the list in the previous paragraph. In some embodiments, the first cleaving agent and the second cleaving agent coexist in the target tissue. In some embodiments, the first CM and the second CM are cleaved by at least one cleaving agent in the target tissue.

[0196] In some embodiments, the EpCAM-activatable antibody also comprises a signal peptide. In some embodiments, the signal peptide is attached to the EpCAM-activatable antibody via a spacer. In some embodiments, the spacer is attached to the EpCAM-activatable antibody in the absence of the signal peptide. In some embodiments, the spacer is attached directly to the MM of the EpCAM-activatable antibody. In some embodiments, the spacer is attached directly to the MM of the EpCAM-activatable antibody in the N- to C-terminal structural arrangement of spacer-MM-CM-Ab.

[0197] Suitable spacers and spacer technologies are known in the art and can be used to routinely incorporate spacers in some embodiments of the provided activatable antibodies. See, e.g., WO2016 / 179285 (e.g., pages 52-53), the contents of which are incorporated herein by reference in their entirety.

[0198] In many embodiments, it may be desirable to insert one or more linkers, e.g., flexible linkers, into an EpCAM-activatable antibody construct to confer flexibility at one or more of the MM-CM junction, the CM-Ab junction, or both. For example, the Ab, MM, and / or CM may not contain a sufficient number of residues (e.g., Gly, Ser, Asp, Asn, particularly Gly and Ser, particularly Gly) to confer the desired flexibility. Thus, the switchable phenotype of such an EpCAM-activatable antibody construct may benefit from the introduction of one or more amino acids to confer a flexible linker. In addition, as described below, when the EpCAM-activatable antibody is provided as a conformationally constrained construct, a flexible linker can be operatively inserted to facilitate the formation and maintenance of a cyclic structure in the uncleaved EpCAM-activatable antibody.

[0199] For example, in certain embodiments, an EpCAM-activatable antibody comprises one of the following formulas (the formulas below represent the amino acid sequence from N-terminal to C-terminal or C-terminal to N-terminal): (MM)-L1-(CM)-(Ab) (MM)-(CM)-L2-(Ab) (MM)-L1-(CM)-L2-(Ab) wherein MM, CM, and Ab are as defined above, and L1 and L2 are each independently the same or different, optionally present or absent, flexible linkers comprising at least one flexible amino acid (e.g., Gly). In addition, the above formula provides additional amino acid sequences that can be placed at the N-terminus or C-terminus of the EpCAM-activatable antibody component. Examples include, but are not limited to, targeting moieties (e.g., ligands for receptors on cells present in target tissues) and serum half-life extending moieties (e.g., polypeptides that bind to immunoglobulin serum proteins) or serum albumin (e.g., human serum albumin (HSA)).

[0200] In some embodiments, the EpCAM activatable antibody is exposed to and cleaved by a protease such that in the activated or cleaved state, after the protease cleaves the CM, the activated antibody comprises a light chain sequence that includes at least a portion of the LP2 and / or CM sequence.

[0201] CM is degraded by at least one protease, with a rate of approximately 0.001–1500×10 4 M -1 S -1 At or at least 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2.5, 5, 7.5, 10, 15, 20, 25, 50, 75, 100, 125, 150, 200, 250, 500, 750, 1000, 1250, or 1500x10 4 M -1 S -1 In some embodiments, the CM is specifically cleaved at a rate of about 100,000 M -1 S -1 In some embodiments, the CM is specifically cleaved at a rate of about 1x10 2 ~approx. 1x10 6 M -1 S -1(i.e., approximately 1x10 2 ~approx. 1x10 6 M -1 S -1 ) is specifically cleaved at a rate of

[0202] For specific cleavage by the enzyme, contact between the enzyme and CM is made. When EpCAM activatable antibodies (e.g., EpCAM antibodies or EpCAM-binding antibody fragments) including Abs bound to MM and CM are in the presence of EpCAM and sufficient enzymatic activity, the CM can be cleaved. Sufficient enzymatic activity can refer to the enzyme's ability to contact CM and perform cleavage. It is easy to imagine that the enzyme may be in the vicinity of CM, but cannot cleave due to other cellular factors or protein modifications of the enzyme.

[0203] Suitable linkers for use in the EpCAM-activatable antibodies and compositions disclosed herein are typically linkers that provide flexibility to the modified Ab (e.g., EpCAM antibody or EpCAM-binding antibody fragment) or EpCAM-activatable antibody and facilitate inhibition of the binding of the EpCAM-activatable antibody to human EpCAM. Such linkers are typically referred to as flexible linkers. Suitable linkers can be readily selected and can be of any suitable length, for example, 1 amino acid (e.g., Gly) to 20 amino acids, 2 to 15 amino acids, 3 to 12 amino acids, and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids, including 4 to 10 amino acids, 5 to 9 amino acids, 6 to 8 amino acids, or 7 to 8 amino acids in length.

[0204] Exemplary flexible linkers for the activatable antibodies, antibodies, and antibody fragments provided herein include glycine polymers (G)n, glycine-serine polymers (e.g., including (GS)n). Suitable linkers and linker technologies are known in the art and can be used to routinely incorporate spacers in some embodiments of the provided activatable antibodies. See, e.g., WO2016 / 179285 (e.g., pages 26, 113-116), the contents of which are incorporated herein by reference in their entirety. Those skilled in the art will understand that the design of an EpCAM activatable antibody can include a fully or partially flexible linker, whereby the linker can include both a flexible linker and one or more moieties that confer a less flexible structure and provide the desired EpCAM activatable antibody structure.

[0205] In some embodiments, the EpCAM-activatable antibody comprises a first binding peptide (LP1) and a second binding peptide (LP2), and in its uncleaved state, the EpCAM-activatable antibody has the N- to C-terminal structural arrangement MM-LP1-CM-LP2-Ab or Ab-LP2-CM-LP1-MM. In some embodiments, the two binding peptides need not be identical to each other.

[0206] In some embodiments, the EpCAM-activatable antibody comprises a first binding peptide (LP1) and a second binding peptide (LP2), and in its uncleaved state, the EpCAM-activatable antibody has the N- to C-terminal structural arrangement MM-LP1-CM-LP2-Ab or Ab-LP2-CM-LP1-MM. In some embodiments, the two binding peptides need not be identical to each other.

[0207] In some embodiments, at least one of the EpCAM activatable antibodies LP1, LP2 is a flexible linker. Suitable linkers and linker technologies are known in the art and can be used to routinely incorporate spacers into some embodiments of the provided activatable antibodies. See, e.g., WO2016 / 179285 (e.g., pages 26, 113-116), the contents of which are incorporated herein by reference in their entirety.

[0208] In some embodiments, the EpCAM activatable antibody comprises a light chain having a sequence disclosed in Table 11. In some embodiments, the activatable antibody comprises a light chain having the sequence of SEQ ID NO: 174. In some embodiments, the activatable antibody comprises a light chain having the sequence of SEQ ID NO: 179. [Table 11] TIFF0007592009000043.tif238160TIFF0007592009000044.tif239162TIFF0007592009000045.tif80161

[0209] In some embodiments, the EpCAM activatable antibody comprises a light chain having a sequence selected from SEQ ID NOs: 170-180 and a heavy chain having a sequence selected from SEQ ID NOs: 103, 125, and 127. In some embodiments, the EpCAM activatable antibody comprises a light chain having a sequence selected from SEQ ID NOs: 170-180 and a heavy chain having the sequence of SEQ ID NO: 103. In some embodiments, the EpCAM activatable antibody comprises a light chain having the sequence of SEQ ID NO: 174 and a heavy chain having the sequence of SEQ ID NO: 103. In some embodiments, the EpCAM activatable antibody comprises a light chain having the sequence of SEQ ID NO: 179 and a heavy chain having the sequence of SEQ ID NO: 103.

[0210] In some embodiments, the EpCAM activatable antibody comprises a light chain having a sequence selected from SEQ ID NOs: 181-188 and a heavy chain having the sequence of SEQ ID NO: 127. In some embodiments, the EpCAM activatable antibody comprises a light chain having a sequence selected from SEQ ID NOs: 189-200 and a heavy chain having the sequence of SEQ ID NO: 125.

[0211] In certain embodiments, the huEpCAM23 antibody is encoded by a plasmid deposited under the terms of the Budapest Treaty on October 4, 2018, with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Va. 20110, ATCC accession numbers PTA-125343 and PTA-125344 or PTA-125345. Examples of EpCAM antibodies, EpCAM-binding antibody fragments, and EpCAM-activatable antibodies, immunoconjugates are provided herein.

[0212] Polynucleotides, vectors, host cells and recombinant methods The present disclosure further provides polynucleotides comprising nucleotide sequences encoding the EpCAM antibodies, EpCAM-binding antibody fragments, and EpCAM-activatable antibodies disclosed herein.

[0213] Once a polynucleotide is obtained, the nucleotide sequence of the polynucleotide can be determined using any method known in the art. For example, if the nucleotide sequence of an antibody is known, a polynucleotide encoding the antibody can be constructed from chemically synthesized oligonucleotides (e.g., as described in Kutmeier, et al., BioTechniques 17:242 (1994)). Briefly, this method involves synthesizing overlapping oligonucleotides containing portions of the antibody-encoding sequence, annealing and ligating these oligonucleotides, and then amplifying the ligated oligonucleotides by PCR.

[0214] In some embodiments, a polynucleotide of the disclosure comprises a sequence set forth in Table 12. [Table 12] TIFF0007592009000047.tif239162TIFF0007592009000048.tif239162TIFF0007592009000049.tif34162

[0215] In some embodiments, an EpBA of this disclosure comprises a heavy chain nucleic acid sequence of SEQ ID NO: 201 and a light chain nucleic acid sequence of SEQ ID NO: 202. In some embodiments, an EpBA of this disclosure comprises a heavy chain nucleic acid sequence of SEQ ID NO: 203 and a light chain nucleic acid sequence of SEQ ID NO: 204. In some embodiments, an EpBA of this disclosure comprises a heavy chain nucleic acid sequence of SEQ ID NO: 205 and a light chain nucleic acid sequence of SEQ ID NO: 204. In some embodiments, an EpBA of this disclosure comprises a heavy chain nucleic acid sequence of SEQ ID NO: 206 and a light chain nucleic acid sequence of SEQ ID NO: 204. In some embodiments, an EpBA of this disclosure comprises a heavy chain nucleic acid sequence of SEQ ID NO: 207 and a light chain nucleic acid sequence of SEQ ID NO: 204.

[0216] In some embodiments, an EpBA of the disclosure comprises a heavy chain nucleic acid sequence of SEQ ID NO: 203 and a light chain nucleic acid sequence of SEQ ID NO: 208. In some embodiments, an EpBA of the disclosure comprises a heavy chain nucleic acid sequence of SEQ ID NO: 203 and a light chain nucleic acid sequence of SEQ ID NO: 209.

[0217] In some embodiments, an EpBA of the disclosure comprises (i) a heavy chain variable region comprising an amino acid sequence identical to the amino acid sequence of the heavy chain variable region encoded by the plasmid deposited with the ATCC® under the designation PTA-125343, and (ii) a light chain variable region comprising an amino acid sequence identical to the amino acid sequence of the light chain variable region encoded by the plasmid deposited with the ATCC® under the designation PTA-125342. Methods of making and using EpCAM antibodies and EpCAM-binding antibody fragments comprising EpBAs are also encompassed by the disclosure.

[0218] In some embodiments, the disclosure provides an EpCAM antibody comprising (i) a heavy chain comprising an amino acid sequence identical to the amino acid sequence of the heavy chain encoded by the plasmid deposited with the ATCC® under the designation PTA-125343, and (ii) a light chain comprising an amino acid sequence identical to the amino acid sequence of the light chain variable region encoded by the plasmid deposited with the ATCC® under the designation PTA-125342. Methods of making and using the EpCAM antibody are also encompassed by the disclosure.

[0219] In some embodiments, the present disclosure provides an EpCAM-activatable antibody or EpCAM-binding activatable antibody fragment comprising (i) a heavy chain variable region comprising an amino acid sequence identical to the amino acid sequence of the heavy chain variable region encoded by the plasmid deposited with the ATCC® under the designation PTA-125343, and (ii) a light chain variable region comprising an amino acid sequence identical to the amino acid sequence of the light chain variable region encoded by the plasmid deposited with the ATCC® under the designation PTA-125344. Methods of making and using the EpCAM-activatable antibody or EpCAM-binding activatable antibody fragment are also encompassed by the present disclosure.

[0220] In other embodiments, the present disclosure provides an EpCAM-activatable antibody or EpCAM-binding activatable antibody fragment comprising (i) a heavy chain variable region comprising the same amino acid sequence as the amino acid sequence of the heavy chain variable region encoded by the plasmid deposited with the ATCC® under the designation PTA-125343, and (ii) a light chain variable region comprising the same amino acid sequence as the amino acid sequence of the light chain variable region encoded by the plasmid deposited with the ATCC® under the designation PTA-125345. Methods of making and using the EpCAM-activatable antibody or EpCAM-binding activatable antibody fragment are also encompassed by the present disclosure.

[0221] Methods for constructing recombinant vectors containing antibody coding sequences and appropriate transcriptional and translational control signals are well known in the art. Once an antibody is recombinantly expressed, it can be purified by any method known in the art for the purification of immunoglobulin molecules, for example, by chromatography (e.g., ion exchange, affinity, particularly affinity for specific antigens after protein A, and sizing column chromatography), centrifugation, differential solubility, or any other standard technique for protein purification. In this regard, U.S. Patent No. 7,538,195 is referenced in this disclosure. The contents of this patent are incorporated herein by reference in their entirety.

[0222] The present disclosure also provides methods for producing an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody disclosed herein by culturing cells under conditions that result in the antibody and / or EpCAM-activatable antibody, wherein the cells contain a nucleic acid molecule encoding the antibody, antibody fragment, or activatable antibody.

[0223] The present disclosure also provides a method for producing an EpCAM-activatable antibody that binds to EpCAM in its activated state, the method comprising: (a) culturing cells containing a nucleic acid construct encoding an EpCAM-activatable antibody, the nucleic acid construct comprising a masking moiety (MM), a cleavable moiety (CM), and an Ab (e.g., an EpCAM antibody or an EpCAM-binding antibody fragment), wherein (i) the CM is a polypeptide that functions as a substrate for a protease, and (ii) the CM is disposed in the EpCAM-activatable antibody such that when the EpCAM-activatable antibody is in its uncleaved state, the MM interferes with the binding of the Ab to EpCAM, and in its cleaved state, the MM does not interfere with or compete with the specific binding of the Ab to EpCAM; and (b) recovering the EpCAM-activatable antibody. Suitable Abs, MMs, and / or CMs include any of the Abs, MMs, and / or CMs disclosed herein.

[0224] immune complex In one embodiment, the present disclosure provides an immunoconjugate comprising an EpCAM antibody or EpCAM-binding antibody fragment, or an EpCAM-activatable antibody (e.g., as disclosed herein) conjugated or covalently linked to a cytotoxic agent. Cytotoxic agents include any agent that is harmful to cells, such as Pseudomonas aeruginosa exotoxin, diphtheria toxin, botulinum toxins A to F, ricin, abrin, saporin, and cytotoxic fragments of such agents. Cytotoxic agents also include any agent that has a therapeutic effect, either prophylactically or therapeutically, in treating a disorder. Such therapeutic agents may be chemotherapeutic agents, protein or polypeptide therapeutic agents, and include therapeutic agents with desired biological activity and / or that modulate a given biological response. Examples of therapeutic agents include, but are not limited to, alkylating agents, angiogenesis inhibitors, antimitotic agents, hormonal therapy agents, and antibodies useful in treating cell proliferative disorders. In certain embodiments, the therapeutic agent is a maytansinoid compound, such as those described in U.S. Patent Nos. 5,208,020 and 7,276,497. The contents of each of these patents are incorporated herein by reference in their entirety. In certain embodiments, the therapeutic agent is a benzodiazepine compound such as a pyrrolobenzodiazepine (PBD) (such as those described in WO2010 / 043880, WO2011 / 130616, WO2009 / 016516, WO2013 / 177481, and WO2012 / 112708) and an indolinobenzodiazepine (IGN) compound (such as those described in WO2010 / 091150, and WO2012 / 128868 and U.S. Patent Publication No. 20170014522). The contents of each of these patents are incorporated herein by reference in their entirety.

[0225] As used herein, a "pyrrolobenzodiazepine" (PBD) is a compound having a pyrrolobenzodiazepine core structure. Pyrrolobenzodiazepines can be substituted or unsubstituted. "Pyrrolobenzodiazepine" compounds can also include compounds having two pyrrolobenzodiazepine cores joined by a linker. The imine functional group (-C=N-) as part of an indolinobenzodiazepine can be reduced.

[0226] In certain embodiments, the pyrrolobenzodiazepine compound is [ka] The hydroxybenzoates comprise a core structure represented by the formula:

[0227] In certain embodiments, the pyrrolobenzodiazepine compound is 4e3 [ka] The hydroxybenzoates comprise a core structure represented by the formula:

[0228] As used herein, an "indolinobenzodiazepine" (IGN) is a compound having an indolinobenzodiazepine core structure. The indolinobenzodiazepine may be substituted or unsubstituted. "Indolinobenzodiazepine" (IGN) compounds may also include compounds having two indolinobenzodiazepine cores joined by a linker. The imine functional group (-C=N-) as part of the indolinobenzodiazepine can be reduced.

[0229] In certain embodiments, the indolinobenzodiazepine compound is [ka] The hydroxybenzoates comprise a core structure represented by:

[0230] In certain embodiments, the indolinobenzodiazepine compound is [ka] The aryl group comprises a core structure represented by:

[0231] The cytotoxic drug may be attached or conjugated directly to an EpCAM-binding substance (e.g., an EpCAM antibody or EpCAM-binding antibody fragment or EpCAM-activatable antibody disclosed herein) or indirectly via a linker using techniques known in the art to produce an "immunoconjugate," "conjugate," "ADC," or "AADC."

[0232] Linker molecules Any suitable linker known in the art can be used to prepare the disclosed immunoconjugates. In certain embodiments, the linker is a bifunctional linker. As used herein, the term "bifunctional linker" refers to a modified agent having two reactive groups, one of which can react with a cell-binding agent and the other of which can react with a cytotoxic compound to link the two moieties together. Such bifunctional crosslinkers are well known in the art (see, for example, Isalm and Dent in Bioconjugation chapter 5, pp. 218-363, Groves Dictionaries Inc. New York, 1999). For example, bifunctional crosslinkers that allow linkage via a thioether bond include N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), which introduces a maleimide group, or N-succinimidyl-4-(iodoacetyl)aminobenzoate (SICBA), which introduces an iodoacetyl group. Other bifunctional crosslinkers that introduce maleimide or haloacetyl groups onto cell-binding agents are well known in the art (e.g., Pierce Biotechnology Inc. PO Box 117, Rockland, IL 61105,(See U.S. Patent Application Publication Nos. 2008 / 0050310 and 20050169933, available from the U.S. Patent Office, San Diego, CA, USA), including but not limited to bismaleimide polyethylene glycol (BMPEO), BM(PEO)2, BM(PEO)3, N-(β-maleimidopropyloxy)succinimide ester (BMPS), γ-maleimidobutyric acid N-succinimidyl ester (GMBS), 6-maleimidocaproic acid N-hydroxysuccinimide ester (EMCS), 5-maleimidovaleric acid NHS, HBVS, N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxy(6-amidocaproate), which is a "long chain" analog of SMCC (LC-SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), 4-(4-N-maleimidophenyl)butyric acid Hydrazide or HCl salt (MPBH), N-succinimidyl 3-(bromoacetamido)propionate (SBAP), N-succinimidyl iodoacetate (SIA), κ-maleimidoundecanoic acid N-succinimidyl ester (KMUA), N-succinimidyl 4-(p-maleimidophenyl)butyrate (SMPB), succinimidyl-6-(β-maleimidopropionamido)hexanoate (SMPH), succinimidyl-(4-vinylsulfonyl)benzoate (SVSB), dithiobismaleimidoethane (DTME), 1,4-bismaleimidobutane (BMB), 1,4-bismaleimidyl-2,Examples include 3-dihydroxybutane (BMDB), bismaleimidohexane (BMH), bismaleimidoethane (BMOE), sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC), sulfosuccinimidyl (4-iodoacetyl)aminobenzoate (sulfo-SICBA), m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester (sulfo-MBS), N-(γ-maleimidobutyloxy)sulfosuccinimide ester (sulfo-GMBS), N-(ε-maleimidocaproyloxy)sulfosuccinimide ester (sulfo-EMCS), N-(κ-maleimidoundecanoyloxy)sulfosuccinimide ester (sulfo-KMUS), and sulfosuccinimidyl 4-(p-maleimidophenyl)butyrate (sulfo-SMPB).

[0233] Heterobifunctional crosslinkers are bifunctional crosslinkers with two different reactive groups. Heterobifunctional crosslinkers containing both an amine-reactive N-hydroxysuccinimide group (NHS group) and a carbonyl-reactive hydrazine group can also be used to conjugate the cytotoxic compounds disclosed herein with cell-binding substances (e.g., EpCAM antibodies, EpCAM-binding antibody fragments, or EpCAM-activatable antibodies). Examples of commercially available heterobifunctional crosslinkers include succinimidyl 6-hydrazinonicotinamide acetone hydrazone (SANH), succinimidyl 4-hydrazide terephthalate hydrochloride (SHTH), and succinimidyl hydrazinium nicotinate hydrochloride (SHNH). Conjugates with acid-labile bonds can also be prepared using the hydrazine-containing benzodiazepine derivatives of the present disclosure. Examples of bifunctional cross-linkers that can be used include succinimidyl-p-formylbenzoate (SFB) and succinimidyl-p-formylphenoxyacetate (SFPA).

[0234] Bifunctional crosslinkers capable of linking a cell-binding substance and a cytotoxic compound via a disulfide bond are known in the art, and include N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), N-succinimidyl-4-(2-pyridyldithio)pentanoate (SPP), N-succinimidyl-4-(2-pyridyldithio)butanoate (SPDB), and N-succinimidyl-4-(2-pyridyldithio)2-sulfobutanoate (sulfo-SPDB) for introducing dithiopyridyl groups. Other bifunctional crosslinkers that can be used to introduce disulfide groups are known in the art and are disclosed in U.S. Patent Nos. 6,913,748, 6,716,821, and U.S. Application Publication Nos. 20090274713 and 20100129314, the contents of each of which are incorporated herein by reference in their entireties. Alternatively, crosslinkers that introduce thiol groups, such as 2-iminothiolane, homocysteine ​​thiolactone, or S-acetylsuccinic anhydride, can also be used.

[0235] In certain embodiments, the bifunctional linker is represented by any one of formulas (a1L)-(a10L):

[0236] Cytotoxic drugs A. Maytansinoids In certain embodiments, the cytotoxic agent is a maytansinoid compound, such as those described in U.S. Patent Nos. 5,208,020 and 7,276,497, the contents of each of which are incorporated herein by reference in their entirety. In certain embodiments, the maytansinoid compound has the following formula: [ka] wherein the variables are as defined above in any one of the thirteenth to fifteenth specific embodiments of the first embodiment above, and any further specific embodiments described therein.

[0237] In a more particular embodiment, the maytansinoid compound is DM4: [ka] is.

[0238] In another embodiment, the maytansinoid compound is DM1: [ka] is.

[0239] B. Benzodiazepines In certain embodiments, the cytotoxic agent is a benzodiazepine compound such as a pyrrolobenzodiazepine (PBD) (such as those described in WO2010 / 043880, WO2011 / 130616, WO2009 / 016516, WO2013 / 177481, and WO2012 / 112708) and an indolinobenzodiazepine (IGN) compound (such as those described in WO2010 / 091150, and WO2012 / 128868 and U.S. Application Publication No. 20170014522). The entire teachings of each of these patents, patent publications, and applications are incorporated herein by reference in their entirety.

[0240] As used herein, a "benzodiazepine" compound is a compound having a benzodiazepine structure. The benzodiazepine core can be substituted or unsubstituted and / or fused to one or more ring structures. It also includes compounds having two benzodiazepine cores connected by a linker. The imine functional group (-C=N-) as part of the benzodiazepine core can be reduced.

[0241] As used herein, a "pyrrolobenzodiazepine" (PBD) compound is a compound having a pyrrolobenzodiazepine core structure. Pyrrolobenzodiazepines can be substituted or unsubstituted. It also includes compounds having two pyrrolobenzodiazepine cores connected by a linker. The imine functional group (-C=N-) as part of an indolinobenzodiazepine can be reduced.

[0242] In certain embodiments, the cytotoxic agent has the formula: [ka] or a pharmaceutically acceptable salt thereof, wherein L c’ is expressed as follows: -NR5-PC(=O)-(CR a R b ) m -C(=O)E(B1), -NR5-PC(=O)-(CR a R b ) m -SZ s (B2), wherein C(═O)E is a reactive ester group such as an N-hydroxysuccinimide ester, an N-hydroxysulfosuccinimide ester, a nitrophenyl (e.g., 2 or 4-nitrophenyl) ester, a dinitrophenyl (e.g., 2,4-dinitrophenyl) ester, a sulfo-tetrafluorophenyl (e.g., 4-sulfo-2,3,5,6-tetrafluorophenyl) ester, or a pentafluorophenyl ester, preferably an N-hydroxysuccinimide ester; Z s is expressed as follows: [ka] wherein: q is an integer from 1 to 5, and U is —H or SO3H or a pharmaceutically acceptable salt thereof, and The remaining variables are as described in any one of the first through twelfth and seventeenth specific embodiments of the first embodiment above, or any further specific embodiments described therein.

[0243] In certain embodiments, the cytotoxic agent has the formula: [ka] or a pharmaceutically acceptable salt thereof, wherein -L for formulas (C1a'), (C1a'1), (C1b') and (C1b'1) C c is expressed as follows: [ka] wherein the remaining variables are as defined above in any one of the first through ninth and twenty-third specific embodiments of the second embodiment, or any further specific embodiments described therein; and L for formulas (C2a"), (C2a"1), (C2b") and (C2b"1) C c’ is expressed as follows: [ka] wherein the variables are as defined above in any one of the tenth to sixteenth and twenty-third specific embodiments of the second embodiment, or any further specific embodiments described therein.

[0244] In certain embodiments, the cytotoxic agent is any one of the following indolinobenzodiazepine compounds or a pharmaceutically acceptable salt thereof: [Table 13] TIFF0007592009000063.tif239161TIFF0007592009000064.tif157161

[0245] The compounds D1, sD1, D2, sD2, DGN462, sDGN462, D3 and sD3 shown above can be prepared by procedures known in the art, such as those described in U.S. Patent Nos. 9,381,256, 8,765,740, 8,426,402 and 9,353,127, and U.S. Patent Application Publication No. 2016 / 0082114, the contents of each of which are incorporated herein by reference in their entirety.

[0246] In certain embodiments, the pharmaceutically acceptable salt of the compound listed above (e.g., sD1, sD2, sD4, sDGN462, sD3, sD4, sD5, sD5', sD6, or sD7) is a sodium or potassium salt. In certain embodiments, the pharmaceutically acceptable salt is a sodium salt.

[0247] In certain embodiments, the cytotoxic agent has the formula: [ka] or a pharmaceutically acceptable salt thereof. In certain embodiments, the pharmaceutically acceptable salt is a sodium or potassium salt.

[0248] In another particular embodiment, the cytotoxic agent has the formula: [ka] It is expressed as:

[0249] Representative immune complexes In a first embodiment, the immunoconjugate comprises an EpCAM-binding substance (EpBA, e.g., an EpCAM antibody or EpCAM-binding antibody fragment or EpCAM-activatable antibody disclosed herein) covalently attached to a cytotoxic drug disclosed herein via the ε-amino group of one or more lysine residues located on the EpBA.

[0250] In a first particular embodiment of the first embodiment, the immunoconjugate has the formula: [ka] wherein: EpBAs (e.g., EpCAM antibodies or EpCAM-binding antibody fragments or EpCAM-activatable antibodies disclosed herein) can be linked to Cy via a lysine residue. L1 is covalently bound to W Lis an integer between 1 and 20, and Cy L1 is expressed as follows: [ka] or a pharmaceutically acceptable salt thereof, wherein Double line between N and C [ka] is a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H or (C1-C4) alkyl, and when it is a single bond, X is -H or an amine protecting moiety and Y is -OH or -SO3H or a pharmaceutically acceptable salt thereof; W'-NR e’ and R e’ -(CH2-CH2-O) n -R k and n is an integer from 2 to 6, R k is -H or -Me, R x3 is (C1-C6) alkyl, L' is represented by the following formula: -NR5-PC(=O)-(CR a R b ) m -C(=O)-(B1'), or -NR5-PC(=O)-(CR a R b ) m -SZ s1 -(B2'), R5 is —H or (C1-C3) alkyl; P is an amino acid residue or a peptide containing 2 to 20 amino acid residues; R a and R b is independently at each occurrence -H, (C1-C3) alkyl, or a charged substituent or ionizable group Q; m is an integer from 1 to 6, Z s1 is the following expression: [ka] and q is an integer of 1 to 5.

[0251] In a second particular embodiment, in the case of the conjugate of formula (L1), Cy L1 is represented by formula (L1a) or (L1a1), where the remaining variables are as described above in the first particular embodiment.

[0252] In a third particular embodiment, in the case of the conjugate of formula (L1), Cy L1 is represented by formula (L1b) or (L1b1), and the remaining variables are as described above in the first particular embodiment. More specifically, R x3 is (C2-C4) alkyl.

[0253] In a fourth particular embodiment, in the case of the conjugate of formula (L1), Cy L1 is represented by formula (L1a), and R a and R b are both H, R5 is H or Me, and the remaining variables are as described above in the first specific embodiment.

[0254] In a fifth particular embodiment, P is a peptide comprising 2 to 5 amino acid residues, with the remaining variables being as described above in the first, second, or fourth particular embodiment. In more specific embodiments, P is selected from the following: Gly-Gly-Gly, Ala-Val, Val-Ala, Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Trp, Cit, Phe-Ala, Phe-N 9 -tosyl-Arg, Phe-N 9-nitro-Arg, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala-Leu-Ala -Leu (SEQ ID NO: 215), β-Ala-Leu-Ala-Leu (SEQ ID NO: 216), Gly-Phe-Leu-Gly (SEQ ID NO: 217), Val-Arg, Arg-Val, Arg-Arg, Val-D- Cit, Val-D-Lys, Val-D-Arg, D-Val-Cit, D-Val-Lys, D-Val-Arg, D-Val-D-Cit, D-Val-D-Lys, D-Val-D-Arg, D-Arg- D-Arg, Ala-Ala, Ala-D-Ala, D-Ala-Ala, D-Ala-D-Ala, Ala-Met, Met-Ala, Gln-Val, Asn-Ala, Gln-Phe and Gln-Ala. More specifically, P is Gly-Gly-Gly, Ala-Val, Ala-Ala, Ala-D-Ala, D-Ala-Ala, or D-Ala-D-Ala.

[0255] In a sixth particular embodiment, Q is —SOH or a pharmaceutically acceptable salt thereof, and the remaining variables are as described above in the first, second, fourth, or fifth particular embodiment, or any other embodiment described therein.

[0256] In a seventh particular embodiment, the immunoconjugate of the first embodiment has the formula: [ka] TIFF0007592009000072.tif166161TIFF0007592009000073.tif166161TIFF0007592009000074.tif166161TIFF0007592009000075.tif167161 TIFF0007592009000076.tif167161TIFF0007592009000077.tif169161TIFF0007592009000078.tif169161TIFF0007592009000079.tif198161 or a pharmaceutically acceptable salt thereof, W L is an integer between 1 and 10, and the double line between N and C [ka] is a single bond or a double bond, with the proviso that if it is a double bond, then X is absent and Y is -H, and if it is a single bond, then X is -H and Y is -OH or -SO3H or a pharmaceutically acceptable salt thereof. In a more particular embodiment, the double bond between N and C is [ka] is a double bond, X is absent, and Y is -H. [ka] is a single bond, X is -H, and Y is -SO3H or a pharmaceutically acceptable salt thereof.

[0257] In some embodiments, the EpBAs of the first through seventh specific embodiments comprise an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody disclosed herein. In some embodiments, the EpBAs of the first through seventh specific embodiments comprise a VH-CDR1 (SEQ ID NO: 5) of X1YX3X4H, where X1 is selected from N and S, X3 is selected from Y, N, F, S, H, D, L, I, and W, and X4 is selected from I and M; the sequence WX2X3PGX6VYIQYX 12 X 13 KFX 17 G, X2 is selected from I and F, X3 is selected from Y and N, X6 is selected from N and D, and X 12 is selected from N and S, and X 13 is selected from E and Q, and X 17is selected from K and Q; and VH-CDR3 (SEQ ID NO: 8) wherein X1 is selected from D and E, X3 is selected from P, A, S, Y, F, G, T, and V, and X4 is selected from Y and W. In some embodiments, the EpBAs of the first through seventh specific embodiments comprise a VH-CDR2 (SEQ ID NO: 7) comprising RSSX4SLLHSX 10 GX 12 TYLX 16 X4 is selected from R and K; 10 is selected from N and D, and X 12 is selected from F and I, and X 16 is selected from Y and S; light chain VL-CDR2 (SEQ ID NO: 40) comprising QTSNLAS; and VL-CDR3 (SEQ ID NO: 11) comprising X1QX3LELPX8T, where X1 is selected from A, L, and Q, X3 is selected from S, G, Y, and N, and X8 is selected from N and W.

[0258] In some embodiments, the VH-CDR1 of EpBA comprises the sequence NYX3IH, where X3 is selected from Y, N, F, S, H, D, L, I, and W (SEQ ID NO: 6). In some embodiments, the VH-CDR3 of EpBA comprises the sequence DGPX4FAY, where X4 is selected from Y and W (SEQ ID NO: 9). In some embodiments, the VL-CDR3 of EpBA comprises the sequence AQX3LELPNT, where X3 is selected from S, G, Y, and N (SEQ ID NO: 12).

[0259] In some embodiments, the EpBAs of the first through seventh specific embodiments comprise an EpCAM antibody or EpCAM-binding antibody fragment, or an EpCAM-activatable antibody, comprising a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3 having the sequences of SEQ ID NOs: 13-15, 42, 40, and 41, respectively. In some embodiments, the EpBAs of the first through seventh specific embodiments comprise an EpCAM antibody or EpCAM-binding antibody fragment, or an EpCAM-activatable antibody, comprising a VH having the sequence of SEQ ID NO: 54 and a VL having the sequence of SEQ ID NO: 89. In some embodiments, the EpBAs of the first through seventh specific embodiments comprise an EpCAM antibody or EpCAM-binding antibody fragment, or an EpCAM-activatable antibody, comprising an HC having the sequence of SEQ ID NO: 103 and an LC having the sequence of SEQ ID NO: 140.

[0260] In some embodiments, the EpBAs of the first to seventh specific embodiments comprise an EpCAM activatable antibody comprising a MM of SEQ ID NO: 155. In some embodiments, the EpBAs of the first to seventh specific embodiments further comprise an EpCAM activatable antibody comprising a CM of SEQ ID NO: 168. In alternative embodiments, the EpBAs of the first to seventh specific embodiments comprise an EpCAM activatable antibody comprising a CM of SEQ ID NO: 169. In one embodiment, the EpBAs of the first to seventh specific embodiments comprise an EpCAM activatable antibody comprising a heavy chain having the sequence of SEQ ID NO: 103 and a light chain having the sequence of SEQ ID NO: 174. In one embodiment, the EpBAs of the first to seventh specific embodiments comprise an EpCAM activatable antibody comprising a heavy chain having the sequence of SEQ ID NO: 103 and a light chain having the sequence of SEQ ID NO: 179.

[0261] In an eighth particular embodiment, the immunoconjugate of the first embodiment has the formula: [ka] wherein: EpBA is an EpCAM-binding agent (e.g., an EpCAM antibody, an EpCAM-binding antibody fragment, or an EpCAM-activatable antibody) disclosed herein, which is linked to Cy through a Lys residue. L2 is covalently bound to W L is an integer between 1 and 20, and Cy L2 is expressed as follows: [ka] It is expressed by:

[0262] In a ninth particular embodiment, the immunoconjugate of the first embodiment has the formula: [ka] wherein: EpBA is an EpCAM-binding agent (e.g., an EpCAM antibody, an EpCAM-binding antibody fragment, or an EpCAM-activatable antibody) disclosed herein, which is linked to Cy through a Lys residue. L2 is covalently bound to W L is an integer between 1 and 20, Cy L2 is expressed as follows: [ka] where m' is 1 or 2; R1 and R2 are each independently H or (C1-C3) alkyl, and Z s1 is the following expression: [ka] and q is an integer of 1 to 5.

[0263] In a tenth particular embodiment, for the immunoconjugate of formula (L2), m' is 1, R1 and R2 are both H, and the remaining variables are as described above in the thirteenth particular embodiment.

[0264] In an eleventh particular embodiment, for the immunoconjugate of formula (L2), m' is 2, R1 and R2 are both Me, and the remaining variables are as described above in the thirteenth particular embodiment.

[0265] In a twelfth particular embodiment, the immunoconjugate of the first embodiment has the formula: [ka] or a pharmaceutically acceptable salt thereof, W L is an integer between 1 and 10.

[0266] In a twelfth particular embodiment, for the immunoconjugate of the first embodiment, Y is -SO3H, -SO3Na, or -SO3K, and the remaining variables are as defined above in any one of the first through sixteenth particular embodiments, or any further specific embodiments described therein. In one embodiment, Y is -SO3Na.

[0267] In some embodiments, the EpBAs of the eighth to twelfth specific embodiments comprise an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody disclosed herein. In some embodiments, the EpBAs of the eighth to twelfth specific embodiments comprise a VH-CDR1 (SEQ ID NO: 5); sequence WX2X3PGX6VYIQYX, where X1 is selected from N and S, X3 is selected from Y, N, F, S, H, D, L, I, and W, and X4 is selected from I and M. 12 X 13 KFX 17 G, X2 is selected from I and F, X3 is selected from Y and N, X6 is selected from N and D, and X 12 is selected from N and S, and X 13 is selected from E and Q, and X 17and VH-CDR3 (SEQ ID NO: 8) wherein X1 is selected from D and E, X3 is selected from P, A, S, Y, F, G, T, and V, and X4 is selected from Y and W. In some embodiments, the EpBAs of specific embodiments 8 through 12 comprise a VH-CDR2 (SEQ ID NO: 7) comprising X1GX3X4FAY, where X1 is selected from D and E, X3 is selected from P, A, S, Y, F, G, T, and V, and X4 is selected from Y and W. In some embodiments, the EpBAs of specific embodiments 8 through 12 comprise a VH-CDR3 (SEQ ID NO: 8) comprising RSSX4SLLHSX 10 GX 12 TYLX 16 X4 is selected from R and K; 10 is selected from N and D, and X 12 is selected from F and I, and X 16 is selected from Y and S; light chain VL-CDR2 (SEQ ID NO: 40) comprising QTSNLAS; and VL-CDR3 (SEQ ID NO: 11) comprising X1QX3LELPX8T, where X1 is selected from A, L, and Q, X3 is selected from S, G, Y, and N, and X8 is selected from N and W.

[0268] In some embodiments, the VH-CDR1 of EpBA comprises the sequence NYX3IH, where X3 is selected from Y, N, F, S, H, D, L, I, and W (SEQ ID NO: 6). In some embodiments, the VH-CDR3 of EpBA comprises the sequence DGPX4FAY, where X4 is selected from Y and W (SEQ ID NO: 9). In some embodiments, the VL-CDR3 of EpBA comprises the sequence AQX3LELPNT, where X3 is selected from S, G, Y, and N (SEQ ID NO: 12).

[0269] In some embodiments, EpBAs of specific embodiments 8 through 12 comprise an EpCAM antibody or EpCAM-binding antibody fragment, or an EpCAM-activatable antibody, comprising a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3 having the sequences of SEQ ID NOs: 13 through 15, 42, 40, and 41, respectively. In some embodiments, EpBAs of specific embodiments 8 through 12 comprise an EpCAM antibody or EpCAM-binding antibody fragment, or an EpCAM-activatable antibody, comprising a VH having the sequence of SEQ ID NO: 54 and a VL having the sequence of SEQ ID NO: 89. In some embodiments, EpBAs of specific embodiments 8 through 12 comprise an EpCAM antibody or EpCAM-binding antibody fragment, or an EpCAM-activatable antibody, comprising an HC having the sequence of SEQ ID NO: 103 and an LC having the sequence of SEQ ID NO: 140.

[0270] In some embodiments, the EpBA of specific embodiments 8 to 12 comprises an EpCAM activatable antibody comprising a MM of SEQ ID NO: 155. In some embodiments, the EpBA of specific embodiments 8 to 12 further comprises an EpCAM activatable antibody comprising a CM of SEQ ID NO: 168. In alternative embodiments, the EpBA of specific embodiments 8 to 12 comprises an EpCAM activatable antibody comprising a CM of SEQ ID NO: 169. In one embodiment, the EpBA of specific embodiments 8 to 12 comprises an EpCAM activatable antibody comprising a heavy chain having the sequence of SEQ ID NO: 103 and a light chain having the sequence of SEQ ID NO: 174. In one embodiment, the EpBA of specific embodiments 8 to 12 comprises an EpCAM activatable antibody comprising a heavy chain having the sequence of SEQ ID NO: 103 and a light chain having the sequence of SEQ ID NO: 179.

[0271] In certain embodiments, for compositions (e.g., pharmaceutical compositions) comprising the immunoconjugate of the first embodiment, or the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, or twelfth specific embodiments, the average number of cytotoxic drugs per antibody molecule in the composition (i.e., the average number of cytotoxic drugs per antibody molecule) (also known as the drug-to-antibody ratio (DAR)) is in the range of 1.0 to 8.0. In some embodiments, the DAR is in the range of 1.0 to 5.0, 1.0 to 4.0, 1.0 to 3.4, 1.0 to 3.0, 1.5 to 2.5, 2.0 to 2.5, or 1.8 to 2.2. In some embodiments, the DAR is less than 4.0, less than 3.8, less than 3.6, less than 3.5, less than 3.0, or less than 2.5.

[0272] In a second embodiment, the immunoconjugate comprises EpBA covalently attached to a cytotoxic agent disclosed herein via the thiol group (-SH) of one or more cysteine ​​residues located on EpBA.

[0273] In a first particular embodiment, the immunoconjugate of the second embodiment has the formula: [ka] wherein: EpBA binds to Cy via a cysteine ​​residue. C1 an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody disclosed herein covalently linked to W C is 1 or 2, Cy C1 is expressed as follows: [ka] or a pharmaceutically acceptable salt thereof, wherein: Double line between N and C [ka] is a single bond or a double bond, with the proviso that when it is a double bond, X is absent and Y is -H or (C1-C4) alkyl, and when it is a single bond, X is -H or an amine protecting moiety and Y is -OH or -SO3H or a pharmaceutically acceptable salt thereof; R 5 is —H or (C1-C3) alkyl; P is an amino acid residue or a peptide containing 2 to 20 amino acid residues; R a and R b is independently at each occurrence -H, (C1-C3) alkyl, or a charged substituent or ionizable group Q; m is an integer from 1 to 6; W'-NR e’ and R e’ -(CH2-CH2-O) n -R k and n is an integer from 2 to 6, R k is -H or -Me, R x3 is (C1-C6) alkyl, and L C is expressed as follows: [ka] wherein: s1 is the site covalently bound to EpBA, and s2 is Cy C1 is a moiety covalently bonded to the -C(=O)- group above, R 19 and R 20 is independently at each occurrence H or (C1-C3) alkyl); m" is an integer from 1 to 10, and R h is —H or (C1-C3) alkyl.

[0274] In a second particular embodiment, in the case of an immunoconjugate of formula (C1), CyC1 is represented by formula (C1a) or (C1a1), and the remaining variables are as described above in the first particular embodiment of the second embodiment.

[0275] In a third particular embodiment, in the case of an immunoconjugate of formula (C1), CyC1 is represented by formula (C1b) or (C1b1), and the remaining variables are as described above in the first particular embodiment of the second embodiment.

[0276] In a fourth particular embodiment, for the immunoconjugate of formula (C1), CyC1 is represented by formula (C1a) or (C1a1), both Ra and Rb are H, R5 is H or Me, and the remaining variables are as described above in the first or second particular embodiment of the second embodiment.

[0277] In a fifth particular embodiment, for the immunoconjugate of formula (C1), P is a peptide comprising 2 to 5 amino acid residues, and the remaining variables are as described above in the first, second, or fourth particular embodiment of the second embodiment. In a further specific embodiment, P is Gly-Gly-Gly, Ala-Val, Val-Ala, Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Trp, Cit, Phe-Ala, Phe-N9-to syl-Arg, Phe-N9-nitro-Arg, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala-Leu-Ala-Leu (SEQ ID NO: 215), β-Ala-Leu-A la-Leu (SEQ ID NO: 216), Gly-Phe-Leu-Gly (SEQ ID NO: 217), Val-Arg, Arg-Val, Arg-Arg, Val-D-Cit, Val-D-Lys, Val-D-Arg, D-Val-Cit, D-Val-Lys, D-Val-Arg, D-Val-D-Ci t, D-Val-D-Lys, D-Val-D-Arg, D-Arg-D-Arg, Ala-Ala, Ala-D-Ala, D-Ala-Ala, D-Ala-D-Ala, Ala-Met, Met-Ala, Gln-Val, Asn-Ala, Gln-Phe and Gln-Ala. In another more specific embodiment, P is Gly-Gly-Gly, Ala-Val, Ala-Ala, Ala-D-Ala, D-Ala-Ala, or D-Ala-D-Ala.

[0278] In a sixth particular embodiment, for the immunoconjugate of formula (C1), Q is —SO 3 H or a pharmaceutically acceptable salt thereof, and the remaining variables are as described above in the first, second, fourth or fifth particular embodiment of the second embodiment, or any further specific embodiments described therein.

[0279] In a seventh particular embodiment, for the immunoconjugate of formula (C1), R19 and R20 are both H, m" is an integer from 1 to 6, and the remaining variables are as described above in the first, second, third, fourth, fifth, or sixth particular embodiment of the second embodiment, or any further specific embodiments described therein.

[0280] In an eighth particular embodiment, in the case of the immunoconjugate of formula (C1), -L-LC- is of the following formula: [ka] and the remaining variables are as defined above in the first, second, third, fourth, fifth, sixth, or seventh specific embodiment of the second embodiment, or any further specific embodiments described therein.

[0281] In a ninth particular embodiment, the immunoconjugate of the second embodiment has the formula: [ka] or a pharmaceutically acceptable salt thereof, wherein the double line between N and C is [ka] is a single bond or a double bond, with the proviso that if it is a double bond, then X is absent and Y is -H, and if it is a single bond, then X is -H and Y is -OH or -SO3H or a pharmaceutically acceptable salt thereof. In a more particular embodiment, the double bond between N and C is [ka] is a double bond, X is absent, and Y is -H. [ka] is a single bond, X is -H, and Y is -SO3H or a pharmaceutically acceptable salt thereof.

[0282] In a third particular embodiment, the immunoconjugate of the invention has the formula: [ka] or a pharmaceutically acceptable salt thereof, wherein: [ka] is EpBA attached to the L2 group via the Lys amine group, [ka] is EpBA linked to the L2 group via the Cys thiol group, R 3 and R 4 are each independently H or Me, m1, m3, n1, r1, s1, and t1 each independently represent an integer of 1 to 6; m2, n2, r2, s2, and t2 each independently represent an integer of 1 to 7; t3 is an integer from 1 to 12, D1 is represented by the following formula: [ka] and q is an integer from 1 to 20. In more particular embodiments, D1 is of the formula: [ka] It is expressed by:

[0283] In a first particular embodiment of the third embodiment, the immunoconjugate of the invention has the formula: [ka] wherein: m1 and m3 each independently represent an integer of 2 to 4, m2 is an integer from 2 to 5, r1 is an integer from 2 to 6, r2 is an integer from 2 to 5, and The remaining variables are as described in the third embodiment.

[0284] In a second specific embodiment, for the immunoconjugates described in the third and first specific embodiments, A is Ala-Ala-Ala, Ala-D-Ala-Ala, Ala-Ala, D-Ala-Ala, Val-Ala, D-Val-Ala, D-Ala-Pro, or D-Ala-tBu-Gly. In a further specific embodiment, for the immunoconjugates described in the third and first specific embodiments, A is L-Ala-D-Ala-L-Ala.

[0285] In a third particular embodiment, the immunoconjugate of the invention has the formula: [ka] TIFF0007592009000105.tif225161TIFF0007592009000106.tif192162TIFF0007592009000107.tif221162TIFF0007592009000108.tif221162TIFF0007592009000109.tif221162TIFF0007592009000110.tif206161TIFF0007592009000111.tif192162 or a pharmaceutically acceptable salt thereof, wherein A is Ala-Ala-Ala, Ala-D-Ala-Ala, Ala-Ala, D-Ala-Ala, Val-Ala, D-Val-Ala, D-Ala-Pro, or D-Ala-tBu-Gly; D1 is represented by the following formula: [ka] and the remaining variables are as described in the third embodiment and its first and second specific embodiments. In a further specific embodiment, A is L-Ala-D-Ala-L-Ala. In a further specific embodiment, D1 is represented by the formula: [ka] It is expressed by:

[0286] In a fourth particular embodiment, the immunoconjugate of the invention has the formula: [ka] TIFF0007592009000115.tif41162, wherein D1 is represented by the following formula: [ka] It is expressed by:

[0287] In a fifth particular embodiment, the immunoconjugate of the invention has the formula: [ka] wherein: CBA is EpBA, q is 1 or 2, D1 is represented by the following formula: [ka] It is expressed as:

[0288] In a sixth particular embodiment, the immunoconjugate of the invention has the formula: [ka] wherein: CBA is EpBA, q is an integer from 1 to 10, D1 is represented by the following formula: [ka] It is expressed as:

[0289] In another particular embodiment, the present disclosure provides a compound of formula: [ka] The present invention provides an EpBA immunoconjugate comprising an EpBA (e.g., an EpCAM antibody, an EpCAM-binding antibody fragment, or an EpCAM-activatable antibody) linked via a γ-maleimidobutyric acid N-succinimidyl ester (GMBS) or N-(γ-maleimidobutyryloxy) sulfosuccinimide ester (sulfo-GMBS or sGMBS) linker to a maytansinoid compound DM21L (also known as LDL-DM) represented by the formula: GMBS and sulfo-GMBS (or sGMBS) linkers are known in the art and have the following structural formula: [ka] It can be expressed as:

[0290] In one embodiment, the immunoconjugate has the formula: [ka] wherein: EpBA is an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody conjugated to a maytansinoid compound via a Lys amine group, and q is an integer from 1 to 10.

[0291] In some embodiments, the EpBA of the EpBA-DM21L complex comprises an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody disclosed herein. In some embodiments, the EpBA of the EpBA-DM21L complex comprises X1YX3X4H, where X1 is selected from N and S, X3 is selected from Y, N, F, S, H, D, L, I, and W, and X4 is selected from I and M, VH-CDR1 (SEQ ID NO: 5); sequence WX2X3PGX6VYIQYX 12 X 13 KFX 17 G, X2 is selected from I and F, X3 is selected from Y and N, X6 is selected from N and D, and X 12 is selected from N and S, and X13 is selected from E and Q, and X 17 is selected from K and Q; and VH-CDR3 (SEQ ID NO: 8) in which X1 is selected from D and E, X3 is selected from P, A, S, Y, F, G, T, and V, and X4 is selected from Y and W. In some embodiments, the EpBA of the EpBA-DM21L complex comprises a VH-CDR2 (SEQ ID NO: 7) in which X1GX3X4FAY, where X1 is selected from D and E, X3 is selected from P, A, S, Y, F, G, T, and V, and X4 is selected from Y and W. 10 GX 12 TYLX 16 X4 is selected from R and K; 10 is selected from N and D, and X 12 is selected from F and I, and X 16 is selected from Y and S; light chain VL-CDR2 (SEQ ID NO: 40) comprising QTSNLAS; and VL-CDR3 (SEQ ID NO: 11) comprising X1QX3LELPX8T, where X1 is selected from A, L, and Q, X3 is selected from S, G, Y, and N, and X8 is selected from N and W.

[0292] In some embodiments, the VH-CDR1 of EpBA comprises the sequence NYX3IH, where X3 is selected from Y, N, F, S, H, D, L, I, and W (SEQ ID NO: 6). In some embodiments, the VH-CDR3 of EpBA comprises the sequence DGPX4FAY, where X4 is selected from Y and W (SEQ ID NO: 9). In some embodiments, the VL-CDR3 of EpBA comprises the sequence AQX3LELPNT, where X3 is selected from S, G, Y, and N (SEQ ID NO: 12).

[0293] In some embodiments, the EpBA of the EpBA-DM21L complex comprises an EpCAM antibody or EpCAM-binding antibody fragment, or an EpCAM-activatable antibody, comprising a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3, having the sequences of SEQ ID NOs: 13-15, 42, 40, and 41, respectively. In some embodiments, the EpBA of the EpBA-DM21L complex comprises an EpCAM antibody or EpCAM-binding antibody fragment, or an EpCAM-activatable antibody, comprising a VH having the sequence of SEQ ID NO: 54 and a VL having the sequence of SEQ ID NO: 89. In some embodiments, the EpBA of the EpBA-DM21L complex comprises an EpCAM antibody or EpCAM-binding antibody fragment, or an EpCAM-activatable antibody, comprising an HC having the sequence of SEQ ID NO: 103 and an LC having the sequence of SEQ ID NO: 140.

[0294] In some embodiments, the EpBA of the EpBA-DM21L complex comprises an EpCAM-activatable antibody comprising a MM of SEQ ID NO: 155. In some embodiments, the EpBA of the EpBA-DM21L complex further comprises an EpCAM-activatable antibody comprising a CM of SEQ ID NO: 168. In alternative embodiments, the EpBA of the EpBA-DM21L complex comprises an EpCAM-activatable antibody comprising a CM of SEQ ID NO: 169. In one embodiment, the EpBA of the EpBA-DM21L complex comprises an EpCAM-activatable antibody comprising a heavy chain having the sequence of SEQ ID NO: 103 and a light chain having the sequence of SEQ ID NO: 174. In one embodiment, the EpBA of the EpBA-DM21L complex comprises an EpCAM-activatable antibody comprising a heavy chain having the sequence of SEQ ID NO: 103 and a light chain having the sequence of SEQ ID NO: 179.

[0295] In certain embodiments, for compositions (e.g., pharmaceutical compositions) comprising EpBA-LDL-DM immune complexes, the average number of cytotoxic drugs per antibody molecule (i.e., the average value of q) (also known as the drug-to-antibody ratio (DAR)) ranges from 3.0 to 4.0, 3.2 to 3.8, or 3.4 to 3.7. In some embodiments, the DAR is 3.2, 3.3, 3.4, 3.5, 3.7, or 3.8.

[0296] Method for producing immunoconjugates As described in the first embodiment above or any specific embodiment described therein, immunoconjugates comprising an EpCAM-binding agent (EpBA, e.g., an EpCAM antibody, an EpCAM-binding antibody fragment, or an EpCAM-activatable antibody) covalently attached to a cytotoxic agent via the ε-amino group of one or more lysine residues located on the EpBA can be prepared by any method known in the art. See, e.g., WO2012 / 128868 and WO2012 / 112687. The entire contents of each of these patents are incorporated herein by reference in their entirety.

[0297] In certain embodiments, the immune conjugate of the first embodiment is prepared by a first method comprising reacting an EpBA (e.g., an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody disclosed herein) with a cytotoxic drug having an amine-reactive group.

[0298] In one embodiment, for the first method above, the reaction is carried out in the presence of an imine-reactive reagent such as NaHSO3.

[0299] In one embodiment, in the first method above, the cytotoxic agent having an amine reactive group has the formula: [ka] or a pharmaceutically acceptable salt thereof, wherein the definitions for the variables are as defined above for formulas (L1a'), (L1a'1), (L1b') and (L1b'1).

[0300] In a particular embodiment, the immunoconjugate of the first embodiment is prepared by a second method comprising the steps of: (a) reacting a cytotoxic drug with a linker compound having an amine-reactive group and a thiol-reactive group to form a cytotoxic drug-linker compound having an amine-reactive group attached thereto; and (b) Reacting EpBA with a cytotoxic drug-linker compound. In one embodiment, the reaction of step (a) is carried out in the presence of an imine-reactive reagent (e.g., NaHSO). In one embodiment, the cytotoxic drug-linker compound is reacted with EpBA without purification. Alternatively, the cytotoxic drug-linker compound is first purified before reacting with EpBA.

[0301] In certain embodiments, the immunoconjugate of the first embodiment is prepared by a third method comprising the steps of: (a) reacting EpBA with a linker compound having an amine-reactive group and a thiol-reactive group to form a modified EpBA having a thiol-reactive group attached thereto; and (b) Reacting the modified EpBA with a cytotoxic drug. In one embodiment, the reaction of step (b) is carried out in the presence of an imine-reactive reagent (e.g., NaHSO3).

[0302] In certain embodiments, the immunoconjugate of the first embodiment is prepared by a fourth method comprising reacting EpBA, a cytotoxic compound, and a linker compound having an amine-reactive group and a thiol-reactive group. In one embodiment, the reaction is carried out in the presence of an imine-reactive reagent (eg, NaHSO3).

[0303] In certain embodiments, for the second, third, or fourth method above, the linker compound having an amine-reactive group and a thiol-reactive group has the formula: [ka] wherein X is a halogen and J D -SH, -SSR d , or -SC(=O)R g and R d is phenyl, nitrophenyl, dinitrophenyl, carboxynitrophenyl, pyridyl or nitropyridyl, and Rg is alkyl, and the remaining variables are as described above for formulas (a1)-(a10), and the cytotoxic agent is a compound of the formula: [ka] or a pharmaceutically acceptable salt thereof, wherein the variables are as defined above for formulas (L1a'), (L1a'1), (L1b'), (L1b'1), (L2a'), (L2a'1), (L2b') and (L2b'1).

[0304] In certain embodiments, for the second, third, or fourth method above, the linker compound having an amine-reactive group and a thiol-reactive group is represented by any one of formulas (a1L)-(a10L), and the cytotoxic agent is represented by the following formula: [ka] wherein the variables are as defined above in any one of the thirteenth to fifteenth specific embodiments of the first embodiment above, and any further specific embodiments described therein.

[0305] In certain embodiments, for the second, third, or fourth method above, the linker is sulfoSPDB, the cytotoxic agent is DM4, and the immunoconjugate has the formula: [ka] or a pharmaceutically acceptable salt thereof, W L is an integer between 1 and 10.

[0306] An immunoconjugate comprising an EpCAM-binding agent covalently bound to a cytotoxic agent via the thiol group (-SH) of one or more cysteine ​​residues located on the EpCAM-binding agent described in the second embodiment above (e.g., an immunoconjugate of any one of the specific embodiments 1 to 23, or any further specific embodiments described therein) can be prepared by reacting an EpBA having one or more free cysteines with a cytotoxic agent having a thiol-reactive group as disclosed herein.

[0307] In one embodiment, the cytotoxic agent having a thiol-reactive group has the formula: [ka] or a pharmaceutically acceptable salt thereof, wherein -L C c is expressed as follows: [ka] wherein the variables are as defined above in any one of the first to ninth and twenty-third specific embodiments of the second embodiment, or any further specific embodiments described therein.

[0308] In another embodiment, the cytotoxic agent having a thiol-reactive group has the formula: [ka] or a pharmaceutically acceptable salt thereof, wherein -L C c ’ is expressed as follows: [ka] wherein the variables are as defined above in any one of the tenth to sixteenth and twenty-third specific embodiments of the second embodiment, or any further specific embodiments described therein.

[0309] In yet another embodiment, the cytotoxic agent having a thiol-reactive group has the formula: [ka] or a pharmaceutically acceptable salt thereof, wherein L C c ’ are as defined above, and the remaining variables are as defined above in any one of the 17th to 23rd specific embodiments of the second embodiment, or any further specific embodiments described therein.

[0310] In certain embodiments, an organic solvent is used to solubilize the cytotoxic drug in the reaction between EpBA and the cytotoxic drug. Exemplary organic solvents include, but are not limited to, dimethylacetamide (DMA), propylene glycol, and the like. In one embodiment, the reaction between EpBA and the cytotoxic drug is carried out in the presence of DMA and propylene glycol.

[0311] In certain embodiments, the cytotoxic agent has the formula: [ka] or a pharmaceutically acceptable salt thereof, and reacting with an EpBA (e.g., an EpCAM antibody or EpCAM-binding antibody fragment or EpCAM-activatable antibody disclosed herein) to form a compound of the formula: [ka] or a pharmaceutically acceptable salt thereof, wherein The doublet between N and C is a single bond or a double bond, with the proviso that if it is a double bond, X is absent and Y is -H, and if it is a single bond, X is -H and Y is -S03H or a pharmaceutically acceptable salt thereof, and WC is 1 or 2. In a more particular embodiment, the doublet between N and C is a double bond, X is absent and Y is -H. In another further specific embodiment, the doublet between N and C is a single bond, X is -H and Y is -S03H or a pharmaceutically acceptable salt thereof. Even more particularly, the pharmaceutically acceptable salt is a sodium or potassium salt.

[0312] In certain embodiments, when Y is —SOH or a pharmaceutically acceptable salt thereof, the immunoconjugate can be prepared by (a) reacting the imine moiety in an imine-containing cytotoxic drug having a thiol-reactive group described above (i.e., formula (C1a′), (C1a′1), (C1b′), (C1b′1), (C2a″), (C2a″1), (C2b″), or (C2b″1), where the doublet between N and C is a double bond, X is absent, and Y is —H) with sulfur dioxide, bisulfite, or metabisulfite in aqueous solution at pH 1.9 to 5.0 to form the following compound: [ka] or a pharmaceutically acceptable salt thereof, and (b) reacting the modified cytotoxic drug with an EpCAM-binding substance disclosed herein (e.g., an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody disclosed herein) to form an immune complex.

[0313] In a first aspect, in the above method, the reaction in step (a) is carried out at a pH of 1.9 to 5.0. More specifically, the pH is 2.5 to 4.9, 1.9 to 4.8, 2.0 to 4.8, 2.5 to 4.5, 2.9 to 4.5, 2.9 to 4.0, 2.9 to 3.7, 3.1 to 3.5, or 3.2 to 3.4. In another specific embodiment, the reaction in step (a) is carried out at a pH of 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.5, 4.6, 4.7, 4.8, 4.9, or 5.0. In yet another specific embodiment, the reaction in step (a) is carried out at a pH of 3.3. As used herein, a specific pH value means the specific value ±0.05.

[0314] In some embodiments, the reaction in step (a) is carried out in the presence of a buffer. Any suitable buffer known in the art can be used in the provided methods. Suitable buffers include, but are not limited to, citrate buffer, succinate buffer, phosphate buffer, glycine-containing buffer (e.g., glycine-HCl buffer), phthalate buffer (e.g., buffer containing sodium hydrogen phthalate or potassium hydrogen phthalate), and combinations thereof. In some embodiments, the buffer is a citrate buffer. In some embodiments, the buffer is a phosphate buffer. In some embodiments, the buffer is a citrate-phosphate buffer. In some embodiments, the buffer is a citrate-phosphate buffer containing citric acid and NaHPO. In other embodiments, the buffer is a citrate-phosphate buffer containing citric acid and KHPO. In some embodiments, the concentration of the buffer may be in the range of 10 to 250 mM, 10 to 200 mM, 10 to 150 mM, 10 to 100 mM, 25 to 100 mM, 25 to 75 mM, 10 to 50 mM, or 20 to 50 mM.

[0315] In a second aspect, the reaction of step (a) is carried out in the absence of a buffer (e.g., a buffer as described in the first aspect). In some embodiments, the method includes (a) reacting an imine moiety in an imine-containing cytotoxic drug having a thiol-reactive group (i.e., formula (C1a'), (C1a'1), (C1b'), (C1b'1), (C2a"), (C2a"1), (C2b"), or (C2b"1), where the doublet between N and C is a double bond, X is absent, and Y is -H) with sulfur dioxide, bisulfite, or metabisulfite in aqueous solution to produce a compound of the formula: [ka] or a pharmaceutically acceptable salt thereof, and (b) reacting the modified cytotoxic agent with an EpCAM-binding substance disclosed herein (e.g., an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody disclosed herein) to form an immune complex. In some embodiments, the reaction in step (a) is carried out in a mixture of an organic solvent and water. More specifically, the reaction in step (a) is carried out in a mixture of dimethylacetamide (DMA) and water. In some embodiments, the mixture of DMA and water contains less than 60% by volume of DMA. Even more specifically, the volume ratio of DMA to water is 1:1.

[0316] In a third aspect, in the method of the above or the first or second aspects, in the reaction of step (a), 0.5 to 5.0 equivalents of bisulfite or 0.25 or 2.5 equivalents of metabisulfite are used for every equivalent of imine-containing cytotoxic drug. In some embodiments, 0.5 to 4.5, 0.5 to 4.0, 0.5 to 3.5, 0.5 to 4.0, 0.5 to 3.5, 0.5 to 3.0, 0.5 to 2.5, 0.8 to 2.0, 0.9 to 1.8, 1.0 to 1.7, 1.1 to 1.6, or 1.2 to 1.5 equivalents of bisulfite or 0.25 to 2.25, 0.25 to 2.0, 0.25 to 1.75, 0.25 to 2.0, 0.25 to 1.75, 0.25 to 1.5, 0.25 to 1.25, 0.4 to 1.0, 0.45 to 0.9, 0.5 to 0.85, 0.55 to 0.8, or 0.6 to 0.75 equivalents of metabisulfite are used per equivalent of imine-containing cytotoxic drug. In other embodiments, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 4.0, 4.5, or 5.0 equivalents of bisulfite or 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1.0, 1.05, 1.1, 1.15, 1.2, 1.25, 1.3, 1.35, 1.4, 1.45, 1.5, 1.55, 1.6, 1.65, 1.7, 1.75, 2.0, 2.25, or 2.5 equivalents of metabisulfite are used per equivalent of imine-containing cytotoxic drug. In yet other embodiments, 1.4 equivalents of bisulfite or 0.7 equivalents of metabisulfite are used per equivalent of imine-containing cytotoxic drug. In other embodiments, 1.2 equivalents of bisulfite or 0.6 equivalents of metabisulfite are used per equivalent of imine-containing cytotoxic drug. As used herein, a particular equivalent weight means a particular value ±0.05.

[0317] In a fourth aspect, in the above method, the reaction in step (a) is carried out at a pH of 2.9 to 3.7, and 1.0 to 1.8 equivalents of bisulfite or 0.5 to 0.9 equivalents of metabisulfite are reacted with 1 equivalent of imine-containing cytotoxic drug. In some embodiments, the reaction in step (a) is carried out at a pH of 3.1 to 3.5, and 1.1 to 1.6 equivalents of bisulfite or 0.55 to 0.8 equivalents of metabisulfite are reacted with 1 equivalent of imine-containing cytotoxic drug. In other embodiments, the reaction in step (a) is carried out at a pH of 3.2 to 3.4, and 1.3 to 1.5 equivalents of bisulfite or 0.65 to 0.75 equivalents of metabisulfite are reacted with 1 equivalent of imine-containing cytotoxic drug. In other embodiments, the reaction in step (a) is carried out at a pH of 3.3, and 1.4 equivalents of bisulfite or 0.7 equivalents of metabisulfite are reacted with 1 equivalent of an imine-containing cytotoxic drug. In yet other embodiments, the reaction in step (a) is carried out at a pH of 3.3, and 1.4 equivalents of sodium bisulfite are reacted with 1 equivalent of an imine-containing cytotoxic drug.

[0318] In a fifth aspect, in the method of the above, or the first, second, third, or fourth aspect, the reaction of step (a) is carried out in a mixture of an organic solvent and water. Any suitable organic solvent can be used. Representative organic solvents include, but are not limited to, alcohols (e.g., methanol, ethanol, propanol, etc.), dimethylacetamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile, acetone, methylene chloride, and the like. In some embodiments, the organic solvent is miscible with water. In other embodiments, the organic solvent is not miscible with water, i.e., the reaction of step (a) is carried out in a two-phase solution. In some embodiments, the organic solvent is dimethylacetamide (DMA). The organic solvent (e.g., DMA) can be present in an amount of 1% to 99%, 1% to 95%, 10% to 80%, 20% to 70%, 30% to 70%, 1% to 60%, 5% to 60%, 10% to 60%, 20% to 60%, 30% to 60%, 40% to 60%, 45% to 55%, 10% to 50%, or 20% to 40% by volume, based on the total volume of water and organic solvent. In some embodiments, the reaction in step (a) is carried out in a mixture of DMA and water, wherein the volume ratio of DMA to water is 1:1.

[0319] In a sixth aspect, in the method of the above, or the first, second, third, fourth, or fifth aspects, the reaction of step (a) is carried out at any suitable temperature. In some embodiments, the reaction is carried out at a temperature of 0°C to 50°C, 10°C to 50°C, 10°C to 40°C, or 10°C to 30°C. In other embodiments, the reaction is carried out at a temperature of 15°C to 30°C, 20°C to 30°C, 15°C to 25°C, 16°C to 24°C, 17°C to 23°C, 18°C ​​to 22°C, or 19°C to 21°C. In still other embodiments, the reaction can be carried out at a temperature of 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, 24°C, or 25°C. In some embodiments, the reaction can be carried out at a temperature between 0°C and 15°C, between 0°C and 10°C, between 1°C and 10°C, between 5°C and 15°C, or between 5°C and 10°C.

[0320] In a seventh aspect, in the method of the above, or the first, second, third, fourth, fifth, or sixth aspect, the reaction in step (a) is carried out for 1 minute to 48 hours, 5 minutes to 36 hours, 10 minutes to 24 hours, 30 minutes to 24 hours, 30 minutes to 20 hours, 1 hour to 20 hours, 1 hour to 15 hours, 1 hour to 10 hours, 2 hours to 10 hours, 3 hours to 9 hours, 3 hours to 8 hours, 4 hours to 6 hours, or 1 hour to 4 hours. In some embodiments, the reaction is allowed to proceed for 4 to 6 hours. In other embodiments, the reaction is allowed to proceed for 10 minutes, 15 minutes, 20 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, etc. In other embodiments, the reaction is allowed to proceed for 4 hours. In yet another embodiment, the reaction is allowed to proceed for 2 hours.

[0321] In an eighth aspect, in the method of the above, or the first, second, third, fourth, fifth, sixth, or seventh aspect, the reacting of step (b) is carried out at a pH of 4 to 9. In some embodiments, the reacting of step (b) is carried out at a pH of 4.5 to 8.5, 5 to 8.5, 5 to 8, 5 to 7.5, 5 to 7, 5 to 6.5, or 5.5 to 6.5. In other embodiments, the reaction of step (b) is carried out at a pH of 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0.

[0322] In some embodiments, in the method of the above or the first, second, third, fourth, fifth, sixth, seventh, or eighth aspect, the reaction in step (b) is carried out in an aqueous solution containing water and an organic solvent. Any suitable organic solvent can be used. More specifically, the organic solvent is DMA. In some embodiments, the aqueous solution contains less than 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 3%, 2%, or 1% by volume of organic solvent (e.g., DMA).

[0323] In some embodiments, in a method disclosed herein or of the first, second, third, fourth, fifth, sixth, seventh, or eighth aspect, the bisulfite is sodium or potassium bisulfite and the metabisulfite is sodium or potassium metabisulfite. In certain embodiments, the bisulfite is sodium bisulfite and the metabisulfite is sodium metabisulfite.

[0324] In some embodiments, in the case of a method disclosed herein or of the first, second, third, fourth, fifth, sixth, seventh or eighth aspect, the modified cytotoxic drug is not purified prior to reaction with the cell-binding agent in step (b). Alternatively, the modified cytotoxic drug is purified prior to reaction with the cell-binding agent in step (b). Any suitable method disclosed herein can be used to purify the modified cytotoxic drug.

[0325] In some embodiments, the reaction in step (a) of the above method does not result in substantial sulfonation of maleimide groups. In some embodiments, 50%, 40%, 30%, 20%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the maleimide groups are sulfonated. The percentage of maleimide sulfonation is equal to the total amount of maleimide-sulfonated cytotoxic drug (a cytotoxic drug having sulfonation only on the maleimide) and disulfonated cytotoxic drug (a cytotoxic drug having sulfonation on both the maleimide and imine moieties) divided by the starting amount of imine-containing cytotoxic drug prior to its reaction with bisulfite or metabisulfite.

[0326] In some embodiments, the immunoconjugate prepared by any of the above methods is subjected to a purification step, in which the immunoconjugate can be purified from other components of the mixture using tangential flow filtration (TFF), non-adsorptive chromatography, adsorption chromatography, adsorption filtration, selective precipitation, or any other suitable purification method, as well as combinations thereof.

[0327] In some embodiments, the immunoconjugate is purified using a single purification step (e.g., TFF). Preferably, the conjugate is purified and exchanged into a suitable formulation using a single purification step (e.g., TFF). In other embodiments, the immunoconjugate is purified using two sequential purification steps. For example, the immunoconjugate can first be purified by selective precipitation, adsorptive filtration, adsorptive or non-adsorptive chromatography, followed by purification using TFF. Those skilled in the art will understand that purification of the immunoconjugate allows for the isolation of a stable conjugate comprising a cell-binding agent chemically linked to a cytotoxic drug.

[0328] Any suitable TFF system can be utilized for purification, including a Pellicon type system (Millipore, Billerica, Mass.), a Sartocon Cassette system (Sartorius AG, Edgewood, NY), and a Centrasette type system (Pall Corp., East Hills, NY).

[0329] Any suitable adsorption chromatography resin can be used for purification. Preferred adsorption chromatography resins include hydroxyapatite chromatography, hydrophobic charge induction chromatography (HCIC), hydrophobic interaction chromatography (HIC), ion exchange chromatography, mixed-mode ion exchange chromatography, immobilized metal affinity chromatography (IMAC), dye-ligand chromatography, affinity chromatography, reversed-phase chromatography, and combinations thereof. Examples of suitable hydroxyapatite resins include ceramic hydroxyapatite (CHT types I and II, Bio-Rad Laboratories, Hercules, Calif.), HA Ultrogel hydroxyapatite (Pall Corp., East Hills, NY), and ceramic fluoroapatite (CFT types I and II, Bio-Rad Laboratories, Hercules, Calif.). An example of a suitable HCIC resin is MEP Hypercel resin (Pall Corp., East Hills, NY). Examples of suitable HIC resins include butyl sepharose, hexyl sepharose, phenyl sepharose, and octyl sepharose resins (all available from GE Healthcare, Piscataway, NJ), and Macro-prep Methyl and Macro-Prep t-Butyl resins (Biorad Laboratories, Hercules, Calif.). Examples of suitable ion exchange resins include SP sepharose, CM sepharose, and Q sepharose resins (all available from GE Healthcare, Piscataway, NJ), and Unosphere S resin (Bio-Rad Laboratories, Hercules, Calif.). An example of a suitable mixed-mode ion exchange device is Bakerbond CBAx resin (JT Baker, Phillipsburg, NJ).Examples of suitable IMAC resins include chelating Sepharose resin (GE Healthcare, Piscataway, NJ) and Profinity IMAC resin (Bio-Rad Laboratories, Hercules, Calif.). Examples of suitable dye-ligand resins include Blue Sepharose resin (GE Healthcare, Piscataway, NJ) and Affigel Blue resin (Bio-Rad Laboratories, Hercules, Calif.). Examples of suitable affinity resins include Protein A Sepharose resin (e.g., MabSelect, GE Healthcare, Piscataway, NJ) (where the cell-binding agent is an antibody) and lectin affinity resins, such as Lentil Lectin Sepharose resin (GE Healthcare, Piscataway, NJ) (where the cell-binding agent has an appropriate lectin-binding site). Alternatively, antibodies specific to the cell-binding agent can be used. Such antibodies can be immobilized, for example, on Sepharose 4 FAST Flow resin (GE Healthcare, Piscataway, NJ). Examples of suitable reverse phase resins include C4, C8, and C18 resins (Grace Vydac, Hesperia, Calif.).

[0330] Any suitable non-adsorbent chromatography resin can be used for purification. Examples of suitable non-adsorbent chromatography resins include, but are not limited to, Sephadex™ G-25, G-50, G-100, Sephacryl™ resins (e.g., S-200 and S-300), Superdex™ resins (e.g., Superdex™ 75 and Superdex™ 200), Biogel™ resins (e.g., P-6, P-10, P-30, P-60, and P-100), and other resins known to those skilled in the art.

[0331] The immunoconjugate comprising EpBA covalently attached to a maytansinoid compound described in the third embodiment herein can be prepared by any suitable method known in the art.

[0332] In certain embodiments, the immunoconjugate comprises EpBA represented by formula (II): [ka] The compound can be prepared by a first method comprising the step of reacting the compound with a maytansinoid compound of formula (I).

[0333] In certain embodiments, the immunoconjugates can be prepared by a second method comprising the steps of: (a) reacting a maytansinoid compound of formula (III) or (IV) with a linker compound described herein to form a cytotoxic drug-maytansinoid compound having an amine-reactive group or a thiol-reactive group attached thereto that is capable of covalently binding to EpBA, wherein formulas (III) and (IV) are: [ka] and (b) reacting EpBA with a maytansinoid-linker compound to form an immunoconjugate.

[0334] In certain embodiments, the immunoconjugates can be prepared by a third method comprising the steps of: (a) reacting EpBA with a linker compound described herein to form a modified anti-EpBA (e.g., a compound of formula (II)) having an amine-reactive or thiol-reactive group capable of covalently binding to a maytansinoid compound of formula (III) or (IV), and (b) reacting the modified EpBA with a maytansinoid compound of formula (III) or (IV) to form an immunoconjugate.

[0335] In certain embodiments, the immunoconjugate can be prepared by a third method comprising reacting EpBA with a linker compound and a maytansinoid compound of formula (III) or (IV) to form the immunoconjugate. In one embodiment, the EpBA and the maytansinoid compound of formula (III) or (IV) are mixed first, followed by the addition of the linker compound.

[0336] In certain embodiments, for the second, third or fourth method above, the linker compound is represented by formula (a1L) to (a10L): [ka] wherein X is a halogen; D -SH or -SSR d and;R d is phenyl, nitrophenyl, dinitrophenyl, carboxynitrophenyl, pyridyl, or nitropyridyl; R g is alkyl; and U is —H or SO 3 H or a pharmaceutically acceptable salt thereof.

[0337] In one embodiment, the linker compound is GMBS or sulfo-GMBS represented by formula (a9L), where U is —H or SO 3 H or a pharmaceutically acceptable salt thereof.

[0338] In a particular embodiment, the immunoconjugate of the invention has the formula: [ka] and the immunoconjugate can be prepared by the second, third or fourth method above, wherein the linker compound is GMBS or sulfo-GMBS represented by formula (a9L), U is —H or SO3H or a pharmaceutically acceptable salt thereof, and the maytansinoid compound is represented by formula (D-1): [ka] wherein D1 is represented by the formula: [ka] It is expressed by: In a further specific embodiment, the immunoconjugate of formula (I-1) is prepared by reacting a maytansinoid compound of formula (D-1) with the linker compound GMBS or sulfo-GMBS to form a maytansinoid-linker compound, and subsequently reacting EpBA with the maytansinoid-linker compound. In an even further specific embodiment, the maytansinoid linker compound is not purified prior to reaction with EpBA.

[0339] In another particular embodiment, the immunoconjugate has the formula: [ka] and the immunoconjugate can be prepared by the second, third, or fourth method above, wherein the linker compound is GMBS or sulfo-GMBS represented by formula (a9L), U is —H or SO3H or a pharmaceutically acceptable salt thereof, and the maytansinoid compound is represented by formula (D-2) above. In a further specific embodiment, the immunoconjugate of formula (I-2) is prepared by reacting the maytansinoid compound of formula (D-2) with the linker compound GMBS or sulfo-GMBS to form a maytansinoid-linker compound, followed by reacting EpBA with the maytansinoid-linker compound. In an even further specific embodiment, the maytansinoid linker compound is not purified before reacting it with EpBA.

[0340] In another particular embodiment, the immunoconjugate has the formula: [ka] The immune complex is represented by the formula (D-3): [ka] The compound is prepared according to the first method above by reacting the compound with a maytansinoid compound of formula (I).

[0341] In another particular embodiment, the immunoconjugate has the formula: [ka] The immune complex is represented by the formula (D-4): [ka] with a maytansinoid compound according to the first method above.

[0342] In another particular embodiment, the immunoconjugate has the formula: [ka] The immune complex is represented by the formula (D-5): [ka] with a maytansinoid compound according to the first method above.

[0343] In another particular embodiment, preferably the immunoconjugate has the formula: [ka] The immune complex is represented by the formula (D-6): [ka] with a maytansinoid compound according to the first method above.

[0344] In some embodiments, the immunoconjugate prepared by any of the above methods is subjected to a purification step, in which the immunoconjugate can be purified from other components of the mixture using tangential flow filtration (TFF), non-adsorptive chromatography, adsorption chromatography, adsorption filtration, selective precipitation, or any other suitable purification method, as well as combinations thereof.

[0345] In some embodiments, the immunoconjugate is purified using a single purification step (e.g., TFF). Preferably, the conjugate is purified and exchanged into a suitable formulation using a single purification step (e.g., TFF). In other embodiments of the present invention, the immunoconjugate is purified using two sequential purification steps. For example, the immunoconjugate can first be purified by selective precipitation, adsorptive filtration, adsorptive or non-adsorptive chromatography, followed by purification using TFF. Those skilled in the art will understand that purification of the immunoconjugate allows for the isolation of a stable conjugate comprising a cell-binding agent chemically linked to a cytotoxic drug.

[0346] Any suitable TFF system can be utilized for purification, including the Pellicon type system (Millipore, Billerica, Mass.), the Sartocon Cassette system (Sartorius AG, Edgewood, NY), and the Centrasette type system (Pall Corp., East Hills, NY).

[0347] Any suitable adsorption chromatography resin can be used for purification. Preferred adsorption chromatography resins include hydroxyapatite chromatography, hydrophobic charge induction chromatography (HCIC), hydrophobic interaction chromatography (HIC), ion exchange chromatography, mixed-mode ion exchange chromatography, immobilized metal affinity chromatography (IMAC), dye-ligand chromatography, affinity chromatography, reversed-phase chromatography, and combinations thereof. Examples of suitable hydroxyapatite resins include ceramic hydroxyapatite (CHT type I and II, Bio-Rad Laboratories, Hercules, Calif.), HA Ultrogel hydroxyapatite (Pall Corp., East Hills, NY), and ceramic fluoroapatite (CFT type I and II, Bio-Rad Laboratories, Hercules, Calif.). An example of a suitable HCIC resin is MEP Hypercel resin (Pall Corp., East Hills, NY). Examples of suitable HIC resins include butyl sepharose, hexyl sepharose, phenyl sepharose, and octyl sepharose resins (all available from GE Healthcare, Piscataway, NJ), and Macro-prep Methyl and Macro-Prep t-Butyl resins (Biorad Laboratories, Hercules, Calif.). Examples of suitable ion exchange resins include SP sepharose, CM sepharose, and Q sepharose resins (all available from GE Healthcare, Piscataway, NJ), and Unosphere S resin (Bio-Rad Laboratories, Hercules, Calif.). An example of a suitable mixed-mode ion exchange device is Bakerbond ABx resin (JT Baker, Phillipsburg, NJ).Examples of suitable IMAC resins include chelating Sepharose resin (GE Healthcare, Piscataway, NJ) and Profinity IMAC resin (Bio-Rad Laboratories, Hercules, Calif.). Examples of suitable dye-ligand resins include Blue Sepharose resin (GE Healthcare, Piscataway, NJ) and Affigel Blue resin (Bio-Rad Laboratories, Hercules, Calif.). Examples of suitable affinity resins include Protein A Sepharose resin (e.g., MabSelect, GE Healthcare, Piscataway, NJ) (where the cell-binding agent is an antibody) and lectin affinity resins, such as Lentil Lectin Sepharose resin (GE Healthcare, Piscataway, NJ) (where the cell-binding agent has an appropriate lectin-binding site). Alternatively, antibodies specific to the cell-binding agent can be used. Such antibodies can be immobilized, for example, on Sepharose 4 FAST Flow resin (GE Healthcare, Piscataway, NJ). Examples of suitable reverse phase resins include C4, C8, and C18 resins (Grace Vydac, Hesperia, Calif.).

[0348] Any suitable non-adsorbent chromatography resin can be used for purification. Examples of suitable non-adsorbent chromatography resins include, but are not limited to, Sephadex™ G-25, G-50, G-100, Sephacryl™ resins (e.g., S-200 and S-300), Superdex™ resins (e.g., Superdex™ 75 and Superdex™ 200), Biogel™ resins (e.g., P-6, P-10, P-30, P-60, and P-100), and other resins known to those skilled in the art.

[0349] Diagnostic and research uses In addition to the therapeutic uses of antibodies discussed herein, the antibody fragments, activatable antibodies, and activatable antibodies provided herein can be employed in many known diagnostic and research applications. The provided EpCAM antibodies and / or EpCAM-binding antibody fragments can be used, for example, for purifying, detecting, and targeting EpCAM, including in both in vitro and in vivo diagnostic methods. For example, the antibodies and / or fragments can be used in immunoassays to qualitatively and quantitatively measure the level of EpCAM (e.g., human EpCAM or cynomolgus EpCAM) expressed by cells in biological samples. See, for example, Harlow, et al., Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 2nd ed. 1988), the entire contents of which are incorporated herein by reference.

[0350] The provided EpCAM antibodies and / or EpCAM-binding antibody fragments may be used, for example, in competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays (Zola, Monoclonal Antibodies: A Manual of Techniques, pp. 147-158 (CRC Press, Inc., 1987)).

[0351] Detectable labeling of EpCAM antibodies, EpCAM-binding antibody fragments, and / or EpCAM-activatable antibodies can be achieved by conjugation to an enzyme for use in enzyme immunoassays (EIAs) or enzyme-linked immunosorbent assays (ELISAs). The conjugated enzyme reacts with an exposed substrate to produce a chemical moiety that can be detected, for example, by spectrophotometric, fluorometric, or visual means. For example, enzymes that can be used to detectably label the disclosed EpCAM antibodies, EpCAM-binding antibody fragments, and EpCAM-activatable antibodies include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triosephosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, and acetylcholinesterase.

[0352] By radioactively labeling EpCAM antibodies, EpCAM-binding antibody fragments, and EpCAM-activatable antibodies, it is possible to detect EpCAM using radioimmunoassay (RIA) (see, e.g., Work, et al., Laboratory Techniques and Biochemistry in Molecular Biology, North Holland Publishing Company, NY (1978)). Radioactive isotopes can be detected by means such as the use of a gamma counter or scintillation counter or autoradiography. Particularly useful isotopes for purposes of the present disclosure are: 3 H, 125 I, 131 I, 35 S, 14 C, preferably 125 I.

[0353] EpCAM antibodies, EpCAM-binding antibody fragments, and EpCAM-activatable antibodies can also be labeled with fluorescent compounds. When the fluorescently labeled antibody, antibody fragment, or activatable antibody is exposed to light of the appropriate wavelength, its presence can be detected by fluorescence. The most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, O-phthalaldehyde, and fluorescamine.

[0354] The EpCAM antibodies, EpCAM-binding antibody fragments, and EpCAM-activatable antibodies can also be detectably labeled with fluorescence-emitting metals such as 125Eu or other metals of the lanthanide series. These metals can be attached to the EpCAM antibodies, EpCAM-binding antibody fragments, and EpCAM-activatable antibodies using metal chelating groups such as diethylenetriaminepentaacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

[0355] In further embodiments, EpCAM antibodies, EpCAM-binding antibody fragments, and EpCAM-activatable antibodies are detectably labeled by conjugation to a chemiluminescent compound. The presence of the chemiluminescent-labeled antibody or antibody fragment is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, acridinium salt, and oxalate ester. Similarly, bioluminescent compounds can be used to label EpCAM antibodies, EpCAM-binding antibody fragments, EpCAM-activatable antibodies, or their derivatives. Bioluminescence is a type of chemiluminescence observed in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of the bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for labeling purposes are luciferin, luciferase, and aequorin.

[0356] EpCAM antibodies, EpCAM-binding antibody fragments, and EpCAM-activatable antibodies are useful for in vivo imaging; EpCAM antibodies, EpCAM-binding antibody fragments, or EpCAM-activatable antibodies labeled with a detectable moiety, such as a radiopaque agent or a radioisotope, are administered to a subject, preferably into the bloodstream, and the presence and location of the labeled antibody or antibody fragment in the host are assayed. This imaging technique is useful for staging and treating malignant tumors. EpCAM antibodies, EpCAM-binding antibody fragments, or EpCAM-activatable antibodies can be labeled with any moiety that can be detected in the host by nuclear magnetic resonance, radiology, or other detection means known in the art.

[0357] The label used in accordance with the disclosed methods can be any detectable moiety capable of directly or indirectly producing a detectable signal. For example, the label can be a biotin label, an enzyme label (e.g., luciferase, alkaline phosphatase, beta-galactosidase, and horseradish peroxidase), a radiolabel (e.g., 3 H, 14 C. 32 P, 35 S, and 125 I), fluorophores such as fluorescent or chemiluminescent compounds (e.g., fluorescein isothiocyanate, rhodamine), contrast agents (e.g., Tc-m 99 and indium ( 111 In) and metal ions (e.g., gallium and europium).

[0358] Any method known in the art for binding an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody to a label may be used, including exemplary methods described by Hunter et al., Nature 144:945 (1962); David et al., Biochemistry 13:1014 (1974); Pain et al., J. Immunol. Meth. 40:219 (1981); Nygren, Histochem. and Cytochem. 30:407 (1982).

[0359] therapeutic application Also included are methods for inhibiting the proliferation of cells expressing EpCAM (e.g., human EpCAM or cynomolgus EpCAM). As provided herein, the disclosed EpCAM antibodies, EpCAM-binding antibody fragments, EpCAM-activatable antibodies, and / or conjugates thereof have the ability to bind to EpCAM present on the surface of cells (e.g., human cells or cynomolgus cells) and mediate cell killing. In certain embodiments, an immunoconjugate containing a toxic payload, e.g., an indolinobenzodiazepine DNA alkylator, is internalized and mediates cell killing via the activity of the toxic payload, e.g., a benzodiazepine, e.g., an indolinobenzodiazepine DNA alkylator. Such cell killing activity can be enhanced by immunoconjugates that induce antibody-dependent cellular cytotoxicity (ADCC) and / or complement-dependent cytotoxicity (CDC).

[0360] As used herein, the terms "inhibit" and "inhibiting" include an inhibitory effect on cell proliferation, including cell death. An inhibitory effect includes a temporary effect, a sustained effect, and a permanent effect.

[0361] Therapeutic applications provided herein include methods for treating a subject with a disease. The diseases treated by the provided methods are diseases characterized by expression (e.g., EpCAM overexpression). Such diseases include, for example, breast cancer, lung cancer, stomach cancer, prostate cancer, ovarian cancer, colorectal cancer, colon cancer, esophageal cancer, tracheal cancer, gastric cancer, bladder cancer, uterine cancer, rectal cancer, or small intestine cancer, pancreatic cancer, or other epithelial cancer, or metastases associated therewith. Those skilled in the art will understand that the methods of the present disclosure can also be used to treat other diseases, not yet described, that are characterized by EpCAM expression.

[0362] In other specific embodiments, the disclosed EpCAM antibodies, EpCAM-binding antibody fragments, EpCAM-activatable antibodies, and / or conjugates thereof are useful for treating cancers that express EpCAM. In some embodiments, the cancer is epithelial or squamous cell carcinoma. In some embodiments, the cancer is breast cancer, lung cancer, stomach cancer, prostate cancer, ovarian cancer, colorectal cancer, colon cancer, esophageal cancer, tracheal cancer, gastric cancer, bladder cancer, uterine cancer, rectal cancer, pancreatic cancer, or small intestine cancer.

[0363] The therapeutic applications provided herein are practiced in vitro and ex vivo alike.

[0364] The present disclosure also provides therapeutic applications of the disclosed EpCAM antibodies, EpCAM-binding antibody fragments, EpCAM-activatable antibodies, and / or conjugates thereof, in which the antibodies, antibody fragments, activatable antibodies, or conjugates are administered to a subject in a pharmaceutically acceptable dosage form. They can be administered intravenously as a bolus or by continuous infusion over a period of time, intramuscularly, subcutaneously, parenterally, intra-articularly, intrasynovially, intrathecally, orally, topically, or by inhalation. They can also be administered intratumorally, peritumorally, intralesionally, or perilesionally to exert local as well as systemic therapeutic effects.

[0365] Also provided are methods for treating, preventing, and / or delaying the onset or progression of, or alleviating symptoms associated with abnormal expression and / or activity of EpCAM in a subject using EpCAM-activatable antibodies that bind to EpCAM, particularly EpCAM-activatable antibodies that bind to and neutralize or otherwise inhibit at least one of the biological activities of EpCAM and / or EpCAM-mediated signaling.

[0366] In some embodiments, the present disclosure provides methods for treating, preventing, and / or delaying the onset or progression of, or alleviating a condition associated with the presence, growth, proliferation, metastasis, and / or activity of cells that express EpCAM or aberrantly express EpCAM in a subject using an EpCAM-activatable antibody that binds to EpCAM, particularly an EpCAM-activatable antibody that binds to, targets, neutralizes, kills, or otherwise inhibits at least one biological activity of cells that express or aberrantly express EpCAM. The present disclosure also provides methods for treating, preventing, and / or delaying the onset or progression of, or alleviating a condition associated with the presence, growth, proliferation, metastasis, and / or activity of cells that express EpCAM in a subject using an EpCAM-activatable antibody that binds to, targets, neutralizes, kills, or otherwise inhibits at least one biological activity of cells that express EpCAM.

[0367] The present disclosure also provides methods for treating, preventing, and / or delaying the onset or progression of, or alleviating symptoms associated with the presence, growth, proliferation, metastasis, and / or activity of cells that abnormally express EpCAM in a subject using EpCAM-activatable antibodies that bind to EpCAM, particularly EpCAM-activatable antibodies that bind to, target, neutralize, kill, or otherwise inhibit at least one biological activity of cells that abnormally express EpCAM.

[0368] The present disclosure provides methods for preventing, slowing the progression of, treating, alleviating symptoms of, or otherwise ameliorating an EpCAM-mediated disease in a subject by administering to the subject in need thereof a therapeutically effective amount of an EpCAM antibody, conjugated EpCAM antibody, EpCAM-activatable antibody, and / or conjugated EpCAM-activatable antibody disclosed herein.

[0369] The present disclosure also provides methods for preventing, slowing the progression of, treating, alleviating symptoms of, or otherwise ameliorating cancer (e.g., epithelial cancers and metastases) in a subject by administering to the subject in need thereof a therapeutically effective amount of an EpCAM antibody, conjugated EpCAM antibody, EpCAM activatable antibody, and / or conjugated EpCAM activatable antibody disclosed herein. EpCAM is known to be expressed in a variety of cancers, including most cancers (and metastases) of epithelial origin.

[0370] In some embodiments, the cancer is an epithelial or squamous cell carcinoma.

[0371] In some embodiments, the cancer is breast cancer, lung cancer, stomach cancer, prostate cancer, ovarian cancer, colorectal cancer, colon cancer, esophageal cancer, tracheal cancer, gastric cancer, bladder cancer, uterine cancer, rectal cancer, pancreatic cancer, or small intestine cancer.

[0372] In some embodiments, the cancer is breast cancer, lung cancer, stomach cancer, colorectal cancer, colon cancer, rectal cancer, small intestine cancer, ovarian cancer, gastric cancer, or esophageal cancer.

[0373] In some embodiments, the cancer is ovarian cancer, uterine cancer, gastric cancer, pancreatic cancer, or colorectal cancer.

[0374] In some embodiments, the cancer cells are ovarian cancer cells. In some embodiments, the cancer is uterine cancer. In some embodiments, the cancer is gastric cancer. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is colorectal cancer. In some embodiments, the cancer is breast cancer. In particular embodiments, the cancer is triple-negative breast cancer. In some embodiments, the cancer is lung cancer. In some embodiments, the lung cancer is non-small cell lung cancer. In some embodiments, the non-small cell lung cancer is non-squamous non-small cell lung cancer.

[0375] The EpCAM antibodies, conjugated EpCAM antibodies, EpCAM-activatable antibodies, and / or conjugated EpCAM-activatable antibodies used in any of these method and use embodiments can be administered at any stage of the disease. For example, such EpCAM antibodies, conjugated EpCAM antibodies, EpCAM-activatable antibodies, and / or conjugated EpCAM-activatable antibodies can be administered to patients suffering from cancer at any stage, from early to metastatic. The terms "subject" and "patient" are used interchangeably.

[0376] In some embodiments, the subject is a mammal such as a human, a non-human primate, a companion animal (e.g., a cat, dog, horse), a livestock animal, a work animal, or a zoo animal. In some embodiments, the subject is a human. In some embodiments, the subject is a companion animal. In some embodiments, the subject is an animal under veterinarian care.

[0377] EpCAM antibodies, conjugated EpCAM antibodies, EpCAM-activatable antibodies, and / or conjugated EpCAM-activatable antibodies, as well as therapeutic preparations thereof, are administered to subjects suffering from or susceptible to diseases or disorders associated with abnormal EpCAM expression and / or activity, such as cancer. Subjects suffering from or susceptible to diseases or disorders associated with abnormal EpCAM antibody expression and / or activity are identified using any of a variety of methods known in the art. For example, subjects suffering from cancer or other neoplastic conditions are identified using any of a variety of clinical and / or laboratory tests, such as physical examinations and blood, urine, and / or stool analy...

Claims

1. EpCAM antibody or EpCAM-binding antibody fragment, the antibody or antibody fragment (a) SEQ ID NOs: 13-15, 42, 40, and 41, respectively; (b) SEQ ID NOs: 13-15, and 39-41, respectively; (c) SEQ ID NOs: 13, 26, 15, and 39-41, respectively; and (d) SEQ ID NOs: 13, 26, 15, 42, 40, and 41, respectively; 1. An EpCAM antibody or EpCAM-binding antibody fragment comprising a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3 consisting of a sequence selected from the group consisting of:

2. The antibody or antibody fragment has a K D Combine with The EpCAM antibody or EpCAM-binding antibody fragment of claim 1.

3. The EpCAM antibody or EpCAM-binding antibody fragment of claim 1, wherein the antibody or antibody fragment specifically binds to an epitope within the extracellular domain of human EpCAM having the amino acid sequence of SEQ ID NO:

2.

4. the antibody or antibody fragment (I) (a1) VH-CDR1 comprising the sequence NYYIH (SEQ ID NO: 13); (b1) VH-CDR2 comprising the sequence WIYPGNVYIQYNEKFKG (SEQ ID NO: 14); (c1) VH-CDR3 comprising the sequence DGPWFAY (SEQ ID NO: 15); (d1) VL-CDR1 comprising the sequence RSSRSLLHSDGFTYLY (SEQ ID NO: 42); (e1) VL-CDR2 comprising the sequence QTSNLAS (SEQ ID NO: 40); and (f1) a VL-CDR3 comprising the sequence AQNLELPNT (SEQ ID NO: 41); or (II) (a2) VH-CDR1 comprising the sequence NYYIH (SEQ ID NO: 13); (b2) VH-CDR2 comprising the sequence WIYPGNVYIQYNEKFKG (SEQ ID NO: 14); (c2) VH-CDR3 comprising the sequence DGPWFAY (SEQ ID NO: 15); (d2) VL-CDR1 comprising the sequence RSSKSLLHSDGFTYLY (SEQ ID NO: 39); (e2) VL-CDR2 comprising the sequence QTSNLAS (SEQ ID NO: 40); and (f2) a VL-CDR3 comprising the sequence AQNLELPNT (SEQ ID NO: 41); The EpCAM antibody or EpCAM-binding antibody fragment of claim 1.

5. the antibody or antibody fragment (a) a VH comprising a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 54, and a VL comprising a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 89; (b) a VH comprising a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 54, and a VL comprising a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 87; (c) a VH comprising a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 55, and a VL comprising a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 87; (d) a VH comprising a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 56, and a VL comprising a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 88; (e) a VH comprising a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 55, and a VL comprising a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the sequence of SEQ ID NO: 89; and (f) a VH comprising a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 56, and a VL comprising a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 89; 2. The EpCAM antibody or EpCAM-binding antibody fragment of claim 1, comprising a VH and a VL selected from the group consisting of:

6. the antibody or antibody fragment (a) a VH comprising the sequence of SEQ ID NO: 54, and a VL comprising the sequence of SEQ ID NO: 89; (b) a VH comprising the sequence of SEQ ID NO: 54, and a VL comprising the sequence of SEQ ID NO: 87; (c) a VH comprising the sequence of SEQ ID NO: 55, and a VL comprising the sequence of SEQ ID NO: 87; (d) a VH comprising the sequence of SEQ ID NO: 56, and a VL comprising the sequence of SEQ ID NO: 88; (e) a VH comprising the sequence of SEQ ID NO: 55, and a VL comprising the sequence of SEQ ID NO: 89; and (f) a VH comprising the sequence of SEQ ID NO: 56, and a VL comprising the sequence of SEQ ID NO: 89; VH and VL selected from the group consisting of: The EpCAM antibody or EpCAM-binding antibody fragment of claim 1.

7. the antibody or antibody fragment (a) a HC comprising the sequence of SEQ ID NO: 103, and a LC comprising the sequence of SEQ ID NO: 140; (b) a HC comprising the sequence of SEQ ID NO: 103, and a LC comprising the sequence of SEQ ID NO: 138; (c) a HC comprising the sequence of SEQ ID NO: 105, and a LC comprising the sequence of SEQ ID NO: 139; (d) a HC comprising the sequence of SEQ ID NO: 106, and a LC comprising the sequence of SEQ ID NO: 139; (e) a HC comprising the sequence of SEQ ID NO: 105, and a LC comprising the sequence of SEQ ID NO: 140; and (f) a HC comprising the sequence of SEQ ID NO: 106, and a LC comprising the sequence of SEQ ID NO: 140; comprising a HC and a LC selected from the group consisting of: The EpCAM antibody or EpCAM-binding antibody fragment of claim 1.

8. EpCAM antibody or EpCAM-binding antibody fragment, the antibody or antibody fragment (A) SEQ ID NOs: 22, 14, 15, 42, 40, and 41, respectively; (B) SEQ ID NOs: 13, 14, 33, 42, 40, and 41, respectively; (C) SEQ ID NOs: 23, 14, 15, 42, 40, and 41, respectively; and (D) SEQ ID NOs: 25, 14, 15, 42, 40, and 41, respectively; VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 consisting of sequences selected from the group consisting of: EpCAM antibodies or EpCAM-binding antibody fragments.

9. the antibody or antibody fragment (a) a VH comprising the sequence of SEQ ID NO: 75, and a VL comprising the sequence of SEQ ID NO: 89; (b) a VH comprising the sequence of SEQ ID NO: 77, and a VL comprising the sequence of SEQ ID NO: 89; (c) a VH comprising the sequence of SEQ ID NO: 76, and a VL comprising the sequence of SEQ ID NO: 89; and (d) a VH comprising the sequence of SEQ ID NO: 84, and a VL comprising the sequence of SEQ ID NO: 89; VH and VL selected from the group consisting of: The EpCAM antibody or EpCAM-binding antibody fragment of claim 8.

10. the antibody or antibody fragment (a) a HC comprising the sequence of SEQ ID NO: 125, and a LC comprising the sequence of SEQ ID NO: 140; (b) a HC comprising the sequence of SEQ ID NO: 127, and a LC comprising the sequence of SEQ ID NO: 140; (c) a HC comprising the sequence of SEQ ID NO: 126 and a LC comprising the sequence of SEQ ID NO: 140; and (d) a HC comprising the sequence of SEQ ID NO: 134, and a LC comprising the sequence of SEQ ID NO: 140; 9. The EpCAM antibody or EpCAM-binding antibody fragment of claim 8, comprising a heavy chain and a light chain selected from the group consisting of:

11. the antibody or antibody fragment is a humanized antibody; The EpCAM antibody or EpCAM-binding antibody fragment of claim 1.

12. The EpCAM antibody or EpCAM-binding antibody fragment of claim 11 , wherein the humanized antibody is a full-length humanized antibody.

13. The EpCAM antibody or EpCAM-binding antibody fragment of claim 12, wherein the full-length humanized antibody is a humanized IgG1 antibody.

14. The antibody fragment may be Fab, Fab', F(ab') 2 , single-chain Fv (scFv), disulfide-linked F v , IgGΔCH 2 , minibody, F(ab') 3 , tetrabody, triabody, diabody, DVD-Ig, Fcab, mAb 2 , (scFv) 2 and scFv-Fc, The EpCAM antibody or EpCAM-binding antibody fragment of claim 1. (a) a VH-CDR1 comprising the sequence NYYIH (SEQ ID NO: 13); (b) VH-CDR2 comprising the sequence WIYPGNVYIQYNEKFKG (SEQ ID NO: 14); (c) a VH-CDR3 comprising the sequence DGPWFAY (SEQ ID NO: 15); (d) VL-CDR1 comprising the sequence RSSRSLLHSDGFTYLY (SEQ ID NO: 42); (e) a VL-CDR2 comprising the sequence QTSNLAS (SEQ ID NO: 40); and (f) a VL-CDR3 comprising the sequence AQNLELPNT (SEQ ID NO: 41); EpCAM antibody or EpCAM-binding antibody fragment comprising:

16. 16. An activatable antibody comprising the EpCAM antibody or EpCAM-binding antibody fragment of any one of claims 1 to 15, (a) a cleavable moiety attached to said antibody or antibody fragment which is a polypeptide that functions as a substrate for a protease; and (b) a masking moiety attached to the activatable antibody or antibody fragment, wherein the masking moiety inhibits binding of the antibody or antibody fragment to EpCAM when the activatable antibody is in an uncleaved state; further comprising the uncleaved activatable antibody has an N- to C-terminal structural arrangement of (masking moiety)-(cleavable moiety)-(antibody or antibody fragment) or (antibody or antibody fragment)-(cleavable moiety)-(masking moiety); Activatable antibodies.

17. 17. The activatable antibody of claim 16, further comprising one or more linkers.

18. The activatable antibody of claim 17, wherein the activatable antibody comprises a linker between the masking moiety and the cleavable moiety, between the cleavable moiety and the antibody or antibody fragment, or comprises linkers both between the masking moiety and the cleavable moiety and between the cleavable moiety and the antibody or antibody fragment.

19. 19. The activatable antibody of claim 18, wherein the one or more linkers are flexible linkers.

20. 19. The activatable antibody of claim 18, wherein the linker between the masking moiety and the cleavable moiety is different from the linker between the cleavable moiety and the antibody or antibody fragment.

21. 17. The activatable antibody of claim 16, wherein the masking moiety comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 151-157.

22. The activatable antibody of claim 16 , wherein the masking portion comprises the amino acid sequence of SEQ ID NO:

155.

23. 18. The activatable antibody of claim 17, wherein the cleavable portion comprises the amino acid sequence of AVGLLAPPGGLSGRSDNI or ISSGLLSGRSDNI.

24. 18. The activatable antibody of claim 17, wherein the cleavable portion comprises the amino acid sequence ISSGLLSGRSDNI.

25. 18. The activatable antibody of claim 17, wherein the masking portion comprises the amino acid sequence of SEQ ID NO: 155 and the cleavable portion comprises the amino acid sequence of AVGLLAPPGGLSGRSDNI or ISSGLLSGRSDNI.

26. 18. The activatable antibody of claim 17, comprising an HC comprising the sequence of SEQ ID NO: 103 and an LC comprising the sequence of SEQ ID NO:

179.

27. EpCAM activatable antibody, (a) an EpCAM antibody or EpCAM-binding antibody fragment comprising a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3 consisting of a sequence selected from the group consisting of: (i) SEQ ID NOs: 13-15, 42, 40, and 41, respectively; (ii) SEQ ID NOs: 13-15, and 39-41, respectively; (iii) SEQ ID NOs: 13, 26, 15, and 39-41, respectively; and (iv) SEQ ID NOs: 13, 26, 15, 42, 40, and 41, respectively; (b) a masking moiety attached to the EpCAM antibody or EpCAM-binding antibody fragment, wherein the masking moiety inhibits binding of the antibody or antibody fragment to EpCAM when the activatable antibody is in an uncleaved state; and (c) a cleavable moiety attached to said EpCAM antibody or EpCAM-binding antibody fragment, which is a polypeptide that functions as a substrate for a protease; Including, the uncleaved activatable antibody has an N- to C-terminal structural arrangement of (masking moiety)-(cleavable moiety)-(antibody or antibody fragment) or (antibody or antibody fragment)-(cleavable moiety)-(masking moiety); EpCAM activatable antibody.

28. The EpCAM activatable antibody of claim 27, wherein the VH-CDR1, the VH-CDR2, the VH-CDR3, the VL-CDR1, the VL-CDR2, and the VL-CDR3 consist of the sequences of SEQ ID NOs: 13-15, 42, 40, and 41, respectively.

29. 28. The EpCAM activatable antibody of claim 27, wherein the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH comprising the sequence of SEQ ID NO: 54 and a VL comprising the sequence of SEQ ID NO:

89.

30. 28. The EpCAM activatable antibody of claim 27, wherein the EpCAM antibody or EpCAM-binding antibody fragment comprises a HC comprising the sequence of SEQ ID NO: 103 and a LC comprising the sequence of SEQ ID NO:

140.

31. 28. The EpCAM activatable antibody of claim 27, wherein the masking moiety comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 151-157.

32. 28. The EpCAM activatable antibody of claim 27, wherein the masking portion comprises the amino acid sequence of SEQ ID NO:

155.

33. 28. The EpCAM activatable antibody of claim 27, wherein the cleavable portion comprises the amino acid sequence of AVGLLAPPGGLSGRSDNI or ISSGLLSGRSDNI.

34. EpCAM activatable antibody, (a) an EpCAM antibody or EpCAM-binding antibody fragment comprising a VH-CDR1, a VH-CDR2, a VH-CDR3, a VL-CDR1, a VL-CDR2, and a VL-CDR3 consisting of a sequence selected from the group consisting of: (i) SEQ ID NOs: 22, 14, 15, 42, 40, and 41, respectively; (ii) SEQ ID NOs: 13, 14, 33, 42, 40, and 41, respectively; (iii) SEQ ID NOs: 23, 14, 15, 42, 40, and 41, respectively; and (iv) SEQ ID NOs: 25, 14, 15, 42, 40, and 41, respectively; (b) a masking moiety attached to the EpCAM antibody or EpCAM-binding antibody fragment, wherein the masking moiety inhibits binding of the antibody or antibody fragment to EpCAM when the activatable antibody is in an uncleaved state; and (c) a cleavable moiety attached to the EpCAM antibody or EpCAM-binding antibody fragment, wherein the cleavable moiety is a polypeptide that functions as a substrate for a protease; Including, the uncleaved activatable antibody has an N- to C-terminal structural arrangement of (masking moiety)-(cleavable moiety)-(antibody or antibody fragment) or (antibody or antibody fragment)-(cleavable moiety)-(masking moiety); EpCAM activatable antibody.

35. 35. The EpCAM activatable antibody of claim 34, wherein the cleavable portion comprises the amino acid sequence of AVGLLAPPGGLSGRSDNI or ISSGLLSGRSDNI.

36. The EpCAM activatable antibody of claim 34 or 35, wherein the EpCAM antibody or EpCAM-binding antibody fragment comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 consisting of the sequences of SEQ ID NOs: 22, 14, 15, 42, 40, and 41, respectively.

37. 37. The EpCAM activatable antibody of claim 36, wherein the masking moiety comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 151-157 and 162-167.

38. The EpCAM activatable antibody of claim 36, wherein the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH comprising the sequence of SEQ ID NO: 75 and a VL comprising the sequence of SEQ ID NO:

89.

39. 39. The EpCAM activatable antibody of claim 38, wherein the EpCAM antibody or EpCAM-binding antibody fragment comprises a heavy chain comprising the sequence of SEQ ID NO: 125 and a light chain comprising the sequence of SEQ ID NO:

140.

40. The EpCAM activatable antibody of claim 34 or 35, wherein the EpCAM antibody or EpCAM-binding antibody fragment comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 consisting of the sequences of SEQ ID NOs: 13, 14, 33, 42, 40, and 41, respectively.

41. 40. The EpCAM activatable antibody of claim 39, wherein the masking moiety comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 151-161.

42. the EpCAM antibody or EpCAM-binding antibody fragment comprises a VH comprising the sequence of SEQ ID NO: 77 and a VL comprising the sequence of SEQ ID NO: 89; or the EpCAM antibody or EpCAM-binding antibody fragment comprises a heavy chain comprising the sequence of SEQ ID NO: 127 and a light chain comprising the sequence of SEQ ID NO: 140; 41. The EpCAM activatable antibody of claim 40.

43. (a) (i) a VH-CDR1 comprising the sequence NYYIH (SEQ ID NO: 13); (ii) VH-CDR2 comprising the sequence WIYPGNVYIQYNEKFKG (SEQ ID NO: 14); (iii) a VH-CDR3 comprising the sequence DGPWFAY (SEQ ID NO: 15); (iv) VL-CDR1 comprising the sequence RSSRSLLHSDGFTYLY (SEQ ID NO: 42); (v) VL-CDR2 comprising the sequence QTSNLAS (SEQ ID NO: 40); and (vi) a VL-CDR3 comprising the sequence AQNLELPNT (SEQ ID NO: 41); an EpCAM antibody or an EpCAM-binding antibody fragment comprising: (b) a masking moiety (MM) attached to the EpCAM antibody or EpCAM-binding antibody fragment, the masking moiety comprising the sequence WWPPCQGGAWCEQRI (SEQ ID NO: 155); and (c) a cleavable moiety (CM) attached to the EpCAM antibody or EpCAM-binding antibody fragment, the cleavable moiety comprising the sequence ISSGLLSGRSDNI (SEQ ID NO: 169). EpCAM-activatable antibody comprising:

44. A cell producing the EpCAM antibody or EpCAM-binding antibody fragment of any one of claims 1 to 15 or the EpCAM-activatable antibody of any one of claims 16 to 43.

45. comprising an EpCAM antibody or EpCAM-binding antibody fragment according to any one of claims 1 to 15, or an EpCAM-activatable antibody according to any one of claims 16 to 43, the antibody, antibody fragment, or activatable antibody is labeled with a label selected from the group consisting of a radiolabel, a fluorophore, a chromophore, an imaging agent, and a metal ion; Diagnostic drugs.

46. A polynucleotide or multiple polynucleotides encoding the EpCAM antibody or EpCAM-binding antibody fragment of any one of claims 1 to 15, or the EpCAM-activatable antibody of any one of claims 16 to 43.

47. 47. A vector or vectors comprising the polynucleotide or polynucleotides of claim 46.

48. 48. A host cell comprising the polynucleotide or polynucleotides of claim 46 or the vector or vectors of claim 47.

49. A method for producing an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody according to any one of claims 1 to 43, comprising: (a) culturing the host cell of claim 48; and (b) isolating an EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody from said host cell or cell culture. A method comprising:

50. 50. The method of claim 49, wherein the host cell is a eukaryotic cell.

51. 51. The method of claim 50, wherein the host cell is a CHO cell.

52. An immunoconjugate comprising an EpCAM antibody or EpCAM-binding antibody fragment of any one of claims 1 to 15, or an EpCAM activatable antibody of any one of claims 16 to 43, and a cytotoxic agent conjugated or covalently attached to the antibody, antigen-binding antibody fragment, or activatable antibody.

53. The following formula: 【Chemical 1】 53. The immunoconjugate of claim 52, represented by the formula: EpBA is an EpCAM antibody, an EpCAM-binding antibody fragment, or an activatable antibody, said EpBA being linked to Cy through a lysine residue. L1 covalently bonded to; W L is an integer from 1 to 20; and Cy L1 is expressed by the following formula: 【Chemistry 2】 or a pharmaceutically acceptable salt thereof, wherein: Double line between N and C 【Chemistry 3】 is a single bond or a double bond, provided that when it is a double bond, X is absent and Y is —H or (C 1 -C 4 ) alkyl; and if it is a single bond, X is —H or an amine protecting moiety and Y is —OH or —SO 3 H or a pharmaceutically acceptable salt thereof; W' is -NR e’ and R e’ Ha-(CH 2 -CH 2 -O) n -R k and n is an integer from 2 to 6, R k is —H or —Me, R x3 is (C 1 -C 6 ) alkyl, L' is represented by the following formula: -NR 5 -P-C(=O)-(CR a R b ) m -C(=O), or -NR 5 -P-C(=O)-(CR a R b ) m -S-Z s1 、 R 5 is -H or (C 1 -C 3 ) alkyl, P is an amino acid residue or a peptide containing 2 to 20 amino acid residues; R a and R b are each independently -H, (C 1 -C 3 ) alkyl, or a charged substituent or ionizable group Q; m is an integer from 1 to 6, Z s1 is the following formula: 【Chemistry 4】 is selected from one of q is an integer from 1 to 5; immune complex.

54. (a) R a and R b are both H, and R 5 is H or Me; (b) P is a peptide containing 2 to 5 amino acid residues; (c) P is selected from Gly-Gly-Gly, Ala-Val, Val-Ala, Val-Cit, Val-Lys, Phe-Lys, Lys-Lys, Ala-Lys, Phe-Cit, Leu-Cit, Ile-Cit, Trp, Cit, Phe-Ala, Phe-N 9 -tosyl-Arg, Phe-N 9 -nitro-Arg, Phe-Phe-Lys, D-Phe-Phe-Lys, Gly-Phe-Lys, Leu-Ala-Leu, Ile-Ala-Leu, Val-Ala-Val, Ala-Leu-Ala-Leu (SEQ ID NO: 215), β-Ala-Leu-Ala-Leu (SEQ ID NO: 216), Gly-Phe-Leu-Gly (SEQ ID NO: 217), Val-Arg, Arg-Val, Arg-Arg, Val-D-Cit, Val-D-Lys, Val-D-Arg, D-Val-Cit, D-Val-Lys, D-Val-Arg, D-Val-D-Cit, D-Val-D-Lys, D-Val-D-Arg, D-Arg-D-Arg, Ala-Ala, Ala-D-Ala, D-Ala-Ala, D-Ala-D-Ala, Ala-Met, Met-Ala, Gln-Val, Asn-Ala, Gln-Phe and Gln-Ala, (d) P is Gly-Gly-Gly, Ala-Val, Ala-Ala, Ala-D-Ala, D-Ala-Ala, or D-Ala-D-Ala; and / or (e) Q is -SO 3 H or a pharmaceutically acceptable salt thereof; 54. The immune complex of claim 53.

55. The immunoconjugate has the following formula: 【Chemistry 5】 【change】 【change】 【change】 【change】 or a pharmaceutically acceptable salt thereof, W L is an integer from 1 to 10; the double line between N and C 【Chemistry 6】 is a single bond or a double bond, provided that if it is a double bond, then X is absent and Y is -H; and if it is a single bond, then X is -H and Y is -OH or -SO 3 54. The immunoconjugate of claim 53, which is H or a pharmaceutically acceptable salt thereof.

56. The double line between N and C 【Chemistry 7】 is a double bond, X is absent, and Y is —H; or The double line between N and C 【Chemistry 8】 is a single bond, X is —H, and Y is —SO 3 H or a pharmaceutically acceptable salt thereof; 54. The immune complex of claim 53.

57. Y is -SO 3 H, -SO 3 Na, or -SO 3 57. The immune complex of claim 56, wherein the immunoconjugate is K.

58. The following formula: 【Chemistry 9】 An immune complex represented by the formula: EpBA is an EpCAM antibody, an EpCAM-binding antibody fragment, or an EpCAM-activatable antibody, said EpBA being linked to Cy through a lysine residue. L2 is covalently bound to W L is an integer from 1 to 20, Cy L2 is expressed by the following formula: 【Chemistry 10】 is represented by m' is 1 or 2; R 1 and R 2 are each independently H or (C 1 -C 3 ) alkyl, and Z s1 is expressed by the following formula: 【Chemistry 11】 is selected from one of q is an integer from 1 to 5; 53. The immune complex of claim 52.

59. m' is 1, and R 1 and R 2 are both H, or m' is 2 and R1 and R2 are both Me; 59. The immune complex of claim 58.

60. The immunoconjugate has a formula selected from the group consisting of: 【Chemistry 12】 or a pharmaceutically acceptable salt thereof, W L is an integer from 1 to 10, 59. The immune complex of claim 58.

61. The immunoconjugate has the following formula: 【Chemistry 13】 or a pharmaceutically acceptable salt thereof:

59. The immune complex of claim 58.

62. The following formula: 【Chemistry 14】 or a pharmaceutically acceptable salt thereof, wherein: W L is an integer from 1 to 10, EpBA is an EpCAM antibody, an EpCAM-binding antibody fragment, or an EpCAM-activatable antibody, wherein the EpCAM antibody, the EpCAM-binding antibody fragment, or the EpCAM-activatable antibody comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 consisting of the sequences of SEQ ID NOs: 13-15, 42, 40, and 41, respectively; 53. The immune complex of claim 52.

63. The immune complex of claim 62, wherein the EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL) comprising the sequences of SEQ ID NO: 54 and SEQ ID NO: 89, respectively.

64. 63. The immune complex of claim 62, wherein the EpCAM antibody or EpCAM activatable antibody comprises a heavy chain and a light chain comprising the sequences of SEQ ID NO: 103 and SEQ ID NO: 140, respectively.

65. 63. The immune complex of claim 62, wherein the activatable antibody comprises a masking moiety comprising an amino acid sequence selected from SEQ ID NOs: 151-157.

66. 63. The immune complex of claim 62, wherein the activatable antibody comprises a masking moiety comprising the amino acid sequence of SEQ ID NO:

155.

67. 63. The immune complex of claim 62, wherein the activatable antibody comprises a cleavable moiety comprising the amino acid sequence of AVGLLAPPGGLSGRSDNI or ISSGLLSGRSDNI.

68. The EpCAM antibody, EpCAM-binding antibody fragment, or EpCAM-activatable antibody has the following structural formula: 【Chemistry 15】 linked via a γ-maleimidobutyric acid N-succinimidyl ester (GMBS) or N-(γ-maleimidobutyryloxy) sulfosuccinimide ester (sulfo-GMBS) linker to the maytansinoid compound DM21L, represented by the formula:

53. The immune complex of claim 52.

69. The GMBS and sulfo-GMBS (sGMBS) linkers have the formula: 【Chemistry 16】 represented by 69. The immune complex of claim 68.

70. The following formula: 【Chemistry 17】 wherein: EpBA is an EpCAM antibody, an EpCAM-binding antibody fragment, or an EpCAM-activatable antibody, and said EpBA is conjugated to said maytansinoid compound via a Lys amine group; q is an integer from 1 to 10; 69. The immune complex of claim 68.

71. A pharmaceutical composition comprising an EpCAM antibody, an EpCAM-binding antibody fragment, an EpCAM-activatable antibody, or an immunoconjugate of any one of claims 1 to 15, and a pharmaceutically acceptable carrier.

72. 10. The EpCAM antibody or EpCAM-binding antibody fragment of any one of claims 1 to 15, the EpCAM-activatable antibody of any one of claims 16 to 43, the immunoconjugate of any one of claims 52 to 70, or the pharmaceutical composition of claim 71 for use in a method of killing cancer cells, the method comprising contacting cancer cells with an effective amount of the EpCAM antibody or EpCAM-binding antibody fragment, the EpCAM-activatable antibody, the immunoconjugate, or the pharmaceutical composition. An EpCAM antibody or EpCAM-binding antibody fragment, an EpCAM-activatable antibody, an immunoconjugate, or a pharmaceutical composition.

73. The EpCAM antibody or EpCAM-binding antibody fragment, EpCAM activatable antibody, immunoconjugate, or pharmaceutical composition of claim 72, wherein the cancer cells are epithelial cancer cells, breast cancer cells, lung cancer cells, colorectal cancer cells, prostate cancer cells, ovarian cancer cells, colon cancer cells, rectal cancer cells, cancer stem cells, uterine cancer cells, gastric cancer cells, pancreatic cancer cells, or colorectal cancer cells.

74. 10. The EpCAM antibody or EpCAM-binding antibody fragment of any one of claims 1 to 15, the EpCAM-activatable antibody of any one of claims 16 to 43, the immunoconjugate of any one of claims 52 to 70, or the pharmaceutical composition of claim 71 for use in a method for treating an EpCAM-expressing cancer, said method comprising administering to a subject in need thereof a therapeutically effective amount of said EpCAM antibody, said EpCAM-binding antibody fragment, said EpCAM-activatable antibody, said immunoconjugate, or said pharmaceutical composition. An EpCAM antibody or EpCAM-binding antibody fragment, an EpCAM-activatable antibody, an immunoconjugate, or a pharmaceutical composition.

75. 75. The EpCAM antibody or EpCAM-binding antibody fragment, EpCAM activatable antibody, immunoconjugate, or pharmaceutical composition of claim 74, wherein the cancer is an epithelial cancer.

76. The EpCAM antibody or EpCAM-binding antibody fragment, EpCAM-activatable antibody, immunoconjugate, or pharmaceutical composition of claim 74, wherein the cancer is breast cancer (e.g., triple-negative breast cancer), lung cancer (e.g., non-small cell lung cancer), colorectal cancer, prostate cancer, ovarian cancer, colon cancer, esophageal cancer, tracheal cancer, gastric cancer, bladder cancer, uterine cancer, rectal cancer, small intestine cancer, or metastasis thereof.

77. 75. The EpCAM antibody or EpCAM-binding antibody fragment, EpCAM-activatable antibody, immunoconjugate, or pharmaceutical composition of claim 74, wherein the cancer is uterine cancer, gastric cancer, pancreatic cancer, colorectal cancer, or metastasis thereof.

Citation Information

Patent Citations

  • Target binding site that forms a complex with amatoxin for cancer treatment

    JP2012523383A

  • Anti-EpCAM antibody

    JP2012529281A

  • Method for preparing the complex

    JP2014506892A

  • Monoclonal antibodies targeting epcam for detection of prostate cancer lymph node metastases

    US20160024207A1

  • ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EpCAM ANTIBODIES

    WO2017023704A1